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SUMMARY
Fulminant hepatitis B (FHBV) is a rare but severe outcome of acute hepatitis B 
virus infection. The severe liver injury is attributed to an exaggerated immune response 
directed at clearing virus by causing lysis of infected hepatocytes. Multiple factors could 
contribute to severity of the disease. Our study has shown that although there are no 
specific variant(s) linked to severity, there are clusters of variants in the c/s-acting 
regulatory elements which can upregulate replication of FHBV strains. The most novel 
concept to come out of this study is that, most of these variants are not unique to FHBV 
sequences but they are significant when they occur in the form of 'motifs' or 
combinations; we showed that these multiple motifs are associated with a common 
functional effect.
We have sequenced: full genomes from 8 patients (5 FHB, 2 chronic contacts and 
1 acute contact case), from beginning of enhancer-I to the end of core gene from 11 
patients, and the core gene only from 3 patients. Clusters of nucleotide substitutions were 
found particularly in Enh-I (nts 1050, 1059, 1249 and 1250), the BCP/Enh-II complex 
and in the X gene. Aberrant cysteine and methionine residues in X gene were associated 
with FHBV sequences. No specific clustering was found in the pre-S/S or polymerase 
genes. Our study found that A]896 has an association with FHBV, but other variants 
elsewhere in the genome distinguishes FHBV-A1896 from other A 1896. A 1896 is strongly 
linked with HBeAg negative/anti-HBe positive infection and associated with early 
clearance of viraemia.
We performed phylogenetic analysis on 30 core gene and 26 X gene sequences 
from patients with FHB and 161 core gene and 88 X gene sequences from non-FHBV 
case in order to identify any common patterns of genetic variation. Sequences from 
epidemiologically unlinked FHB patients cluster together on phylogenetic trees, indicating 
that particular strains are linked to FHB. The second novel concept is that the cluster 
identity was closely related to clinical outcome and progression of FHBV disease. There 
were significantly higher rates of evolution in FHBV sequences, consistent with an 
elevated rate of replication. Substitution of nucleotides in the cis-acting elements and 
amino acid residues in the X protein, the pre-core variant A ]896, are linked to FHBV 
pathogenesis in the form of particular combinations, or motifs which are predominantly or 
uniquely associated with FHBV sequences.
In functional analysis, We than showed that variants motifs affect the functional 
properties in vitro. We tested sequences from 11 FHB and 7 chronic carrier controls, not 
associated with FHB in contacts, and 2 subtype controls. Luciferase expression in 
hepatocytoma cell line (HuH7), driven from cloned BCP/Enh-II sequences, was high (>7 
arbitrary units) in 7 FHB and intermediate (2-7 arbitrary units) in two others. Two of 9
controls had intermediate, and the others low(<2) expression. Specific variant motifs 
were associated with raised luciferase expression, in particular at nt 1766/1768, 
1762/1826 and 1727/1740. High luciferase expression correlated with rapid progression 
of disease, clearance of viraemia and presence of A1896; controls with A ]896 had normal 
expression. Thus multiple sequences have had a common phenotype. Finally, a series of 
radiolabelled oligonucleotides with control and FHBV sequences, encompassing the 
major binding sites of transcriptional factors in the BCP, were bound to nuclear extract 
and shift assays performed. For all variant oligonucleotides, two complexes were missing 
compared to control sequences. This led to a unified theory to account for most FHBV 
sequences: that failure of inhibitory transcription factors to bind to variant BCP sequences 
led to increased replication.
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CHAPTER-1
INTRODUCTION
Chapter-1 Introduction
1.1 HEPATITIS B VIRUS (HBV): MOLECULAR BIOLOGY
1.1.1 BRIEF BACKGROUND
Before the discovery of etiologic agents, two types of viral hepatitis were known 
on the basis of epidemiological studies. Type A was considered to be predominantly 
transmitted by a faecal-oral route, whereas type B was transmitted parenterally by human 
serum. Thus, hepatitis B was also known as 'serum hepatitis'. In 1963, Blumberg first 
discovered an antigen in the blood of an Australian aborigine which, after several years of 
investigation, was found to be associated with acute hepatitis B (Blumberg et al., 1967). 
It was then named hepatitis associated antigen (HAA) and currently is designated hepatitis 
B surface antigen (HBsAg). HBsAg in blood has proved a convenient marker for 
hepatitis B infection providing a wealth of information about the epidemiology and course 
of infection. Early investigations of HBsAg led to the recognition of the description of 
persistence or chronic HBV infection. Persistent infection is defined by circulation of a 
relatively high concentration of HBsAg particles for years. The blood of persistently 
infected patients, also known as 'carriers', provides a good source of viral antigens for 
physical and chemical characterisation. Most of the HBsAg in blood is in the form of 
particles; they are pleomorphic or round, approximately 22 nm diameter and devoid of 
nucleic acid (Bayer et al., 1968). However, larger, double-shelled particles (Dane 
particles) were detected in the serum of a carrier (Dane et al., 1970). These particles were 
the only antigenic form known to contain nucleic acid and it was suggested that these 
were the complete form of HBV. Almeida et al. (1971) removed the outer shell of Dane 
particles using a non-ionic detergent, revealing a new specificity which was termed 
hepatitis B core antigen (HBcAg). Hirschman et al. (1971) first detected small amounts of 
DNA polymerase activity in crude pellets obtained from HBsAg positive serum by high­
speed centrifugation and found endogenous template for the polymerase. Mistakenly, they 
postulated that the template of the enzyme preparation was RNA, as the polymerase 
reaction was interrupted by RNase treatment. Kaplan et al., (1973) found DNA 
polymerase activity in a high-speed centrifugation pellet from HBsAg positive serum; the 
reaction product had a sedimentation coefficient of 15S. The reaction was inhibited by 
actinomycin D suggesting that the template was DNA, not RNA. The enzyme, the 
template and the reaction product appeared to be internal components of the core particle. 
Soon after this, the circular, partially double-stranded DNA was characterised (Robinson 
et al., 1974).
The discovery of HBV led the way for the identification of further hepatitis 
viruses. Currently five definite hepatitis viruses are known, hepatitis A-E; there is some 
doubt over the relationship between ‘hepatitis G’ and hepatitis. These letters do not
1
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indicate taxonomic relatedness, but only to the fact that these very different viruses may 
all cause clinical hepatitis.
Patients infected with HBV develop either an acute self limiting infection or 
persistence or may not cause disease. It was postulated that this virus might be the cause 
of liver cancer, leading to the search for an HBV-like agent in woodchucks (.Marmota 
monax), which had been observed to develop liver cancer. Woodchuck hepatitis virus 
(WHV) was subsequently discovered (Summers et al, 1978), with a morphology 
indistinguishable from HBV and a genome with approximately 60% nucleotide sequence 
identity with its human counterpart (Galibert et al, 1982). A series of similar viruses has 
now been recovered from a variety of animal species, including the ground squirrel 
hepatitis virus (GSHV) in Beechy ground squirrels (Marion and Robinson, 1980), a 
species that is distantly related to marmots, and duck hepatitis B virus (DHB V) in Peking 
ducks {Anas domesticus), which also sometimes develop liver cancer (Zhou et al, 1980). 
Less well characterised viruses have been recovered from grey herons living in their 
natural habitat, domestic geese, marsupials and other hosts (Sprengel et a l, 1988; Tenant 
et al, 1992). HBV and its relatives constitute the family Hepadnaviridae, the term derived 
from their hepatotropism and DNA genome (Marion et al, 1983). All of them have 
common properties: being enveloped with 3-3.3 kb partially double stranded DNA; 
having a virion associated polymerase; production of excess subviral particles; narrow 
host range; and development of persistent infection. However, there are also a number of 
biological differences between them including variation in host range, tissue tropism, 
pathogenic spectrum and routes of transmission.
1.1.2 VIRION AND GENOME ORGANISATION
Electron microscopic studies on serum revealed that HBV infected cells produce 
multiple types of virus-related particles. Among these, the 42 nm diameter double shelled 
Dane particles are the infectious HBV virions. There are, in addition, 20 nm spheres and 
20 nm diameter filaments of various lengths. The outer shell of a Dane particle, also 
known as the envelope, is a lipoprotein membrane containing the HBV surface proteins 
(HBs). The Dane particle comprises a 27 nm inner body, the nucleocapsid or core 
particle, surrounded by a 7 nm outer coat. Core particles are composed of core proteins or 
HBcAg and enclose the viral DNA, viral DNA polymerase, the terminal protein covalently 
bound to the minus DNA strand and a protein kinase.
2
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F ig u r e  1.1 Genom e organisation o f  HBV. The outer lines represent the different classes o f 
R NA  transcripts. The four major ORFs, pre-core (Pre-C)/core (C), p re-S l/p re-S 2/S , P and X , are 
indicated in the inner shaded arrows. The lines in centre represent the partially double stranded 
D N A  genom e show ing m -actin g  regulatory elem ents. GRE = glucocorticoid-responsive elem ent, 
prom = promoter, Enh = enhancer, e =  encapsidation signal.
T he H B V  genom e is 3.2 kb long, re laxed  c ircu lar, partially doub le  s tranded  D N A  
and con tains fo u r open reading fram es (O R F s). The coding  o rgan isa tion  is highly 
com pact, i.e. every  nucleo tide in the genom e is w ithin a coding  reg io n , and  o v er h a lf o f  
the sequence is translated  in m ore than one fram e. A s show n in F igu re  1.1 there are fou r 
O R F s w hich encode the viral ‘en v e lo p e’ o r su rface , nuc leocapsid , po lym erase  and X  
pro teins (G anem  et al., 1987). T he largest O R F  (P -O R F ) encodes the viral po lym erase , 
covers som e 80%  o f the genom e and is translated  from  the 3.5 kb p regenom ic R N A  (see 
below ). T he po lym erase  protein is also an ind ispensable com ponen t o f  the viral R N A  
encapsidation  p rocess. It contains four functional dom ains: reverse tran scrip tase , D N A  
po lym erase , R N aseH  and  a 5' term inal b inding p ro tein  (TP), w hich  serves as a p rim er for 
reverse transcrip tion  o f  the p regenom ic R N A  (W ang and Seeger, 1992).
T he second  O R F  contains tw o in-phase start codons defin ing  tw o  overlapping  
po lypep tides. The larger translation product is the precore/core 25kD  pro tein  w hich  is
3
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translocated, via a signal polypeptide at its extreme amino-terminal end, into the 
endoplasmic reticulum (ER). Here it undergoes truncation of amino and carboxy terminal 
residues and is secreted into the blood as hepatitis B e antigen (HBeAg). This protein is 
not a structural component of the virus but probably plays a role in modification of the 
host immune defence against HBV. When translation initiates at the second ATG, the 
21kD core protein is produced, which self-assembles in the cytoplasm to form 
nucleocapsid particles which package the viral polymerase and pregenomic RNA, thereby 
facilitating viral replication. Both pre-core and core proteins are translated from full length 
terminally redundant 3.5 kb transcripts with slightly different 5' ends. The longer pre­
core mRNAs contain the pre-core initiation codon and code for HBeAg; the shorter 
pregenomic mRNA lacks this.
The third ORF encodes X protein (HBx) which is a transcriptional transactivator 
for the transcription of HBV as well as viral and cellular promoters {in vitro).
The fourth open reading frame, the surface gene, contains three in-phase 
translational start codons which define the amino termini of three overlapping 
polypeptides, designated large, middle and small surface proteins. All share the same 
carboxy terminus, HBsAg or SHBs. The middle (MHBs) and large proteins (LHBs) have 
additional pre-surface regions, known as pre-Sl and pre-S2, at the amino terminus, 
which are involved in binding to hepatocyte receptor(s) during viral entry to the cell.
1.1.3 VIRAL LIFE CYCLE
The life cycle of all hepadnaviruses can be divided into several steps: i) attachment 
of the virus to the host cell, ii) viral penetration and release of its genome, iii) expression 
of viral genes and replication of viral genome and iv) virion formation and release (Figure 
1 .2 )
i) Attachment to the host cell
Virus attachment is one of the cmcial steps that determines the host range and 
organ tropism of viruses. So far, little is known about the mechanism of attachment of the 
HBV virion to the cell membrane of the human hepatocyte, the natural host of HBV. Viral 
surface proteins are crucial molecules in recognising a possible receptor on the membrane 
of hepatocytes. Studies on the attachment of HBV surface proteins have been hampered 
by the lack of a susceptible tissue culture system. Much work has been done on the viral 
surface proteins that may be involved in host cell interaction. For HBV and DHBV 
several lines of evidence indicate that pre-S proteins participate in cellular receptor 
binding. For HBV, the pre-Sl domain of LHBs and two elements of the pre-S2 domain 
in the MHBs have attachment sites for hepatocyte membranes or hepatoma cells. Pre-Sl 
mediated attachment was found by Neurath et al (1986) using HepG2 hepatoblastoma 
cells, but not using animal liver cells or human carcinoma cells of non-hepatic origin.
4
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Binding could be blocked by antibodies to amino acids 21 to 47 of the pre-Sl protein, 
neutralising infectivity of HBV (Neurath et al., 1989). However, no liver protein has 
been identified that specifically binds to the pre-S 1 peptide. The pre-S 1 sequence is also 
believed to bind to a novel form of membrane bound interleukin-6 (Neurath et al, 1992).
There are three hepatocyte attachment sites in the pre-S2 domain. The pre-S2 
linked glycan of MHBs has a weak but distinct affinity for HepG2 cells, but not for 
mouse hepatocyte culture or the human carcinoma HeLa cell line. Pre-S2 attachment to 
cells can be mediated by modified human serum albumin (pHSA) pre-treatment of liver 
cell membranes, which strongly increases the binding of HBV (Pontisso et a l, 1989, 
Korne et al, 1990). However, recent studies suggested that the role of MHBs is 
dispensable for both morphogenesis and infectivity, as patients with chronic HBV can 
harbour variants devoid of MHBs which are infectious in vivo (Kann et a l,  1995)._
The SHBs is not only indispensable for virion morphogenesis, but also for 
infectivity. Human hepatocyte membranes seem to bind SHBs via membrane-bound 
endonexin II (E-II), a protein which specifically binds to HBsAg (Hertogs et a l, 1993). 
Human E-II is a 34kD protein and is also known as annexin-V (Walker et al,. 1992). 
Anti-HBs antibody developed spontaneously in rabbits immunised with human liver E-II 
and also in chickens immunised with the F(ab')2 fragments of anti-human liver E-II 
immunoglobulin G (Hertogs et al, 1994). These antibodies are also able to compete with 
E-II for the binding of HBsAg, indicating that the anti-idiotypic antibodies mimic a region 
of E-II that interacts with small HBsAg. Later, HBsAg conjugated to gold particles was 
shown to bind to human hepatocyte and were internalised (Bruin de et a l, 1995). 
Inhibition by anti-E-II or anti-idiotypic antibodies of HBsAg-gold particle binding to 
hepatocytes supports the idea of specific attachment through the SHBs.
ii) Viral penetration and genome release
The mechanism of HBV entry into the hepatocyte is not well understood. Some 
data suggest that the entry of the nucleocapsid into the cytoplasm may occur by pH 
independent mechanisms (Rigg and Schaller, 1992), because there is evidence that uptake 
of DHBV into hepatocyte does not require proteolysis and acid pH.
Nothing is known about the delivery of the genome into the nucleus. In the 
DHBV system, DNA is found in the nucleus 24 hrs after infection, and is converted to 
covalently closed circular (ccc) molecules (Tuttleman et al, 1986). However, it is not yet 
known whether the free DNA or the core particles are transported to the nucleus. Some 
speculate that core particles themselves are transported to the nucleus since the core 
protein contains a nuclear localisation signal at its carboxy terminal end (Yeh et a l, 1990) 
and the diameter of the core particle is at the limit of the functional nuclear pore size, as 
determined by experimental measurements in Xenopus oocytes (Feldherr et a l, 1984).
5
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H ow ever, the possib ility  that co re  partic les d isassem ble in the cy toplasm  and  deliver their 
D N A  to the nucleus has not been excluded.
Infectious 
HBV virion
Receptor
Endo'plasmic
reticulum
Strand
DNA
-Strand
DNA
I protein
3.5 kb RNA 
pregenome
+ precore 
proteins
F igu re 1.2 L ife cy c le  o f  HBV in sim plified  diagram: (1) attachment to and (2) penetration o f  
the host cell; (3) uncoating and transport o f  viral genom e to the nucleus; (4) conversion o f  ccc 
D N A  and (5) R NA  transcription; (6) transport and translation o f  RNA; (7) assem bly and 
encapsidation into core particle; (8) reverse transcription o f  pregenomic R N A  and plus strand 
D N A  synthesis; (9 ) envelopm ent and export from the cell; (10) core particle may transport to 
nucleus for am plification o f ccc D N A . (This picture is taken from Nassal and Schaller, 1993)
6
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iii) Genome replication
The main steps of genome replication occur in the nucleus, and there are four 
fundamental steps, as reviewed by Ganem and Varmus, (1987). Firstly, the partially 
double-stranded virion DNA is converted into ccc DNA which is used as the template for 
the synthesis of viral RNAs (Mason et al., 1982; Miller et al, 1984). Formation of ccc 
DNA from relaxed circular DNA requires; i) dissociation of terminal protein (TP) from the 
5' end of the minus strand DNA and removal of a terminally redundant segment from the 
same strand, ii) ligation of the 5' and 3' ends of minus strand DNA and iii) the removal of 
the RNA primer from the 5' end of the plus strand DNA and completion of plus strand 
DNA synthesis. The ccc DNA has an extremely long half life as this form is found in the 
liver cells of chronically infected animals. This indicates that infected cells may maintain 
their ccc DNA pool by reinfection of the hepatocyte (Tuttleman et al., 1986).
Once inside the host cell nucleus, ccc DNA serves as the template for the synthesis 
of viral RNAs using host RNA polymerase II. The ccc DNA preparations from cloned 
DNAs are infectious in vivo (Will et al., 1982; Segeer et al., 1984). Transcription of the 
genome results in both genomic and subgenomic mRNAs. 3.5 kb, 2.1 kb and 2.4 kb 
transcripts have all been isolated from infected liver cells. The 2.1 and 2.4 kb transcripts 
are the mRNAs for surface proteins (Cattaneo et al., 1983; Standring et al.; 1984 and 
Will et al., 1987). The pregenomic RNAs serve as both mRNAs for core and polymerase 
proteins and also as a template for the viral reverse transcriptase (Summers and Mason, 
1982, Enders et al., 1985, Buscher et al., 1985 and Will et al., 1987). The mRNAs are 
transported to, and translated in, the cytoplasm. Virion assembly occurs only when 
sufficient quantities of core, polymerase protein and pregenomic RNAs accumulate in the 
cytoplasm. Core proteins self assemble and encapsidate pregenomic RNA into the 
nucleocapsid along with the viral polymerase.
The core protein alone is able to self assemble via a dimeric intermediate (Nassal, 
1992a; Zhou and Standring, 1992). However, for efficient encapsidation of RNA and 
polymerase, hepadnaviruses have evolved a strategy to package pregenomic RNA along 
with the polymerase into core particles. The polymerase protein binds directly to a cis 
acting recognition site, the encapsidation signal (e) consisting of some 94 nucleotides (nt) 
close to the 5' end of pregenomic RNA (Junker-Niepman et al., 1990). e is a hairpin-like 
secondary structure consisting of two stems, a bulge, a loop and a non-paired U. This 
moderately stable structure is sufficient for encapsidation. Packaging of polymerase 
protein into the core particle occurs via an RNA-protein interaction with the encapsidation 
signal rather than by a covalent bond to the core protein. Mutational analyses revealed that 
the sequence in the loop and first two of the six nucleotides in the bulge are important for 
productive interaction with polymerase protein (Rieger and Nassal, 1995). e is also 
present in pre-core mRNA but due to movement of the ribosome during protein synthesis,
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this RNA can not fold to form the secondary structure (Nassal et al., 1990). e sequence is 
also present in the 3' end of pregenomic RNA, but this copy is not involved in 
encapsidation (Nassal and Schaller, 1993). The 3.5 kb pregenomic RNA is greater than 
genome length and bears a terminal redundancy (R), which includes one copy of the 
encapsidation signal and one copy of direct repeat 1 (DR1). DR1 is an 11 to 12 nt 
sequence located at both the 5' end and 3' end (DR1*) of the pregenomic RNA. A third 
copy of the repeat, called direct repeat 2 (DR2), is located upstream of the DR1*. DR1 
and DR2 are the sequences required for the initiation of minus and plus strand DNA 
synthesis respectively.
As encapsidation proceeds, or after it is completed, reverse transcription of the 
pregenomic RNA begins, generating the minus (-) strand DNA. The pregenomic RNA 
serves as the template for minus strand synthesis. In the woodchuck system, it was found 
that reverse transcription initiates at the 3' end direct repeat 1 (DR1*) on the pregenomic 
RNA, which contains a short sequence (UUCA), essential for initiation (Seeger et al.,
1990). A similar mechanism was observed in HBV where the 3' end DR1* was believed 
to initiate the synthesis of minus strand and, as the synthesis progressed, the RNA 
template was simultaneously degraded by RNase H. It was assumed that minus strand 
DNA synthesis was a continuous process starting de novo from within the 3' proximal 
DR1* and then proceeding continuously along the RNA template (Seeger et al., 1991a). 
However, recent studies suggest that the polymerase protein binds to the bulge of e at the 
5' end of the pregenomic RNA, copies a part of it (Rieger and Nassal, 1996) which is 
complementary to UUCA (Nassal and Rieger, 1996) and this protein-oligonucleotide 
complex is subsequently efficiently translocated to 3' DR1*. This short oligonucleotide, 
covalently linked to the polymerase protein, serves as a short primer for the reverse 
transcriptase (Nassal and Rieger 1996). Two complementary nucleotides at its 3' end are 
sufficient to direct the oligonucleotide to the correct target site (Nassal and Schaller, 
1996). The minus strand DNA remains covalently attached to the TP domain of the 
polymerase protein through a phosphodiester linkage (Gerlich et al., 1980; Wimmer, 
1982). As elongation proceeds, the presence of heterogeneous length DNA of less then 
3200 bases is not uncommon. However, in a full cycle of DNA synthesis, reverse 
transcription continues until the pregenome is completely transcribed. This generates a 9 
nucleotide redundancy (r) in minus strand DNA (Seeger et al, 1991b).
The last step in the viral replication process is plus (+) strand synthesis using 
minus strand DNA as the template. Plus strand DNA synthesis is primed by an RNA 
oligomer originating from the 5' end of the pregenomic RNA, bearing a copy of DR1 
(Seeger et a l, 1986; Will et al, 1987). This DR1 oligoribonucleotide is generated by 
RNaseH activity which degrades the pregenomic RNA. Following completion of minus 
strand DNA synthesis, the RNA primer is translocated to DR2 sequences on the minus 
strand where it acts as a primer for plus strand DNA synthesis (Seeger et a l, 1986).
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During plus strand elongation the genome is circularised but, in a majority of cases, 
polymerisation ceases before the plus strand is complete. Thus the mature virus particle 
contains relaxed circular, partially double-stranded DNA (Summers and Mason, 1982, 
Lien et al., 1986). The reason for incomplete plus strand synthesis remains unknown. 
The envelopment of core particles may result in a shortage of nucleotides, consequently 
leading to premature termination of plus strand elongation
iv) Envelopment of core particles and virion release
Pregenomic RNA is translated to produce core and polymerase proteins in the 
cytoplasm; core particle assembly and genome maturation also occur in the cytoplasm. 
Thereafter, core particles can follow one of the three alternative paths (reviewed by Kann 
et al, 1995): i) they acquire the virion envelope and are released into the blood-stream, ii) 
remain in the cytoplasm and are degraded, or iii) are transported to the nucleus by a still 
unknown mechanism where they maintain persistent infection of the cell.
As with the core and polymerase proteins, translation of LHBs also initiates in the 
cytoplasm as pre-S domains do not contain signal peptide (Gallina et a l, 1992). 
However, as peptide synthesis continues, the signal peptides I and II in the S domain 
insert the growing LHBs into the ER. Signal peptide I rapidly translocates the growing 
MHBs to the ER lumen. After assembly, core proteins exhibit an affinity for ER 
membranes containing inserted LHBs molecules (Bruss and Ganem, 1991). The virion 
envelope is composed of mixed aggregates of LHBs, MHBs and SHBs. During 
secretion, virions and accompanying HBs particles are moved from the ER via the Golgi 
apparatus to the cell surface (Ganem, 1991). During transport of the virion, the glycoside 
chains of HBs proteins are modified and covalent disulphide bridges are formed within 
and between HBc and HBs subunits. Release of HBs particles and virions does not 
require any specific signal (Gerlich, 1993a).
The half life of the core particle within the cell is not known. Many infected liver 
cells contain core particles within the nucleus but most of them appear to be empty due to 
their low density within the nucleus. The entire core particle cannot cross the nuclear 
membrane in either direction (Guidotti et al, 1994a). Thus, one possibility is that core 
particles may be trapped within the nucleus when the nuclear membrane dissolves during 
cell division. Another possibility is that core particles assemble within the nucleus, 
requiring a certain concentration of core protein dimers (Seifer et al,. 1993). This may be 
possible as the core protein contains nuclear localisation signals at its C-terminal end (Yeh 
et al., 1990; Eckhardt et a l, 1991). Any viruses with deletions or mutations in these 
signals fail to accumulate core proteins in the nucleus (Eckhardt et a l 1991).
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1.1.4 TRANSCRIPTION AND ITS REGULATION
i) HBV transcripts
Viral transcripts are produced from a low number of ccc DNA molecules in the 
nucleus using host transcription factors to produce a set of unidirectional and overlapping 
transcripts (Schaller and Fischer, 1991). HBV has four classes of mRNAs which are 
transcribed under the control of two enhancers (Schaller and Fischer, 1991; Siddiqui, 
1991). RNAs initiate from four sets of promoters and terminate at a single 
polyadenylation site. All mRNAs are unspliced and therefore the shorter RNAs are fully 
overlapped by the larger species.
3.5 kb RNAs: The 3.5 kb RNAs are the major transcription products 
comprising the entire genome and including a short terminal redundancy which duplicates 
sequence elements essential for genome replication and circularisation (Seeger et ah,
1991). The core promoter, which is liver cell specific, controls the synthesis of two 
closely related, but functionally unrelated subsets of genomic transcripts, which function 
as pre-core and pregenomic RNAs. Of these, the shorter pregenomic RNA (initiating at nt 
1818) is the most abundant, serving both as both the template for reverse transcription 
and as mRNA for core and polymerase proteins (Schaller and Fischer, 1991). The pre­
core mRNAs initiate 20 to 30 bases upstream of pre-core ORF (1783/84, 1790±1) and 
serve as mRNA for the synthesis of a pre-core gene product (Yaginuma et al., 1987).
2.4 kb RNA: The 2.4 kb RNA or pre-Sl transcript, specifies the synthesis of 
LHBs which spans the pre-Sl, pre-S2 and S domains. In contrast to most other HBV 
transcripts, the pre-Sl transcript is characterised by possessing a unique 5’ end, probably 
specified by a TATA box positioned at an appropriate distance of 30 nt upstream of the 
cap site (Will et al, 1987). Transcription of the mRNA is controlled by a pre-Sl promoter 
element (SP-1) which is highly liver specific and is the least active promoter element in 
HBV.
2.1 kb RNAs: The second major family is the 2.1 kb RNAs or preS2/S 
transcripts, having heterogeneous 5' ends which synthesise two gene products from the 
same ORF. Several shorter RNAs serve for the synthesis of the SHBs whereas the longer 
major species allows the translation of MHBs. Synthesis of these RNAs is controlled by a 
promoter element called pre-S2/S promoter (SP-II), which is not stringently liver specific. 
This promoter lacks TATA-like signals and is similar to the GC rich elements of the 
TATA-less SV-40 late promoter (Cattaneo et al, 1983).
0.9 kb RNA: A transcript of approximately 0.9 kb serves as a separate RNA for 
X-gene expression. The product of X-mRNA is repressed under conditions supporting 
viral replication which reflects their low abundance among the transcripts.
Like other eukaryotic transcripts, all hepadnaviruses' mRNAs terminate in a 
regulated process. Genomes of hepadnaviruses contain one common stop signal,
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TATAAA, shortly after the start site of pregenomic RNA (Ganem and Varmus, 1987). 
This stop signal is active only when the RNA initiation site is more than 400 bases distant 
(Cherrington et al, 1992). Thus, this signal is ignored during the first pass of RNA 
polymerase II after initiation at the core promoter. After transcription, all RNAs are 
modified by the addition of a methylated nucleotide to the 5' end, known as the cap, and 
addition of a poly-A tail at the 3' end. All known HBV RNAs are unspliced although 
numerous potential splice signals are present in RNAs. Spliced derivatives of HBV 
genomic RNAs have been observed in HCCs, in infected liver and in transfected cells (Su 
et al., 1989; Chen et al., 1989; Terre et al., 1991). Their role in the life cycle remains 
uncertain, since mutational inactivation of the splice sites does not impair HBV replication 
in these cells.
ii) Transcriptional regulation
a)C is-acting elements regulating transcription: Promoters are usually 
composed of modular elements consisting of 6 to 10 bases, sometimes palindromic or 
direct repeats. These elements bind single or dimerized transcription factors which co­
operate for the activation or suppression of transcription. A typical eukaryotic promoter 
contains a TATA box approximately 30 nt upstream of the RNA initiation site, to which 
binds a TATA binding protein (TBP), also known as transcription factor HD (TFHD); this 
complex is recognised by RNA polymerase II. In HBV, transcription of the four major 
classes of transcripts is controlled by four functionally defined promoters. These 
promoters direct initiation of RNA synthesis upstream of the core/precore genes, large 
surface gene (pre-Sl), middle /small surface genes (pre-S2/S) and X gene. The pre-Sl 
gene promoter (SP-I) has a typical TATA box and a sharply defined 5' end. As with other 
TATA-less promoters, the mRNAs for preS2/S, core/precore and X-gene have multiple 
initiation sites (Schaller and Fischer, 1991).
All promoter elements and their constituent sequence motifs have been studied in 
detail using conventional techniques, such as chloramphenicol acetyl transferase (CAT) 
assays and their specificity has been examined in cell lines of various origins. In addition, 
the size limit required for maximum activity has been determined by deletion analysis. 
These promoter elements are of varying length and their activity increases in a tissue 
specific manner. In HepG2 cells, the core promoter was found to be stronger than SP-II 
and SP-I in the absence of homologous enhancer. However, when coupled with 
enhancer-I, the core and the X promoters showed similar strengths whereas SP-I and SP- 
II had decreased activity (Antonicci and Rutter et al., 1989). All promoters were more 
active in liver cells than in non-liver cells and the SP-II and X promoters were active in all 
mammalian cell types (Seifer et al., 1990). The pre-S2 promoter requires transcription 
factor SP-1 (Raney et al., 1992) and the large surface gene promoter requires hepatocyte
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nuclear factor-I (HNF-I) (Shaul et al, 1986; Chang et al, 1989). The pre-core/core 
promoter, on the other hand, requires binding to the liver-specific transcription factors 
HNF-III (hepatocyte nuclear factor-III) and C/EBP (CCAAT/enhancer binding protein) 
for its activation (Yuh et al, 1992).
Promoter activities are often regulated by enhancer elements. These regulate 
transcriptional activity of a given promoter in an orientation- and position-independent 
manner. Two enhancer regions with liver-specific characteristics have been detected in 
HBV genome. Enhancer I (Enh-I) is located between the open reading frames of the 
surface and X genes and partially overlaps the X promoter (Shaul et al, 1985; Tognoni et 
al, 1985). The other lies in the X-ORF, upstream of the core promoter and is designated 
enhancer II (Enh-II) (Yee, 1989).
Enhancer I was first mapped at approximately 450 nt upstream of the core 
promoter (nt 1080-1234). It is necessary for core gene expression (Shaul et al, 1985), 
and is activated in both a host- and tissue-specific manner (Siddiqui et a l, 1986). Later 
studies found that the enhancer I element significantly increased the activity of the core, 
surface and X promoters (Chang et al, 1987; Roossink and Siddiqui, 1986). The region 
between nt 964-1217 was found to be essential for X promoter activity (Treinin et a l,
1987). The tissue specificity of the surface promoter was markedly enhanced when 
coupled with enhancer I elements (Bulla and Siddiqui, 1988), however, the X promoter 
displayed considerably reduced tissue specificity, although it contains the same enhancer 
element (Raney et al, 1990; Antonucci and Rutter, 1989). There is however debate 
concerning the liver cell specificity of Enh-I. Studies found that Enh-I stimulated 
heterologous promoters in non-liver cell lines (Vannice and Levinson, 1988), although it 
showed preferential activity for hepatoma cell lines when combined with the core 
promoter (Honigwachs et al, 1989). This may be due to the combined effect of Enh-I 
and core promoter, as binding of transcription factors to the core promoter in hepatoma 
cells allows high transcriptional activity (Yen et al, 1993).
A number of transcriptional factors, both liver cell specific and ubiquitous, bind to 
Enh-I (Dikstein et al, 1990; Trujillo et al, 1991) (Figure 1.3). Only two of them are 
hepatocyte specific: C/EBP, which binds to several sites of Enh-I and shows 
concentration dependent activity (Dikstein et al, 1990), and an unidentified factor called 
hepatitis B liver factor (HBLF), also known as 2c binding factor (Guo et a l, 1991). 
HBLF was shown to play a key role in the overall enhancer function by interacting with 
the ubiquitous factor EF-C (Trujillo et al, 1991), and was later named as HNF-III (Chen 
et a l, 1994). The EF-C recognition site, also known as the EP element, is a 20 bp 
sequence which requires the adjacent GB element for efficient Enh-I function (Garcia et 
al, 1993; Gustin et al, 1993). The GB element is the binding site of HNF-IV, RXRa 
(retinoid X receptor) and also COUP-TF (chicken ovalbumin upstream promoter 
transcription factor). The EP element interacts with transcription factors MIBP1 and
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R FX 1, w hich  associa te  in vivo to form a complex which binds to the MIF-1 element o f  
the c-myc gene (Blake et al., 1996). Finally, Enh-I contains a site that b inds AP-1 and 
C R E B , w'hich appears to mediate transactivation o f Enh-I by X-protein  (Maguire et al., 
1991).
Enhancer or liver- Basal X promoter or
Modulatory domain specific basal module accessory module
963 1301
2c GB EP
E 33 C/EBP Modulatory domain 966-1119
E l HNF-III/HBLF
Liver specific module 1119-1168
P’.'T-I COUP-TF
HNF-IV Accessory module 1168-1308
r x i NF-1 (Trujillo et al., 1991)
m RXRa/PRAR
E 3 MIBP1
Figure 1.3 Schem atic representation o f  the functional domains, individual cis-elem en ts and their 
binding factors in HBV Enh I (nt 966-1308). HNF-III/H BLF binds to 2c site; GB elem ent binds 
to H N F-IV , R X R a/PR A R  and C OUP-TF factors; and EP elem ent or EF-C site interacts with  
M IB P /R FX I. The E elem ent is the binding site for N F-1, C /EBP, C R E B /A TF and A P-1.
Yee (1989) identified a second enhancer (Enh-II) located in a 92 base pair H B V  
D N A  fragm en t spanning  nt 1685-1773, over lapp ing  the core p rom oter  region. It is highly 
tissue specific since it functions only in som e highly differentiated hum an  hepa tom a cell 
lines (H e p G 2 , H uh6). Further studies sh o w ed  that either enhancer cou ld  activate m ajor 
H B V  prom oters  in several hepatoma cell lines (Su and  Yee, 1992) and both together 
affect the overall level o f  HBV gene expression. A  20 base pair sequence  m o tif  w as found  
to be essential for  Enh-II activity (C hen et al., 1993) and any deletion in the region 
between nt 1704-1734 reduced the enhancer activity significantly. S im ilarly , by analysis  
o f  a  series o f  substitution mutations, it w as found  that the region betw een  nt 1707-1718
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represents an essential functional motif of HBV Enh-II. However, the region between nt 
1721-1735 also has an effect on overall enhancer activity. The region between nt 1708- 
1719 shows a similarity with the enhancer element of rat tyrosine aminotransferase (TAT) 
gene and two different enhancer elements of the human transferrin gene, suggesting the 
involvement of common transcription factors.
In parallel, a group in China (Yuh and Ting, 1990), identified Enh-II between nts 
1636 and 1741 which activated the transcription activity of both Sp-I and Sp-II promoters 
in a liver specific manner. The same group (in 1992) identified a region between nt 1744- 
1851 as the basic core promoter (BCP) which directed the initiation of both pre-core and 
pregenomic messages. Sequence upstream from nt 1744 (nt 1636-1743) was referred to 
as the core upstream regulatory sequence (CURS). It has a strong stimulatory effect on 
the BCP. The latter has sufficient promoter activity to allow synthesis of the 3.5 kb 
pregenomic transcripts and virion production, but the addition of the CURS allows 
increased virion production. CURS stimulated BCP by 1900-fold in HepG2 cells and 
180-foid in Huh7 cells. The minimal constituents of Enh-II displaying liver cell specificity 
were identified as box a and box (3 (Yuh and Ting, 1993). Box a  is a 23 nt sequence (nt 
1645-1669) which showed very strong BCP activation in HepG2 and Huh7 cells (120- 
and 14-fold respectively), whereas box (3 (nt 1705-1721) moderately activated the BCP in 
these cells. Gel shift experiments revealed a liver-specific box a  binding protein. A 
negative regulatory element (NRE) upstream of the Enh-II (nt 1613-1636) was identified 
which can repress both the enhancer and the upstream regulatory functions of Enh-II 
sequences (Lo and Ting, 1994). Mutational analysis revealed that the sequence from nt 
1616-1621 was required for repression of enhancer activity by the NRE. The presence of 
the NRE indicates that HBV gene transcription is controlled by the combined efforts of 
both positive and negative regulation.
So far, no canonical TATA or CAAT elements have been found in the core 
promoter. It is therefore not clear exactly what sequence elements regulate the 
transcription of either transcripts. Three AT rich regions have been mapped on BCP 
which function as a TATA box (Okamoto et al, 1994). The first AT rich region, ATA (nt 
1752-1755), and the second TTAAA (nt 1758-1762) are located 23 to 28 bp upstream of 
the initiation site of two pre core mRNAs (nt 1783±1, and 1789±1). The third AT rich 
region, ATAAATT (nt 1789-1795), is the initiation site for the shorter pregenomic RNA, 
which is located 23 bp upstream of the start site (nt 1818). Occasionally in eukaryotic 
systems, a second kind of minimal promoter element, called an initiator, can function as a 
TATA element. An initiator can occupy a position that directly overlaps the start site or 
can also co-operate with a TATA box placed approximately 35 bp upstream, to enhance 
its activity (Smale et al, 1989, Zenzie et al, 1992). A 15 bp sequence in the BCP has 
been identified which directs the precise initiation of both pre-core and pregenomic
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transcrip ts  (Chen et al., 1995). This sequence fragm ent (nt 1790-1804) functions either as 
an initiator elem ent for pre-core or a TA T A  box for pregenomic RNA.
Enh II
NRE CURS BCP
E gg SP-1 = 1623-1632, 1733-1743, 1745-1754 
g g ]  HNF-IV =1652-1684, 1751-1780 
EZ3 HNF-III =1680-1696, 1715-1726 
RXR/PPAR =1753-1779 
C/EBP =1743-1773
rrn  Enh-ll(1636-1741) Yuh et. al., 1990
p p l Enh-II (1685-1773) Yee 1989
P 7] CURS (1643-1742) Yuh et. al., 1992
P71 BCP (1743-1849) Yuh et. al., 1992
I | NRE (1611-1634) Lo et. al., 1994
Figure 1.4 Schem atic representation o f  Enh-II/core promoter com plex and nuclear factor binding 
in different regions.
Like Enh-I ,  a num ber o f  transcription factors bind to the core prom oter/Enh-II 
com plex  (F igure  1.4). One o f  the principal liver-specific factors that b inds  to Enh-II is 
C /E B P  (L opez-C abrera et al., 1990, 19 9 1). Other liver-enriched factors,  H N F -III  and 
H N F -IV ,  have also been shown to transactivate by binding to the upstream  sequence 
(Y uh et al., 1992; Johnson et al., 1995; G ou et al., 1993). It b inds to the transcription 
fac to r  T F -IID  and also to SP-1. Recently , three b inding sites for transcription factor SP-1 
have also been m apped in the core prom oter (Zhang et al., 1993). A  very recent study 
sh o w ed  that a m em ber of the nuclear receptor superfam ily which includes R X R , PR A R  
(perox isom e proliferator-activated receptor), C O U P T F l  and A R P  l bind to the B C P  and 
can m odulate  the level of transcription (Raney et al., 1997).
T he two surface promoters are only approxim ate ly  400  bp apart,  but are regulated 
quite  differently. The pre S l prom oter (SP-I) has a classic T A T A  box with a Y Y l  initiator 
m o tif  at the transcriptional initiation site (Seto et a l, 19 9 1). The transcription factor H N F -  
I b inding  site lies approximately 75 bp upstream o f  this m otif (C h an g  et al., 1989). 
A lthough H N F -I  is a liver specific factor, a ub iquitous factor, O ct-1 , is required  fo r  its 
function (Z ohu  et al., 1991a). A nother binding site for  the transcription factor H N F -I I I
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has been mapped 54 to 65 nt upstream of the TATA box. The pre-S2/S promoter (SP-II) 
is TATA-less, but contains at least two regions that can individually initiate transcription 
(Zohu et al., 1991b). The upstream initiator transcribes mRNA for MHBs, while the 
downstream one transcribes SHBs.
b)Transcription regulation by viral gene product: When the HBV 
genome was first sequenced, an ORF coding for a polypeptide of approximately 17kD 
was identified. Since it did not correspond to any known HBV proteins nor showed any 
homology to other proteins it was named 'X'. Nowadays X protein continues to remain 
an enigma. Based on its position at the 3' end of the viral transcripts and the evolutionary 
relatedness of HBV with retroviruses, it was postulated that X protein may be a regulator 
of gene expression, similar to the HTLV-1 tax protein (Miller and Robinson, 1986).
In most viruses, the first gene products to be expressed are transcription factors 
which activate promoters of other viral genes in a temporally ordered manner. Such 
products are called immediate early (IE) genes. For HBV, the time order of gene 
expression has not yet been analysed, but it has been speculated that HBV X protein 
(HBx) is the first protein to be expressed (Wu et al., 1991), as peak levels of X 
transcripts were observed in the early stages after transfection; however, these transcripts 
disappeared quickly.
The X gene product is capable of stimulating activity of a variety of viral and 
cellular promoters including both the HBV enhancers and the core and surface gene 
promoters. The X protein transactivates transcription from a wide range of viral 
promoters coupled to HBV enhancers, including the long terminal repeat of HIV-1 (Seto 
et a l, 1988), Rous sarcoma virus and SV-40 enhancer/early promoters in CV-1 cells 
(Spandau and Lee, 1988) and the herpes simplex virus thymidine kinase (HSV-TK) 
promoter (Spandau and Lee, 1988). The cellular promoters include the c-fos and c-myc 
promoters, the (3 interferon promoter and also HLA-DR and MHC class-1 promoters 
(Balsano et al., 1991; Zhou et al., 1990). In addition the list also includes RNA 
polymerase III promoters (Aufiero and Schneider, 1990). An 8 to 10 fold stimulation of 
the synthesis of HBsAg, HBcAg and genomic transcripts by X-transactivation of HBV 
genomes lacking a functional X gene has been observed in human hepatoma cells during 
transient expression of X gene (Colgrove et al, 1989). An increased level of activity has 
been reported for the corresponding promoters when coupled individually to reporter 
genes such as cat (chloramphenicol acetyl transferase) or luc (luciferase) (Colgrove et al., 
1989, Raney et al., 1990). The mechanism responsible for activation by the X protein is 
not clear, but its interaction with many targets seems unlikely in view of the low 
concentration in HBV infected liver cells (Pfaff et al, 1987). X protein does not directly 
interact with cw-acting DNA elements, but some data suggest it activates the formation of 
diacylglycerol, a protein kinase C activator which phosphorylates the transcription factors 
AP-1 (Kekule et al, 1993), AP-2 (Seto et a l, 1990), ATF-2, CREB (Maguire et a l,
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1991) and possibly SP-1 (Lucito and Schneider, 1992). These factors act on many 
promoter/enhancers including that of HBV. The X protein also interacts with the TATA 
binding protein (TBP), suggesting that it plays an important role in modulating the 
tanscriptional regulatory pathway (Qadri et al, 1995).
However, there is much debate regarding the role of X protein in the viral life 
cycle. There is no X gene in duck hepatitis B virus (DHBV), raising the question whether 
the X protein is essential for viral gene expression and replication. Blum et al. (1992) 
showed that a nonsense mutation in the X gene in an HBV genome still allows the 
synthesis of wild type levels of viral proteins, replicative intermediates and virion export 
when transfected into either hepatoma cells or primary rat hepatocyte cultures. In contrast, 
Colgrove et al., (1989) had previously shown, in almost identical experiments, that an 
HBV genome with a mutated X gene initiation codon expressed approximately 10 fold 
lower amounts of viral transcripts than wild type HBV upon transfection into hepatoma 
cells. This study also demonstrated that transactivation of HBV and heterologous genes 
occurs when X protein is expressed in its native state. The contradiction of these studies 
may be explained due to the use of a dimer form of the genome in the plasmid by Blum et 
al., while the latter group used recircularised DNA.
Nevertheless, since the X gene is conserved in all mammalian hepadnaviruses, 
and as the X protein has a transactivating function, it is likely that this transactivation is 
important in the viral life cycle. In woodchuck, WHV X protein deficient mutants were 
viable for replication in vitro, but levels of viral DNA were reduced in transfected cells. 
The mutants, however, did not initiate a detectable infection in susceptible woodchucks 
(Zoulim et al., 1994). Therefore, X protein is indispensable for viral infection in vivo. 
Furthermore, the X protein plays a key role in HBV-associated carcinogenesis, since X 
protein can transform cells in culture (Hohne et al, 1990) and some strains of transgenic 
mice expressing high levels of the protein develop HCC (Kim et al, 1991).
1.1.5 HBV: PROTEINS
i) Core
The HBV core protein (HBcAg) is a 183 or 185 amino acid (aa) polypeptide with 
a molecular weight of approximately 21,399 daltons (p21). Translation of HBV core 
protein initiates at the second ATG, 29 codons downstream of the core ORF (Ou et al.,
1986). Core protein contains many hydrophilic, charged amino acids and is 
phosphorylated in vivo and in vitro when expressed from either heterologous or 
homologous promoters (Roosinck and Siddiqui, 1987). Phosphorylation of core protein 
occurs at serine 170 or 172 and phosphorylated core protein can assemble into particles in 
the absence of viral genomes (Roosinck and Siddiqui, 1987). Core protein is translated in 
the cytoplasm of infected cells. It packages the pregenomic RNA and the polymerase 
protein as it assembles into core particles or nucleocapsids. A cellular protein kinase C is
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also packaged within the particle (Albin and Robinson, 1980), Expression of core protein 
in vitro a so leads to the formation of empty core particles with a diameter of 27 nm 
(Pasek e ta l,  1979).
tional studies have provided convincing evidence that the core polypeptide 
contains two functionally distinct domains. The first 147 or 149 residues of core 
po ypeptide form a hydrophobic domain which is resistant to proteolytic digestion (Seifer 
' domain enables core proteins to self assemble inlo core particles
1989). In contrast, the last 36 residues of core polypeptide are extremely 
g ch and display a protamine-like structure which is referred to as the protamine 
domain (Gallina etaL, 1989). This domain is highly protease-sensitive and is involved in 
cid interactions (Nassal et al., 1992b) during packaging of the pregenome. The 
arginine residues are clustered in four blocks, three of which contain the motif 
 ^  ^ ^  deletion analysis, it was found that HBV core proteins truncated up to aa 
from the C terminus are assembly-competent for capsid formation (Gallina et a l, 
89; Stahl er al, 1989). Bimbaum et a l (1990) showed that core protein up to 144 aa 
ong can form core particles in bacteria whereas deletion beyond residue 139 abrogated 
P mbly. Effective encapsidation of viral genomes requires at least 164 amino 
acids from the amino-terminal (N-terminal) end; variants ending at aa 164 have a 
y reduced capacity to complete positive strand DNA synthesis, which makes the 
terminal domain an essential component in HBV replication (Nassal et al, 1992b). 
t the N terminus are more deleterious, as truncation up to residue 10 prevents 
capsid formation (Salfeld et al, 1989). However, chimeric core polypeptides bearing 
reign sequences in the epitope regions and at the C-terminal regions still 
pro uce particles (Seifer and Standring, 1995). A minimal assembly domain of HBV core 
polypeptide thus requires approximately 130 aa residues (10-144).
oncentration of HBc polypeptide is also important for assembly. First the 
core protein dimerises (Zhou and Standring, 1992), requiring a minimal concentration of 
0.8 pM (Seifer al, 1993). These dimers then assemble to icosahedral particles of T=3 
1 QQ SU^ Un^ S core protein monomers forming one particle (Bimbaum et a l,
 ^ COre are assembled their structure is stabilised by disulphide bonds
(Zhou and Standring, 1992; Nassal eta l, 1992b).
ii) HBeAg
epadnaviruses have evolved the ability to express a secretory form of core 
protein known as HBeAg or e antigen. As HBeAg is translated from the first ATG of the 
core ORF, it contains 29 amino acids upstream of the core start codon (Ou et at., 1986), 
precore sequence. The first 19 aa of this amino-terminal extension act as a 
signal peptide which translocates the protein into the endoplasmic reticulum (ER) as p25e 
mss and Gerlich 1988; Standring e ta l, 1988). During the secretory pathway, 19 of
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these 29 amino acids are cleaved off by the signal peptidase which generates an 
intermediate protein product that remains in the ER or is released back to the cytoplasm as 
p23e (Garcia et al, 1988) The remaining 10 aa of pre-core sequence prevent the assembly 
of HBeAg into core particles by interacting with the HBV core protein sequence 
(Wasenauer et al., 1992). p23e is either secreted from HBeAg-producing cells or 
incorporated into the outer cell membrane for expression (Schlicht and Schaller, 1989). 
This membrane-expressed p23e may play a role in the antibody-mediated elimination of 
infected cells. The p23e in the ER is further cleaved at the arginine rich C-termmal domain 
by a Golgi protease and is secreted from the cell as pl6e, pl8e or p20e; all three of these 
share identical N-termini but have different carboxy ends (Wang et a l, 1991). 
Sometimes, part of the HBe protein does not reach the ER but remains in the cytoplasm as 
the uncleaved form p25e. Like core protein, p25e contains a nuclear transport signal at the 
arginine rich carboxy domain (Yeh et al, 1990). Thus, HBe proteins of variable length 
are found in all compartments of the cell. However, HBe protein has not been detected in 
any of the compartments of hepatocytes in transgenic mice, using immuno-histochemical 
techniques (Guidotti e ta l 1994).
HBeAg is not essential for the viral life cycle and its exact function in the biology 
of HBV infection is still unclear. HBeAg is found in the serum of HBV infected 
individuals where it generally correlates with a high level of viremia. Elimination of 
HBeAg is generally accompanied by detectable levels of anti-HBe immune response and a 
decrease in viremia. HBeAg non-producing variants of woodchuck hepatitis virus (WHV) 
were found to be infectious for new born woodchucks but it could not induce persistent 
infection (Chen et al, 1992). This suggested that HBeAg suppresses the immune 
elimination of HBeAg-expressing cells, possibly by blocking cytotoxic T cell activity 
against HBV core associated epitopes (Milich et a l, 1990). Infants bom to HBeAg 
positive mothers become chronic carriers in more than 90% of the cases (Stevens et a l, 
1975). In contrast, HBV infection in adult age leads to chronicity in about 5-10% of the 
cases (Aldershvile et al, 1980). This may be due to immunologic tolerance in neonates 
induced by viral proteins to which they are exposed in utero (Thomas et al., 1988), 
shown in transgenic mice (Milich eta l, 1990). The HBe/HBcAg-specific T cell tolerance 
may be due to the secreted HBeAg gaining acceiss to the thymus and leading to functional 
deletion of HLA class-II restricted HBe/HBcAg-specific T helper (Th) cells (Milich et a l , 
1991).
In similarity with the duck system (Chamg et al., 1987), HBeAg seems to be non- 
essential for viral replication in human. HBeAg negative HBV strains appeared to be 
highly replicative than HBeAg producing strains when transfected into HCC cells 
(Lambert et a l, 1993). Transient over-expression of pre-core gene resulted in striking 
inhibition of HBV replication (Scaglioni et al., 19'97). This was due to interaction of non­
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secreted p23e with core protein (p21) forming hybrid core particles devoid of pregenomic 
RNA.
iii) Surface
All three HBV surface proteins are encoded by a single open reading frame of 389 
or 400 codons depending upon the subtype. Three polypeptides are produced from three 
in-phase start codons in the S open reading frame. The three proteins are termed LHBs, 
MHBs and SHBs. The LHBs is a 39 kD protein translated from first ATG of the S ORF 
(Heerman et al., 1984); initiation at the second ATG generates the 31 kD MHBs (Machida 
et al., 1983). Both share the common C-terminal S domain and are quantitatively minor 
components of the circulating pool of surface related antigens. MHBs accounts for 
approximately 5-15% of the total, and the LHBs represents only 1-2% of the total 
(Ganem, 1991) HBs proteins, while SHBs is the most abundant. All three proteins are 
found either glycosylated or unglycosylated at Asn 146 of the SHBs sequence. The 
MHBs is additionally glycosylated at Asn 4 (Heerman and Gerlich, 1991). Extensive 
production of surface proteins reveals a large number of non-infectious particles in the 
sera of highly viremic carriers. Most abundant are spheres of 17-25 nm; less abundant are 
filaments of 22 nm diameters of variable length.
a) Small surface protein: SHBs is synthesised on membrane bound 
ribosomes of the rough ER and consists of a 226 amino acid (aa) long polypeptide chain. 
Expression of SHBs in cell culture results in the secretion of 22 nm HBs particles, 
suggesting that no other viral factor is necessary for sub-viral particle formation (Liu et 
al., 1982). This is in contrast to the 42 nm virion, for which SHBs alone is not sufficient 
(Brass and Ganem, 1991). SHBs appears as both unglycosylated 24 kD or glycosylated 
27 kD forms, and its sequence contains three hydrophobic regions separated by two 
moderately hydrophilic domains. The hydrophobic regions are folded into a  helices; the 
amino terminal helix from aa 11-29 constitutes the signal polypeptide I and helps to 
translocate the protein into the ER (Eble et al., 1990). The second hydrophobic helix, aa 
80-90, constitutes signal II, and allows translocation of downstream sequence (Eble et 
al., 1987). Between the first two hydrophobic domains is the first hydrophilic region (aa 
29-79), and is exposed on the cytoplasmic side of the ER membrane. This domain lies on 
the interior of the virion particle and may facilitate attachment of the virions as well as the 
envelopment of the core particles (Prange and Streeck, 1995).
The second hydrophilic loop, consisting of aa 99-168, faces into the ER lumen 
where it acquires carbohydrate modification (Eble et al., 1987; Stirk et al., 1992). This 
hydrophilic region carries the major group- and subtype-specific epitopes and forms the 
outer surface of SHBs spheres, filaments and virions. This region contains clusters of 
cysteine residues that form inter- and intramolecular disulphide bridges (Guerrero et al.,
1988). Eight of the 14 cysteine residues present in SHBs are located in this domain.
20
Chapter-1 Introduction
These are highly conserved among the HBV subtypes (Prange et al., 1995) and when 
cross-linked, result in a very compact protease sensitive structure. Sequence between aa 
124-147 is widely known as the 'a' determinant which is common to all subtypes 
(Gavilanes et al, 1982). This very important conformational determinant was proposed to 
form a double loop structure by cross linking between cysteine residues (Ashton-Rickardt 
and Murray, 1989). Antibodies raised against this determinant are important in inhibiting 
virus binding to hepatocytes (Petit et a l, 1991). However, recent evidence from natural 
variants and the complexity of the epitopes suggest that this epitope cluster could include 
the entire hydrophilic region and is presently termed the major hydrophilic region (MHR) 
(reviewed in Wallace and Carman, 1997).
Almost all characterised antigenic subtypes have sequence variations in the area 
between aa 120-160. The most common subtype determinants are d or y (Le Bouvier, 
1971) and w or r (Bancroft et al, 1972). These specificities have allowed identification of 
four subtypes, adw, ayw, adr and ayr, where a is common to all subtypes. Determinant d 
contains a lysine at position 122, whereas y has an arginine (Peterson et a l, 1984). 
Similarly, determinant w has a leucine at position 160, whereas r has an arginine 
(Okamoto et al, 1988). Replacement of these basic amino acids by other amino acids 
causes total loss of subtype determinants (Okamoto et al, 1988). Recently a further 
putative subtype allele that has either isoleucine or threonine at position 126 of SHBs has 
been identified (Ohnuma et al, 1993). Other aa exchanges are also important for the 
formation of subtype specificity (Gerin eta l, 1983). Subtyping by monoclonal antibodies 
or by sequencing gives a much larger number of subtypes than classical serology. Allele 
w can be subdivided into further subspecificities w 1 to w4 (Heermann and Gerlich, 
1991). These subdivisions make a total of 8 subtypes, two adw , four ayw, adr and ayr. 
With the identification of the q determinant (Maginus et a l, 1975), the number increased 
from eight to nine. This subdivides adr into adrq+ or adrq\ The occurrence of subtypes 
depends on ethnic group or epidemiologic relation. Among the four main subtypes, adw 
and ayw are predominantly found in Western Europe (Schmidt et a l, 1972), while adr 
and ayr are confined to the East Asian population (Courouce et a l, 1974). The subtype 
adw4 is found in Western Amazonia and in Polynesia, suggesting a common origin of 
these populations. Six genotypes A-F have been identified, which differ by more than 8% 
in their protein sequence (Okamoto et al, 1988; Norder et a l, 1992). Genomes encoding 
subtype adw were found in the genomic groups A, B and C, while genomes encoding 
ayw were all in genotype D. Subtypes adr and ayr occurred in genotype C alongside adw 
(Okamoto et a l, 1988). In a later study from Indonesia, genomes encoding ayw were 
also encountered in genotype B (Sastrosoewignjo etal., 1991). S genes of subtype ayw4 
and adw4 differed by 4% or more from all previously defined genotypes and from each 
other, which eventually classified them as two new genotypes, E and F respectively 
(Norder et al, 1992).
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b)MiddIe surface protein: MHBs is a minor component of the virion and 
contains the S domain and the 55 aa long pre-S2 domain (Stibbe and Gerlich, 1983). The 
pre-S2 domain is hydrophilic, protease sensitive and contains no cysteine residues. It is 
exposed on the surface of the virion of HBs particles and sometimes partially covers the S 
domain of MHBs. Treatment of HBs spheres with trypsin cleaves MHBs at arginine 47 
(Stibbe and Gerlich 1983) and increases the HBs reactivity of that particle (Heermann et 
al, 1984). The pre-S2 domain is cotranslationally translocated into the ER lumen by 
signal-I in its downstream S domain (Eble eta l, 1990). MHBs is glycosylated at Asn 4, 
therefore the 30 kD unglycosylated form appears as a 34 kD N-glycosylated form in 
polyacrylamide gel analysis. Additional N-glycosylation in the S domain results in a 36 
kD protein.
Pre-S2 domains bind to artificially polymerised human serum albumin (pHSA) 
(Machida e ta l, 1984; Krone et al, 1990). A correlation between high level viremia and 
the presence of pHSA receptor was observed in many studies. Only pHSA of primate 
origin bound to pre-S2 domain of MHBs (Machida et a l 1989; Neurath et al, 1988). 
Furthermore, pHSA binds to liver cells, although its binding is not species-specific 
(Trevison et al, 1982). Antibody against the pre-S2 domain (aa 1-24) was able to 
neutralise HBV in experimentally infected chimpanzees (Neurath et a l, 1986) and 
immunisation of chimpanzees with a conjugated pre-S2 peptide (aa 14-32) or the whole 
pre-S2 domain protected them against HBV challenge (Itoh et al, 1986).
HBV particles from carrier plasma bind to HepG2 cells in an organ and species 
specific manner after prolonged incubation (Heermann and Gerlich, 1991), and this is 
mediated by a glycoside structure linked to pre-S2. Recombinant MHBs from mouse 
fibroblasts that contains a simple mannose rich glycan in the pre-S2 domain does not bind 
to HepG2 cells, while recombinant MHBs from Chinese hamster ovary (CHO) cells 
containing a mixed type of glycan does bind (Gerlich et a l, 1993b). The receptor for this 
site is probably a liver cell lectin specific for mixed types of N-linked glycan. Lectin is 
absent or has a very low activity in fresh liver membrane, suggesting that it may not play 
an important role in natural infection process (Pontisso et a l, 1989). In vivo HBV 
infection is highly efficient while hepatoma cell lines can barely be infected, although they 
can be transfected efficiently (Sells et al, 1987). This raises the question as to whether 
the postulated lectin is related to a certain state of differentiation or dedifferentiation of the 
liver cell.
The pre-S2 domain is more immunogenic then HBsAg (Neurath et al, 1984). The 
epitopes are not conformational and can be generated easily by synthetic peptides 
(Heermann et al, 1987). Several subtype-specific epitopes are present in the pre-S2 
domain (Neurath et al, 1990). The pre-S2 sequence is conserved between subtypes in the 
N-terminal portion in contrast to the highly variable C-terminal portion.
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c) Large surface protein: LHBs consists of three domains: pre-Sl, pre-S2 
and S. In the mature virion or HBs particles, the pre-S domains are accessible to 
antibodies (Heermann et al, 1984), receptors (Neurath et al., 1992) and proteases 
(Heermann et al, 1987). During translation, the entire pre-Sl domain of LHBs faces the 
cytoplasmic side of the ER membrane (Brass et al, 1994; Prange and Streeck, 1995). 
Like the pre-S2, pre-Sl does not contain any signal sequence or hydrophobic region, 
however, signal-II of the S domain directs the LHBs to the ER (Brass et al., 1996). Asn 
4 of the pre-S2 domain and Asn 15 of the pre-Sl domain are unglycosylated, probably 
due to their cytoplasmic location (Heermann et al., 1984). The pre-Sl domain contains no 
cysteine residues and the protein is myristylated at Gly 2 (Persing et al., 1987). During 
virion or HBs particle maturation, the pre-Sl domain is reconfigured and translocated to 
the surface of the particles (Gerlich, 1993a). Over-expression of LHBs was found to 
prevent the secretion of virions (Persing et al., 1986), but formation of 20 nm filaments 
occurs within the ER (Chisari eta l, 1987). The accumulation of LHBs in the ER results 
in the formation of 'ground glass' cells viewed using light microscopy (Chisari et a l,
1987); retention of LHBs in the ER is due to a short peptide from aa 6-19 (Kuraki et a l, 
1989). Morphological change from HBs spheres to HBs filaments results when there is 
an increased proportion of LHBs produced in transfected cells (Marquardt et a l, 1987), 
suggesting that the LHBs is responsible for the morphology of HBs filaments.
The pre-Sl domain of LHBs functions as an attachment site of HBV to liver cells 
(Neurath et al., 1986). The peptide from aa 27-48 of pre-Sl domain is believed to 
recognise a cellular receptor since antibody against this peptide resulted in inhibition of 
attachment. A direct correlation was found between the degree of binding and the 
proportion of LHBs in natural HBs particles. Virions bound better than HBs filaments, 
which bound much better than spheres (Pontisso et al., 1989). The pre-Sl attachment site 
was also found to recognise monocytes and lymphocytes (Pontisso et al., 1992), 
membrane bound interleukin-6 (Neurath etal., 1992) and competed with an IgA receptor 
on the liver cell membrane (Pontisso et al., 1992).
The pre-S 1 domain is one of the most variable regions of the HBV genome. This 
may be due to its overlap with the polymerase ORF in an area not essential for replication 
(Gerlich, 1993a). Alternatively, it may be that the surface structure is more intensively 
selected for by immune pressure. However, within the chronically infected person, or 
within a defined chain of infection, pre-Sl is not usually mutated (Uy et al, 1992).
iv) X protein
The transactivation function of the X protein is discussed earlier. The smallest of 
HBV ORFs was initially designated as 'X' because its function was not known at that 
time (Galibert et al, 1979). The X ORF partially overlaps with Enh-II/CP, DR2, DR1,
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pre-core and pregenomic RNA start sites and also the 5' end of the polymerase gene. 
HBV X protein (HBx) consists of 154 aa residues and its exact function is still unknown. 
Expression of X ORF in prokaryotic and eukaryotic cells resulted in the formation of a 
16.5 kD polypeptide that reacted with serum samples from HBV infected individuals 
(Meyer et al, 1986; Pfaff et al., 1987). Anti-HBx antibodies have been detected in acute 
infection (Vitvitski-Trepo et al, 1990), but more frequently in chronic carriers with active 
disease (Haruna et al, 1991). In vivo, HBx is localised to the cytoplasm, nucleus or cell 
membrane (Wang et al, 1991) and in vitro , to the nucleus (Hohne et al, 1990).
Apart from transcriptional transactivation, HBx may play a key role in HBV 
associated carcinogenesis. High level expression of X gene was found to induce 
malignant transformation of certain culture cells, like NIH3T3 cell line (Shirakata et a l,
1989). Such activity was also observed in immortalised hepatocytes expressing SV-40 
large tumour antigens (Hohne eta l, 1990). Integration of HBV DNA and overexpression 
of HBx was evident in hepatoma cell lines and in human hepatocellular carcinoma (HCC). 
Recently, it has been found that X protein inhibits p53 gene function in vitro (Wang et al., 
1994); in transgenic mice, X protein induces liver cancer (Kim et al., 1991).
HBx has no direct DNA binding activity. Therefore, its fra«s-activating and 
oncogenic function is probably mediated by protein-protein interactions with a number of 
cellular proteins. The hypothesis is that HBx may bind to form a stable complex with 
cellular factors. HBx binds to CREB or ATF-2, two factors through which it apparently 
can effect transactivation in vitro and alter their DNA binding specificity (Maguire et al., 
1991). HBx was also found to act by inhibiting the digestion of cellular factors, since it 
has a sequence similarity to pancreatic trypsin inhibitor (Takada and Koike, 1990). Amino 
acid substitution in this region can affect transactivation function.
It was suggested that HBx may enzymatically modify a host factor by 
phosphorylation as it has protein kinase activity (Wu et al, 1990; Schek et al, 1991). It 
also has dinucleotide kinase (Shaul, 1991) and protease inhibitor (Arii et a l, 1992) (or 
squelching factor) activity (Shaul, 1991). It was found that X protein has an amino acid 
sequence homologous to the functionally essential region of the kunitz-type serine 
protease inhibitor known as the kunitz domain (Takada and Koike, 1990). This kunitz 
domain-like region of X protein was indispensable for its transactivating function. Three 
separate sites of HBx, aa 65-72, aa 105-115, and aa 131-142, also known as U22, XI 
and Z44 site respectively were found to interact with cellular proteins (Takada and Koike, 
1994). Furthermore, these interaction sites also coincide with the structures necessary for 
serine protease inhibitor activity.
v) Polymerase
The longest ORF in the HBV genome encodes the viral polymerase protein, which 
consists of four domains (Schlicht et al, 1991). The N-terminal domain encodes for
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terminal protein, necessary for priming of minus strand DNA synthesis, also known as 
primase. The next domain functions as a spacer. The third domain encodes for reverse 
transcriptase, and the last carboxy domain is RNaseH domain. Like retroviral reverse 
transcriptase, HBV polymerase protein also contains amino acid motif YMDD at aa 535- 
539 and sequence comparisons with known proteins with RNaseH activity revealed a 
weak homology at a position located downstream to the YMDD sequence (Johnson et al., 
1986). Mutational analyses of polymerase gene revealed that the YMDD motif is essential 
for reverse transcriptase activity and mutations in the RNase H homology region can 
result in the production of polymerase protein that still produces minus strand DNA but 
devoid of plus strand synthesis (Radziwill et al., 1990). Polymerase protein is also 
indispensable for its encapsidation function. Several point mutations, deletions and 
insertions throughout the gene revealed that all functional domains in the gene product are 
an absolute requirement for the encapsidation of pregenomic RNA and that the packaging 
function of the polymerase protein is separated genetically from its enzymatic activity 
(Bartenschlager et al., 1990).
1.1.6 MOLECULAR VARIANTS OF HBV
RNA viruses and retroviruses have a tendency to high rates of nucleotide 
substitution in their genomes (Holland et al, 1982), because of polymerase errors 
associated with the lack of a proof-reading function of reverse transcriptase (Steinhauer 
and Holland, 1987). Thus, multiple variants can be generated by replication competent 
strains constituting the 'quasispecies'. Variants without any phenotypic effect, known as 
'silent mutants', become incorporated into the mixture of strains by random sampling and 
others are selected by host immune pressure, antiviral agents or differences in cell biology 
(Carman et al., 1993a). In HBV the genome is more constrained than in retroviruses, 
however, these processes are clearly common (Carman et al., 1993a; 1993b).
i) Pre-core gene
The pre-core and core proteins are translated from the common ORF and are 
initiated from two different start codons but have a common stop codon. The pre-core 
region, which is the 87 nt upstream of the core ORF, is indispensable as it contains the 5 ' 
end of the encapsidation signal (Junker-Niepmann etal., 1990), DR1 and the start site of 
pregenomic RNA. Variation in the pre-core region affects the secondary structure of the 
RNA encapsidation signal. There are certain epitopes for B and T cells which are common 
between the two proteins, others are peculiar to one polypeptide. The difference in the 
antigenic epitopes between the two proteins may be because of conformational differences 
related to the 10 aa pre-core peptide at the N-terminal end of HBeAg and the C-terminal 
arginine rich domain of the HBeAg (Carman et al., 1993b). HBeAg is not essential for 
the viral life cycle as it is not a structural component of the virion (Chen et al., 1992).
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Nevertheless, HBeAg is important as it is believed to play a role in modulating the host 
immune defence against HBV (Thomas eta l, 1988; Carman et al, 1992a). Variations in 
the pre-core gene can interfere with HBeAg production and thus affect host immune 
response. Clearance of virus is accompanied by the elimination of infected hepatocytes by 
cellular and humoral immune responses. There is little evidence that B cells play a major 
role in the clearance of virus during acute infection but a number of studies suggest T cell 
epitopes are recognised by cytotoxic T lymphocytes (CTLs), at least in the acute phase 
(Mondelli et al., 1982; Bertoletti et al., 1991). Although the exact mechanism is 
unknown, during chronic hepatitis the initial target is probably HBeAg, presented on the 
hepatocyte membrane (Schlicht and Schaller, 1989; Yamada et al., 1990), which may 
result in the elimination of HBeAg producing cells. Thus, the HBeAg non-producing 
virus may escape from the host immune response and be 'selected' from HBeAg 
producing strains.
The most common variant in the pre-core region is a G to A variation at nt 1896 
(AI896), resulting in the premature termination of pre-core protein (Carman et al, 1989; 
Brunetto et al., 1989; Tong et al, 1990; Okamoto et al,. 1990). This mutation converts 
the TGG, a tryptophan at codon 28 to TAG, a stop codon. Since it occurs upstream of the 
core start codon, and as the core protein is produced from a separate mRNA, core particle 
production is not affected (Figure 1.5). Other mutations have also been described in the 
pre-core region. These are either an insertion/deletion leading to a frame shift (Santantonio 
et al., 1991), appearance of an in-frame stop codon or a mutation within the pre-core start 
codon (Foirdalisi et al, 1990) (Figure 1.6). A G to A mutation at nt 1897 (A1897) results 
in the stop codon TGA. A mutation at the pre-core start codon (ATG to ACT or to ATA), 
deletion in any of the four Gs at nt 1896-1899 leading to frame shift of codons, also 
results in an HBeAg negative phenotype (Fiordalisi et a l, 1990; Okamoto et al, 1990). 
All these interfere with the synthesis of HBeAg. Variants associated with pre-core amino 
acid substitution have also been reported (Carman et a l, 1992b; Boner et a l, 1995); 
substitution of proline by serine at aa 15 was found in anti-HBe positive Chinese patients. 
This occurs due to a nt variation at 1856 (T1856), which is never detected in patients 
containing Alg% variant. Fifty per cent of the patients with T1856 also shared a G to A 
substitution at 1898, where a glycine is converted to serine, but its functional significance 
is not clear. Another mutation from G to A at nt 1899 has been described in some studies 
(Carman et al, 1989; Brunetto et al, 1989; Naoumov et a l, 1992), mostly linked with 
A 1896- Again, its exact role in disease severity is still unknown however it was mostly 
found in severe cases and rarely found alone in HBeAg positive cases.
26
©c
03
oo
CD
CD
00
ccci__oo
CD
CD
CO
CD
'cS'
(X
O
o
o
0)
CL
03x
CD 
< —  
I -
o
o
CCo
o
o
03
CD 
C^-
0
CO
o3TJ
O
C
o
COc
2
h1
o
aL0
CM
Q_
CD
<03
CQ
X
CD
<
Ocox
CD
<o
CQ
X
Cl. CO 
<D C
t  I
C  «3oo V
‘55 U
0  aH << HII II
o  ®
03
<
- ac
o3
a
o
.0
03
1—
0  u
1
03
(->
CL
0—
O
CO
U33T3
O
1—
O h
c
o
c
03
1—
H
ITi
03
u
3OX
c
x
a
H<
03
E
03
— o
Uh ifa
2
O
03
-a
03
o3
u- a
<D oS
S-c
O 
13
o  4-J
s  sryi ' o3 
03
X)
gx<a
CQ
X
03t-i
o3co
C
"3
o!—
O h
o
CQ
QQ
-ac3
03
CQ
X
03
C3
T 3
03
4—1
03
03
&
03
S-H
03
C
03
GX
X
03
X
£
<
CO
O n
OO
c3
CM O  
CM X  
CL 3
GX to  
<  *3
f f l  3  
E  C
t+- 3
°  a , 
O  X
3
03
03v-
CL
03
X
C/3
03in
CM
CL
cd2
o
03 
GX
.£'55
CL
03
X
H
J 3
03
'E
oS
c l
27
tr
an
sl
at
io
na
l 
sto
p 
co
do
n 
at 
am
in
o 
ac
id 
po
si
tio
n 
28 
in 
the
 
pr
e-
co
re
 
re
gi
on
, 
st
op
pi
ng
 
pr
od
uc
tio
n 
of 
H
B
eA
g.
Chapter-1 Introduction
Pre-core start codon 
1814
Start of £
a t g I c a a  CTT TTT CAC CTC TGC CTA ATC ATC TTT TGT TCA TGT CCT 
  A  A I
1858
/ I  \ w
T C C  T A T T T
TT
1859 ^  ^
ACT GTT CAA GCCTCC AAG CTG TGC CTT GGGTGG CTT TGG GGC
| I I I I
A A A AA
A Nucleotide insertion 
*  Nucleotide de etion
Core s:art codon 
1901
AT3
Figure l .6 Som e variants identified in the pre-core region. Pre-core and core start site> 
are show n in box. Start o f  encapsidation signal is shown by arrow.
A 1896 frequently appeal in chronic carriers in the M editerranean (Carman et al., 
B iunetto  ct al., 1989) and Far Eastern countries (O kam oto  et al., 19°0) during  
oconversion  to anti-HBe and is associated with high level viremia. It is less com m on in 
SA  and Not them Em ope which is genotype dependent.  In genotypes B, C. D  and 
the H B V  genom e contains a T at nt 1858 ( T l858), which is opposite  nt 18%  in the 
vps ida tion  stem stiuctuie making a w obble pairing with G l896, w hereas  selection o f  
A 1896 creates a  more stable pairing with T 1858. In N orthern  E urope  and  the USA . w here  
g  no type A is com m on, the genome contains a  C at this position. T he  change from G  to A 
1 8 )6  w ou ld  inteifeie with he encapsidation signal stability and  hence lead to very 
p o o r  encaps ida tion  (Laskus etal., 1994a; Lok etal., 1994). A l896 is rarely selected in the 
&enotype A oi F, but when selected, it is a lw ays  in the p resence o f  T I856. H o w ev er ,  
e A to negative strains without A 1896 seemed to cause m ore  severe  liver damage than the 
s tra ins  with A 1896 (Lindh etal., 1996). This w as  believed to be due to presence o f  C 1858. 
iS96 is co m m o n ly  found in chronic and fulm inant cases , but is less com m on in acute 
ses. This m ay  be because a long term or an im balanced  im m u n e  p ressure is required for 
its selection. Selection of A l896 from normal G |g96 takes a long p e r iod ,  and during this 
s tage a m ix tu re  o f  strains are found.
ii) Core gene
H B V  core protein contains T helper (Ferrari et al., 1991), C T L  (Bertoletti et al., 
1991; M issale  etal., 1993) and B cell epitopes (W aters et al., 1986; Salfeld et al., 1989; 
Collucci et al., 1988), some of which are co m m o n  to H B eA g  and  are under  s trong  
m m u n e  pressure .  Selection of H BeA g negative variants so m etim es  leads to loss o f
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tolerance against HBeAg epitopes and is accompanied by amino acid substitution in the 
core protein (Carman, 1995a) especially in the B cell and T helper (Th) cell epitopes. A 
higher degree of core variation is observed in anti-HBe positive patients with severe 
disease and in fulminant cases (Carman et al, 1995b) compared to HBeAg positive 
patients, with variation occurring mostly in B and Th cell epitopes. Variants in Th cell 
epitopes have also been reported in patients with hepatoma (Hosono et al., 1995). HBeAg 
positive cases with core variation have also been described (Ehata et al, 1992); these tend 
to cluster in non-antigenic areas, particularly between aa 84-101. Amino-acid 
substitutions at specific positions have also been described. A substitution of threonine to 
serine at aa 12 was found in cases with severe disease, but always with A 1896 (Caiman et 
al, 1994) and only in Mediterranean patients. This substitution is believed to play a role 
in escape from the CD4 restricted Th cell response, as aa 12 is in a Th cell epitope. 
Greater numbers of core variants are also found in anti-HBe positive patients who do not 
respond to interferon than those who do respond (Fattovich et a l, 1995). Similarly, in 
HBeAg positive patients, a lower response to interferon is found in cases with higher 
numbers of core variations (Naoumov et al, 1995)
iii) Surface gene
Reports on variation in pre-Sl and pre-S2 are still few. Variation in the pre-S2 
ATG has been reported a few times (Santantonio et a l, 1991), but it is not likely to be a 
result of cellular immune pressure since the large protein is still present and contains this 
domain.
Most variation in the S ORF is seen in the SHBs. Some of the variants described 
in the MHR are subtype related and others are selected during or after immune therapy, 
vaccination or in the course of chronic infections (reviewed in Carman, 1996).
The most common vaccine induced escape mutant is the glycine (Gly) to arginine 
(Arg) substitution at aa 145 described in a number of studies. The first described case was 
observed in a vaccinated infant born to HBeAg and HBsAg positive mother and 
developed chronic disease (Carman et al, 1990). The infant was given hepatitis B 
immunoglobulin (HBIG) at birth and at 1 month and a course of vaccine at 3, 4 and 9 
months. Monoclonal antibody against the 'a' determinant bound poorly, although sera 
from the mother had shown normal binding activity. Gly to Arg at aa 145 was responsible 
for the loss of binding with neutralising antibodies. However, the mother had the normal 
glycine at that position. Similar cases have been reported in other studies (Fujii et a l, 
1991; Okamoto et al, 1992). In all cases, the nucleotide sequences from both mother and 
child were identical apart from aa 145. Naturally occurring Arg 145 variants also occur; in 
a patient from Indonesia Arg 145 appeared along with a two amino acid insertion between 
aa 122-123 and resulted in fulminant hepatic failure (Carman et a l, 1995c). The patient 
was anti-HBe and HBeAg positive and HBV DNA positive (by dot-blot hybridisation).
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Serum HBsAg was undetected using one commercial kit but was highly reactive with 
another.
Variants in other positions in the same area have also been described. In one study 
from Spain (Wallace et al., 1994), 7 cases were reported where sera were untypable or 
typed very weakly as ay using monoclonal antibodies. Sequencing of this region 
associated the y determinant at aa 122, however variations were found in other sites at aa 
120, 143 and 144, affecting reactivity either singly or in combination. Similar variants 
were also described by Moriyama et al, (1989, 1991). Substitution of aspartate to 
asparagine at aa 144 along with other changes at aa 126, 131 and 133 were found. They 
may have affected the antigenicity of the MHR.
Insertion of amino acids has been described in several studies (Yamamoto et al., 
1994; Carman et al., 1995c; Hou et al., 1995). In one study, a patient was found to have 
two amino acids inserted between aa 122 and 123 and in another case a 3 amino acid 
insertion between aal23 and 124. Sera were positive for HBV DNA by dot-blot 
hybridisation or PCR, but commercial assays detected HBsAg poorly. A further patient 
who was HBeAg and anti-HBs positive had an insertion of 8 amino acid between aa 123- 
124. These reports suggest that this area is flexible (aa 122-124) and not functionally 
important in the viral life cycle.
iv) X-gene
X-gene is the smallest ORF in HBV, however this region is of great importance 
not only because the HBx protein is a transcriptional transactivator, but also because it 
overlaps with Enh-II/C-promoter, the C-terminal end of the polymerase gene and DR1. 
Many cases have been described with deletions, insertions, and point mutations in the X- 
gene (Laskus et al., 1994; Okamoto et al., 1994). Some of the point mutations are 
significant at the nucleotide level, especially when in Enh-II/CP region, and others at the 
amino acid level, affecting the X and/or polymerase protein. A number of variants in the 
X-gene are associated with fulminant cases and others have been found in chronic 
carriers. These changes are responsible for either upregulating or downregulating 
transcriptional activity. Variants at the 3’ end of the X gene, resulting in higher replication 
and transcriptional activity, were reported from a fulminant case (Baumert et al, 1995). A 
number of variants in the same region, believed to be associated with downregulation of 
pre-core mRNA transcription, have been described from asymptomatic carriers, patients 
with chronic persistent hepatitis (CPH) and fulminant cases. Most common amongst these 
are T1762 and A1764, located in the BCP within the binding sites of nuclear factor. Okamoto 
et al. (1994) described these two variants in anti-HBe positive asymptomatic and CPH 
cases, as well as HBeAg positive CPH cases; however, they were not seen in HBeAg 
positive asymptomatic carriers. They were believed to downregulate HBeAg production 
as other studies reported a similar occurrence in HBeAg negative, anti-HBe positive
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asym ptom atic  cases (Sato et a l,  1995; Kurosaki et al., 1996). In tw o patients , these tw o 
variants appeared as they seroconverted to an ti-H B e. H ow ever, they were subsequently  
described  equally from both H B eA g positive and negative cases (L askus et al., 1995). 
O th er  variants in Enh-II/CP  leading to am ino acid changes in X protein are less com m on.
1374 1400 1450 1500 1^50 1600 16p0 17^0 1^50 18p0 1838
X gene ___________________
Asymptomatic carrier
Common ch an ges  
Deletions
17801750
< (9
Csl TT>£> ' Or-- r-
1763-70
Chronic HBV
Fulminant hepatitis]
Interferon 
treated patients
Chronic patients 
with reactivation
Common ch an ges
Insertions
Deletions
Insertions 1626-28 
Common ch an ges
Deletions
Deletions
Insertions
9V 7<(30
•  • • •
CO CsJ 'S T v O  m vO iflvo
3nj 
1766/67
1658-65
1757-177,7
1753-177^
1763-1770 
___________ I
1750-1770
V <e?oi-4
• • • •
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1763-1770
1748-1768
11 nt
1775/76
F igu re  1.7 C linical associations with variation in the X gene are show n sim p listica lly .
Deletions, insertions, and point mutations are also found  in patients with H C C  
(T ak ad a  and Koike, 1990), thalassaem ia (Feitelson et al,. 1994), renal d ia lysis  (Feitelson
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et al., 1995) and also from chronic patients without the usual serological markers (Blum 
et al., 1991; Liang et al., 1990). Deletions overlapping the start codon and DR2, and 
deletions or insertions within the core promoter have also been observed in interferon a 
(IFNa) treated and chronic HBV patients (Laskus et al., 1994). The X ORF was 
interrupted in all of the described variants (Figure 1.7), resulting in expected truncation of 
X protein. Deletions in the same region were described by Repp et al. (1992): an 8 nt 
deletion was detected in approximately 15% of the clones from 5 of 6 patients, resulting 
in truncation by 26 aa and insertion of 5 novel amino acids. Deletions, insertions, and/or 
point mutations affecting nuclear factor binding sites have also been described from 
immunosuppressed patients with severe liver disease (Gunther et al., 1996). Most of 
these changes created HNF-I or HNF-III binding sites, and/or duplication of C/EBP and 
HNF-IV binding sites; these resulted in a drastic reduction in the level of pre-core mRNA 
and increase in replication. Truncated X gene have also been linked to a low serum DNA 
level. In one study (Horikita et al., 1994), X gene deletions were seen in asymptomatic 
carriers with low serum DNA level. However, such changes were not seen after 
fulminant reactivation with high serum DNA level. Low levels of viral DNA due to 
deletions in the X gene in asymptomatic carriers but not in patients with chronic active 
hepatitis (CAH) has also been reported from other studies (Fukuda et al., 1995). The 
HBx deleted strain can only survive in the presence of full length strain. Finally, two 
serologically non-A-E viral hepatitis cases (Uchida et al., 1995), both negative for 
HBsAg and anti-HBe, had an 8 nucleotide deletion at nt 1770-1777, creating a tmncated 
X protein; interestingly, no full length X gene was detected by direct sequencing. The 
deleted X gene and BCP may have suppressed HBV DNA replication and expression.
1.2 HBV: PATHOLOGY AND IMMUNOPATHOGENESIS
1.2.1 EPIDEMIOLOGY AND TRANSMISSION OF VIRUS
Infection with HBV results in a broad spectrum of liver disease, ranging from 
subclinical infection to acute, self limited hepatitis and often fatal fulminant hepatitis. 
Exposure to HBV particularly when it occurs early in life, may also result in an 
asypmtomatic carrier state that can progress to chronic active hepatitis, cirrhosis of the 
liver and eventually hepatocellular carcinoma. There are 400 to 500 million HBV carriers 
in the world today. The HBsAg carrier rate varies world-wide from 0.1-0.2% in Britain, 
the USA and Scandinavia, to 3 percent in Greece and Italy and up to 10-15% in Africa 
and the Far East. Carriage of HBV can be even higher in some isolated communities such 
as Alaskan Eskimos or Australian Aborigines. In endemic areas such as east Asia, sub- 
Saharan Africa and the Amazon basin, where carrier rates range from 8-25 percent,
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prevalence of anti-HBs is from 60-85 percent. However, these numbers reduce with 
vaccination.
Percutaneous transmission is one of the principal modes of transmission of 
hepatitis B. Infection can occur with transfusion of blood or blood products, although the 
risk has reduced dramatically in recent years by routine blood screening. Persons at 
greatest risk of acquiring hepatitis by the percutaneous route are haemophiliacs, who 
receive clotting factor concentrates prepared from large pools of plasma, intravenous drug 
abusers and hemodialysis patients and staff. Despite the reduced risk of hepatitis B found 
among the recipients of blood, the hazard of parenteral exposure acquired by sharing 
contaminated needles by drug abusers continues to be responsible for many hepatitis B 
cases. Transmission of HBV by the percutaneous route may sometimes occur as a result 
of inapparent inoculation following the use of shared razors, toothbrushes, communal 
bathbrushes or towels, and by tattooing, acupuncture, or ear piercing.
In low prevalence countries, most adult infections occur by sexual contacts or 
blood contacts with chronically infected persons. In non-human primates, experimental 
infection with semen was successful, but the per-oral administration of HBV 
contaminated saliva failed to infect chimpanzees. Therefore kissing is not a significant 
means of transmission, although biting may be. HBV DNA has been detected in the saliva 
of HBsAg carriers, but the concentration is much lower than found in serum. 
Transmission by sexual contact among spouses and sexual partners is a substantial risk. 
This is particularly true among homosexual males. In the United States, as many as a half 
of hospitalised patients with hepatitis B are homosexual males.
Prenatal and transplacental transmission of HBV from infected mother to 
offspring is the most important mechanism for maintenance of an HBV carrier population 
in high carriage areas (such as Asia or Africa). Almost all women who are HBeAg 
positive transmit the virus to their newborn infants, most of whom become persistently 
infected. In contrast, transmission is less common from anti-HBe positive carriers. Eighty 
to ninety percent infants bom to HBeAg positive mothers become carriers during the first 
2-3 months of life. Infected babies born to anti-HBe positive mothers are much more 
likely to have a transient infection. When a child is infected before the age of 1 year, the 
risk of chronicity is high (80-90 percent); however, infection in adults gives rise to a 
carrier rate of only 1-2 percent.
Infection from mother to infants is not usually in utero, but at the time of birth and 
during close contact afterwards. The vims apparently does not cross the placenta easily, 
perhaps 5-10% of children bom to HBsAg positive mother may be infected in utero.
Hospital staff in contact with patients and patients blood, usually have a higher 
carrier rate than the general community. This applies particularly to staff on renal dialysis 
or oncology units. The patient's attendant is infected through contact with blood from 
pricking or from skin abrasions.
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1.2.2 PATHOLOGY AND CLINICAL FEATURES
i) Acute hepatitis
Acute hepatitis is characterised by diffuse inflammation o f  the liver. Liver cell 
necrosis  involves single hepatocytes or small g roups o f  cells, particularly in the centre o f  
lobules. The m ost characteristic clinical feature is jaundice, also know n as the icteric 
phase . H ow ever,  som e patients  develop anicteric hepatitis, being developm ent o f  clinical 
sy m p to m s  without jaundice . The non-icteric patient is more likely to becom e a chronic 
carrier than the icteric one. Som etim es a patient may have inapparent o r  sub-clinical 
hepatitis  with neither sym ptom s nor signs.
SYMPTOMS
ALT
igG anti-HBc
HBsAg \ \
IgM anti-HBc
Anti-HBs
Anti-HBe
M onths after exposure 
Fig 1.8 Profile of serological markers o f  hepatitis B during the course o f  infection  
and convalescence.
An acute hepatitis patient usually presents a spectrum  o f  serum  viral an tigens ,  and 
antibodies as well as HBV  DN A  (Figure 1.8). The first m arker is p robab ly  virus 
detectable by P C R  and H B sA g which is fo llow ed by elevated levels o f  serum  alanine 
am inotransferase (ALT). Anti-HBc IgM and IgG appear prior to clinical sy m p to m s .  
H B eA g  and H B V  D N A  by hybridisation appear at about the sam e time. D isappearance o f  
these m arkers and seroconversion to anti-HBe precedes clearance o f  H B sA g; appearance 
o f  an ti-H B s is associa ted  with recovery.
ii) Chronic hepatitis
In adult cases  with acute infection, serum  H B sA g  appears w ith in  3-4 m o n th s  after 
ex posu re .  In about 5%, antigenemia is detected for m ore than 6 m on ths ,  def in ing  the 
carrier state. The major determinants o f  chronicity o f  H B V  infection is age o f  exposure;
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about 90 percent chance w hen exposed  perinatally to <1 percent in adult stage. Every 
year,  about 5 -1 0  percent o f  these adult-onset carriers spontaneously  lose H B sA g  and 
seroconvert  to anti-HBs. In contrast,  90%  of babies infected perinatally or w ithin the first 
five years o f  life become carriers and have a lesser chance o f spontaneous recovery during 
their lifetime. Som e chronically infected patients have little clinical, biochemical or 
histologic ev idence o f liver disease, these are know n as asym ptom atic  carriers.
SYMPTOMSSYMPTOMS
ALT
HBsAg
IgM anti-HBc
ALT
/Anti-HBeHBeAg
HBV/DNA
Months after reactivationMonths after exposure (years)
Fig 1.9 serological profile o f  hepatitis B progressing to chronicity, fo llow ed  years 
later by termination o f  replicative phase.
In chronic HBV infection, H B eA g and H BV D N A  remain detectable for  som e 
years  (Figure 1.9). Anti-HBe m akes an appearance in the form  o f  im m une com plexes 
with H B eA g. Eventually, at a rate o f  5 percent a year, anti-HBe becom es p redom inant.  
W ith the appearance of anti-HBe, a m arked reduction o f  viral replication and reduction o f  
circulatory H B V  DNA to low levels usually occurs.  A nti-H B s appears  once H B sA g  is 
cleared. H o w ev er ,  in som e patients ,  loss o f  H B eA g represents the selection o f  H B eA g  
negative variants ( A l896). Patients have progressive  liver d isease , elevated A LT levels, 
and high serum  D N A  and yet are H B eA g negative. Such patients appear to have poorer 
p rognosis  with a greater risk o f  develop ing  an aggressive chronic hepatitis.
1.2.3 IM M UNOPATHOGENESIS
The pathogenic m echanism s o f  acute and chronic liver d isease , involv ing  both 
viral and host factors, and the reasons for the developm ent o f  hepatocellular ca rc inom a in 
chronically infected patients, are only partially defined because o f  the lack o f  an 
infectible/susceptible cell culture system . M ost studies sugges t  that H B V  is not directly
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cytopathic, or at least not highly cytopathic, and experimental evidence suggests that the 
humoral and cellular immune responses to viral antigens are required, not only for viral 
clearance, but also play a role in pathogenesis.
i) Acute HBV
In acute HBV infection, intense hepatocyte lysis occurs, apparently as a result of a 
polyclonal multispecific immune response. The increase in serum ALT levels in acute 
infection is one of the manifestations of this phenomenon. Serum bilirubin concentrations 
increase in proportion to the severity of the hepatic damage. The immune response in 
acute HBV infection is targeted to HBsAg, HBc/HBeAgs and to the non-structural 
polypeptides of HBV (Mondelli et al., 1982; Mishra et al., 1992). HBsAg, HBeAg and 
HBeAg have all been detected on the hepatocyte membrane (Mondelli et al., 1982).
a) Humoral immune response: The role of the antibody response to HBc and 
HBeAgs in immunopathogenesis is not clear. A high titre of anti-HBc antibodies is found 
during both acute and chronic phases of the disease, suggesting that they do not 
contribute to neutralising viral infectivity (Milich et a l, 1986). In acute infection, anti- 
HBc IgG and IgM appear prior to symptoms. The presence of a strong IgM anti-HBc 
response is an indication of the acute phase, but also persists at low levels in chronic 
hepatitis. IgG is present in high titres in acute infections, but persists at lower levels 
during the lifetime of recovered patients. The high titres of anti-HBc may be related to T- 
cell independence; as athymic mice could produce IgG and IgM antibodies to HBeAg 
(Milich et al., 1986). Mapping of B cell epitopes on core particles has been undertaken by 
many groups using panels of overlapping synthetic peptides, screened against monoclonal 
and polyclonal antibodies. Most of the early studies suggested a highly conformational 
and discontinuous structure to the HBc antigenic determinant (Ferns and Tedder, 1988; 
Salfeld et al., 1989). HBeAg was found to be destroyed by SDS denaturation and lost its 
antigenic specificity (Ohori et al., 1980) exposing HBeAg specificity. A major 
immunogenic determinant, recognised by four different monoclonal antibodies was found 
by Waters et al. (1988). A single conformation dependent epitope was identified in the 
hydrophilic region between aa 74-83 which overlapped with a linear HBe-related 
determinant (Salfeld et al., 1989). However, other studies reported several linear epitopes 
of HBeAg arguing against its strict conformational dependence. Five linear antigenic 
epitopes were identified within the peptides covering residues 1-20, 61-85, 76-83, 121- 
140 and 141-161 (Salberg et al., 1994). These were recognised by only a minority of the 
antisera examined, indicating that the major recognition epitope is not linear. A B cell 
epitope was found between aa 107-118, which was highly reactive against all polyclonal 
and monoclonal antibodies: it was thus suggested to be a linear epitope of a larger 
conformational determinant (Colucci et al., 1989). Another was found in the arginine rich 
domain (aa 150-159), specific for HBeAg but not HBeAg (Machida et al., 1989); a final
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epitope (aa 74-123), recognised by the majority of anti-HBc containing antisera, was 
identified by Tordjeman et al (1993). Presence of many linear epitopes throughout the 
entire length of the core protein suggested that antigenicity is due to many epitopes and 
not always conformation dependent. This is probably irrelevant to pathogenesis, as 
previous studies showed that HBeAg activates B cells only in the particulate form (Milich 
et a l, 1986).
Although most of the primary amino acid sequence is identical, both HBeAg and 
HBeAg display different antigenic properties that are used for diagnosis. In contrast to 
anti-HBc, antibodies to HBeAg become predominant at various intervals after the 
appearance of anti-HBc, (or may not develop) and are related to the clearance of virus in 
self limited acute infections. By deletion analysis and using a panel of monoclonal and 
polyclonal antibodies, Salfeld et al. (1989) identified two B cell epitopes in pl7e (the 
secretory form of HBeAg) polypeptide. One is linear (HBel), mapped between aa 76 to 
89, and overlaps with the HBeAg epitope. The other is conformational (HBe2) and 
requires the intramolecular participation of amino acid sequence between 10-140. The 
HBe2 sequence is also present in HBeAg but this epitope is masked in the assembled core 
particle.
The antibody response to HBsAg (anti-HBs) is a T cell dependent process (Milich 
et a l, 1986). As the anti-HBs antibodies which are directed to the HBs epitope, are 
readily detectable in patients who clear the virus and recover from acute infections, and as 
they are undetectable in patients with chronic infections, these antibodies are thought to 
play an important role in virus clearance (Milich et a l, 1986). During natural infection, 
antibodies to pre-Sl and pre-S2 appear earlier than the antibodies to HBsAg and correlate 
with the disappearance of serological markers for HBV replication (Milich et a l, 1985). 
Both anti-pre-S and anti-HBs are neutralising antibodies and prevent virions binding to 
the hepatocyte. The pre-S2 region is significantly more immunogenic than the S region 
and its regulation is independent of S regulation. The pre-S2 region generates T helper 
cell activity that can induce B cells to produce antibodies to pre-S2 region as well as S 
region; this can circumvent S region non-responsiveness (Milich et a l, 1985). HBeAg 
specific T helper cells can induce anti-pre-S 1 antibody production in the absence of anti- 
pre-S2 and anti-S production (Milich et al, 1987).
Antibodies to the RNaseH domain of the HBV polymerase protein are found in 
the sera of both chimpanzees and humans early in the infection, shortly after the 
appearance of anti-HBc. They persist in chronic carriers with ongoing viral replication, 
but decline and disappear at the time of virus clearance from the serum (Weimer et al.,
1990).
b) Cell-mediated immune response: Experimental evidence suggests that 
the T cell response to HBV epitopes account for cellular injury and virus clearance in
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acute hepatitis B. In addition, elimination of virus-infected hepatocytes is suggested to be 
dependent on the recognition of the viral determinants, in association with HLA (human 
leukocyte antigens), by T lymphocytes on the infected hepatocytes. Usually, class-H 
restricted CD4+ cells can recognise exogenous antigen after internalisation and intracellular 
processing by antigen presenting cells (APC). On the other hand, CD8+ HLA class-I 
restricted T cells are generally activated by antigens which are endogenously synthesised 
by infected cells and presented on the cell membrane. Although, as a general rule, HLA 
class-II restricted CD4+ cells recognise exogenously synthesised peptides presented on the 
APC and exert their activity by releasing antiviral mediators (interleukins [ILs] and 
tumour necrosis factors [TNFs]), hepatocytes may be able to present HLA class-II 
determinants on their membrane following HBV infection (Van Den Oord et al., 1986). 
This suggests that class-II restricted CD4+ cells can participate in immune clearance of 
HBV infected cells. A study by Penna et a l (1992) reported that HBsAg specific CTLs 
recognised endogenously synthesised HBsAg presented by class-II molecules as well as 
that expressed by APC, suggesting a role in hepatocellular injury.
The majority of experiments have shown proliferation of HLA class-II restricted 
CD4+ cells to HBs, HBc and HBe antigens indicating a strong polyclonal and 
multispecific immune response in patients with acute hepatitis B, but a lower T cell 
responsiveness to HBc/HBeAgs in patients with chronic infection (Ferrari et al., 1990; 
Jung et al., 1991; Tsai et a l, 1992). In all studies, the HBcAg-specific responses were 
stronger than HBsAg specific responses. Acutely infected patients were found to show a 
vigorous response to HBeAg in terms of proliferation of HLA class-II restricted CD4+ 
cells and interferon y production during the acute phase associated with clearance of 
HBsAg and HBeAg from serum, but this response was absent in chronic patients. A 
number of investigators have reported HBeAg peptides that are recognised by a majority 
of the patients with acute hepatitis B. Ferrari et al (1992) investigated 23 patients with 
acute hepatitis; 22 of them showed a strong HLA class-II restricted CD4+ response to aa 
50-69. Two additional CD4+ epitopes were recognised, at aa 1-20 and 117-131, identified 
by 60% and 73% patients respectively. Another group used different peptides and defined 
aa 1-25 and aa 61-85 as predominant T cell recognition sites (Jung et a l, 1993). The 
immunodominant epitopes are expressed in both HBc and HBe antigens. In fact, both 
antigens are cross-reactive at the T cell level. However, these two antigens show 
preference in Th subset induction. A recent study reported that HBeAg and HBeAg elicit 
different subsets of Th cells (Milich et al., 1997). In transgenic mice, HBeAg was found 
to be preferentially but not exclusively elicited Th, subsets; on the other hand, HBeAg 
elicited Th2 or Th0 subsets. This difference was believed to be due to structural 
differences between the two immunogens, and recognition by two different HLA class-II 
determinants (Milich et al, 1995)
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It is widely acknowledged that class-II restricted HBc/HBeAg specific CD4+ T cell 
response play a critical role in viral clearance. This could be achieved in several ways. 
Firstly, CD4+ cells can induce virus specific CTL because the intensity of class-II 
restricted T cell response to HBc/HBeAg during acute infection parallels the HLA class-I 
restricted CTL response to all the viral antigens (Penna et al., 1991; Nayersina et al., 
1993). Secondly, HBeAg specific T helper cells help HBsAg specific B cells to produce 
anti-HBs antibodies.
Since it has been found from murine experiments that T helper cell tolerance 
specific for HBc/HBeAgs may be the basic immunological defect in neonates bom to 
HBeAg positive carrier mothers, an investigation was performed on cellular immunity to 
HBeAg in HBV carrier children in such group (Hsu et al., 1992). A significant 
proliferative response of PBMC (peripheral blood mononuclear cell) to HBeAg was 
found in five of eleven children with an elevated ALT level but none of the nine HBeAg 
positive children with a normal ALT level. This could be due to maternal HBeAg inducing 
specific non-responsiveness to T helper cells against HBe and HBcAgs in the at-risk 
neonates.
The class-II restricted HBsAg specific response is much less vigorous in the same 
patients. The reason for relatively weaker HBsAg specific T cell response of patients who 
respond quite vigorously to the HBeAg is not well understood. An anti-HBs specific T 
cell response was reported during the preclinical incubation of the disease (Vento et al.,
1987). This could become either exhausted as a result of stimulation by high dose of vims 
or paralysed by the high concentration of surface antigens (Chisari et al., 1995). 
Information about class-II restricted CD4+ response to polymerase protein and X protein 
is sketchy.
Antiviral CTLs are believed to play a major role in eradication of infection by 
killing vims infected cells through recognition of viral peptides presented by HLA class-I 
molecules. Acutely infected patients develop a vigorous, polyclonal CD8+ CTL response 
against multiple epitopes in the HBeAg, HBsAg and polymerase proteins (Penna et al., 
1991; Nayersina et al., 1993). Most of the CTL epitopes defined so far are HLA A2 
restricted and contain the predicted HLA A2 binding motif with leucine at position 2 and 
valine at the C terminus end (Bertoletti et al, 1993; Nayersina et al., 1993). Until now, a 
single HLA A2 restricted CTL epitope has been identified in HBeAg, located between aa 
11-27 (Bertoletti et al, 1991). This endogenously synthesised epitope is recognised by T 
cells from all HLA A2 positive patients with acute infection. Using a panel of tmncated 
and overlapping peptides, the optimal stimulatory sequence is a 10 mer (aa 18-27) 
containing the HLA A2 motif. Another CTL epitope was reported in acutely infected 
patients, located at aa 141-151 of HBeAg. CTL recognition of this epitope is restricted by 
two independent class-I molecules, HLA A31 and HLA AW-68, both of which respond
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to the same 11 aa residues. This epitope is completely overlapping with a functional 
domain of core protein that is essential for nuclear localisation and genome packaging.
Several HBsAg specific class-I restricted CTL epitopes have been identified in 
acutely infected patients (Nayersina et al, 1993) and five epitopes have been found in the 
polymerase protein. Most of them are specifically restricted by the HLA A2 allele. This 
number is considerably higher than that found for HBeAg. The extreme hydrophobicity 
of the surface protein may be one of the reasons for high representation of HLA A2 
restricted CTL epitopes (Falk et a l, 1991). The HBsAg specific CTL response is also 
polyclonal and multispecific in acutely infected patients.
CTL can also play a role in clearing virus without killing the infected cells. In 
transgenic mice, it has been found that CTL suppressed HBV gene expression by a non- 
cytolytic process (Guidotti et al., 1994b) which is mediated by IFN-y and tumour 
necrosis factor a  (TNFa).
ii) Chronic HBV
A number of defects have been characterised in patients with chronic hepatitis B . 
The suppression of humoral and cellular immune response to clear the virus is one of the 
most important reasons. A deficient production of interferon and suppression of the 
ability of the host to respond to interferon are probably another major factor (Thomas et 
al., 1988).
Antibodies against all three classes of surface antigens, which are detectable early 
in acute infection, are not detectable in the chronic state. Appearance of anti-pre-S/S 
antibodies is followed by the clearance of HBsAg. Failure to clear HBsAg from the blood 
is the hallmark of chronic HBV infection. Production of HBs and HBe antigens in excess 
of that required for the virion formation may impair or reduce the effectiveness of 
neutralising anti-HBs antibodies by preventing binding to the infectious virions (Thomas 
et al, 1988) and thus, may induce immunotolerance. Production and secretion of surplus 
HBs particles of 22 nm size can divert anti-HBs away from intact whole virions, and thus 
reduce the chance of neutralisation by anti-HBs. HBeAg, an immune modulator can 
induce tolerance against HBe/HBcAg specific peptides displayed on hepatocyte 
membrane, and reduces the degree of inflammation. Antibodies to HBeAg may also 
interfere with the expression of HBeAg specific T cell epitopes on the hepatocyte 
membrane (Mondelli et al, 1982). Anti-HBc and anti-HBe block the CTL activity 
probably by modulating the recognition of HBc/HBeAg specific peptides displayed on 
hepatocytes (Pignatelli et al., 1987). In chronic infection, significantly higher level of 
HBcAg/anti-HBc and HBs/anti-HBs immunocomplexes were produced in the presence of 
excess antigens (Maruyama et al, 1994). Integrated HBV DNA in the cellular genome 
(Shafritz et al., 1981) and escape mutation can also lead to persistence of HBV infection. 
CTLs can suppress antibody production. A study by Bamaba et a l, (1990) demonstrated
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the generation of HBsAg-specific liver derived T cell clones which could specifically kill 
anti-HBs producing B cells and thus may contribute to downregulating anti-HBs antibody 
production. CTLs can also suppress anti-HBs antibody production by releasing a 
secratible soluble factor (TSF), sometimes found in chronic carriers (Yamauchi et al.,
1988).
During chronic infection, the HLA class-II restricted CD4+ T cell response to all 
viral antigens including HBc/HBeAgs, is much less vigorous than in patients with acute 
hepatitis (Ferrari et al, 1990; Jung et al., 1991; Penna et a l, 1991). Although these T 
cells can be detected in the liver, they appear to be present at low frequencies (Ferrari, et. 
al, 1987). Types of CD4+ Th subsets elicited by HBeAg, sometimes may have clinical 
relevance. Predominance in acute infection of HBcAg-specific Th, subsets, which 
produce IL-2 and IFNs, favours CTL mediated clearance; in contrast, predominance of 
HBcAg-specific Th2 cells favours antibody production over cell mediated immunity 
(Maruyama et a l, 1994). Using peptide pulsed or transfected target cells, it was found 
that, in contrast to the vigorous CTL response to all the viral antigens detectable in the 
PBMC of the patients who clear the virus, HBV persistence is typically associated with a 
weak and undetectable CTL response. In one observation, none of the six HLA A2 
positive patients with chronic hepatitis produced a detectable CTL response to any of the 
HLA A2 restricted HBs or HBc specific epitopes (Nayersina et a l, 1993). While a 
vigorous response to CTL epitopes plays an important role in clearing the virus in self­
limited acute infection, the weakness or absence of CTL response in chronic infection is 
probably responsible for indolent necroinflammatory liver disease (Chisari et al., 1995). 
Recently, Thurz et al. (1995) reported a greater frequency of HLA class-II allele 
DRB 1*1302 among children in The Gambia who recovered from HBV infection 
compared to those who had persistent infection. This suggested that presence of this allele 
may confer protection against chronic HBV infection. This has been confirmed by others.
Variants in the antigenic determinants may contribute to the chronicity in several 
ways: they may 'escape' from immune recognition or can show antagonistic effect on T 
cell receptor (TCR) recognition of standard peptide. In a study by Bertoletti et al. (1994), 
two HLA A2 positive chronic patients were found to show a vigorous CTL response 
against HBeAg (aa 18-27) despite their inability to clear the virus. Both of them contained 
variants at aa 21 and 27 which decreased HLA binding to the variant peptide and the TCR 
recognition. Interestingly, these were not detected in an additional five chronic patients in 
the same study who did not show any CTL activity against the epitope 18-27. The variant 
epitope acted as a TCR antagonist by inhibiting the CTL response to wild type epitope.
During chronic infection, there is evidence of failure of interferon production and 
activation of infected liver cells, so viral protein synthesis is not decreased and there is 
poor enhancement of HLA display. These may result in failure of presentation of viral 
peptides to the immune system. Production of suboptimal levels of interferon a and y by
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PBMC in chronic patients was reported in several studies (Abb et a l, 1985; Ikeda et al., 
1986a). However, a reduced interferon production was also seen in the lymphocytes 
taken from self limited acute HBV infection (Levin and Hahn, 1982), indicating that 
reduced interferon production is one of the causes of persistence in some cases. In 
chronic infection, there is also evidence of abnormal activation of hepatocytes by 
interferon: levels of hepatic 2-5A synthetase, an enzyme induced by interferon, were 
minimally elevated (Ikeda et al, 1986b) and the density of HLA class-I protein, which is 
induced by interferon, was not significantly increased above normal level.
Since lymphocyte production is dependent on specific lymphocyte activation, 
absence of enriched lymphokine releasing cells may be associated with failure of vims 
elimination in chronic patients (Jung et al, 1991).
1.3 FULMINANT HEPATITIS
Fulminant hepatitis is a devastating illness in which liver failure occurs within a 
short period of time. Rapid deterioration of liver function occurs due to extensive 
hepatocellular destruction.
1.3.1 DEFINITIONS AND AETIOLOGY
i) Definition
There are two definitions commonly used. In 1970, the term fulminant hepatic 
failure (FHF) was first introduced and defined as i) development of stage II to IV hepatic 
encephalopathy within 8 weeks of onset of illness, ii) a prothrombin time of less than 40s 
and no known history of liver disease (Trey and Davidson, 1970). Since then, this 
definition has been widely used, although over the years several changes in the period 
between the appearance of symptoms and the onset of encephalopathy have been 
proposed. A group at King's College Hospital, London have defined an additional late- 
onset hepatic failure (LOHF) in which encephalopathy appears between 8 to 26 weeks 
after the onset of symptoms (Gimson et al, 1986). A later definition defined FHF as 
acute liver failure complicated by hepatic encephalopathy less than 2 weeks after the onset 
of jaundice (Bemuau et al, 1986a) and is used by a group in Paris. According to this 
group, acute liver failure complicated by encephalopathy 2 weeks to 3 months after the 
jaundice, is defined as 'subfulminant liver failure'. 'Subacute liver failure' designates 
acute liver failure with a protracted course not associated with hepatic encephalopathy 
(Tandon et al, 1982). Both groups have found that patients with the earliest onset of 
encephalopathy have the best chance of spontaneous recovery, confirmed in other studies 
(Takahashi et al, 1991). A new terminology of FHF has been proposed based on studies 
of more than 600 patients admitted to King's College Hospital, London between 1972 
and 1985. This group (O'Grady et al, 1993) suggested 'hyperacute liver failure' for
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cases where encephalopathy appears within 7 lays of the onset of jaundice. This group of 
patients have a high rate of cerebral oedema vith very good prognosis. The term 'acute 
liver failure' was suggested for cases with an in terval o f  between 8 and 28 days from 
jaundice to encephalopathy; these patients alsc have a hiigh incidence of cerebral oedema 
but much poorer prognosis without liver trans]lantation. The term 'sub-acute liver failure' 
was suggested for cases when encephalopathyoccurs wiithin 5 to 12 weeks of symptoms.
In the original definition of acute liver failure, tine absence of previous history of 
liver disease had been a prerequisite. But the new termiinology includes cases of acute 
liver failure due to reactivation resulting froii Delta viirus superinfection or Wilson's 
disease.
ii) Aetiology
Fulminant hepatitis can be caused by vfuses or agents other than hepatitis viruses. 
Any virus that causes an acute hepatitis can al>o cause fiulminant hepatic failure. Viruses 
are the most common cause of acute livfr failure world-wide and account for 
approximately 70% of the cases, although the t/pe of viruses varies geographically.
Hepatitis A virus (HAV) is directly hepitotoxic, s<o an unusually large inoculum or 
diminished host defence may contribute to he development of a fulminant course. 
However, fulminant hepatitis A is rare and mostly prevalent in developing countries 
(Joshi et al., 1983). In developed countries t is somettimes related to travel to highly 
endemic areas (Gimson et al., 1983a) or HAV >uperinfecttion on pre-existing liver disease 
(Akriviadis and Redeker, 1989). The survival rite of patients with fulminant A hepatitis is 
relatively high, 40% or more (Bernuau et al, 1983).
HBV is still the major cause of viral fulminamt hepatic failure. Details about 
fulminant B hepatitis (FHB) are discussed later in this chapter.
Fulminant hepatic failure caused by unknown aettiology is categorised as non A 
non B (NANB) fulminant hepatitis, often presumed to be caused by one or more viral 
agents (Wright, 1993). Super-infection or co-infection with HBV has been reported in 
some cases (Wright et al, 1992). The prevalence of hepattitis C vims (HCV) and hepatitis 
E vims (HEV) has been reduced in western countries, however, a fulminant course due to 
HCV has been reported recently from Europe (Liang et all, 1993) and from Japan (Yanagi 
et al, 1991). Some of the patients in the latter study, though positive for anti-HCV and 
HCV RNA, were found to be superinfected with HAV or HBV. The survival rate in 
NANB fulminant hepatitis due to HCV was significantly ilower than that caused by HAV 
or HBV alone (Yanagi et al, 1991). The involvement: of HCV in NANB fulminant 
hepatitis remains a matter of controversy: an investigation in the USA revealed that only a 
few cases of NANB FHF were positive for HCV markers? (Liang et al, 1993). One study 
by Wright et al, (1992) found that at least 50 percent off the cases diagnosed as NANB 
were actually caused by HBV as HBV DNA was detectable only using PCR.
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There are no risk factors for NANB fulminant hepatitis and no specific diagnostic 
tests. Clinical features are different from those of type A and B fulminant hepatitis 
(Gimson et al, 1983b). The disease is recognised by the absence of viral markers and its 
tendency to run a prolonged, pre-encephalopathic phase; 83 percent of patients in one 
series of subfulminant liver failure were due to presumed NANB hepatitis (O’Grady et 
al., 1993). Fulminant NANB hepatitis with late onset was found to be severe with a very 
low survival rate. Re-infection of the transplanted organ has not been reported.
Hepatitis D vims (HDV) infection occurs either as a coinfection with HBV or as a 
superinfection of patients with chronic HBV infection. Fulminant D hepatitis does not 
differ clinically from fulminant HBV with coinfecting HDV (Bemuau et al., 1986a). Such 
cases of HDV associated infection have been reported from Western Europe and the USA 
(Smedile et al., 1982; Govindrarajan et al., 1984) and it is evident from these reports that 
the risk of fulminant hepatic failure is higher in patients with coinfection than with HBV 
alone.
Hepatitis E vims (HEV) genome has been detected in the serum of patients with 
fulminant NANB hepatitis (Sallie et al., 1991) but this is rare in Western countries. 
Pregnant women are at high risk of developing fulminant hepatitis due to HEV (Nanda et 
al., 1994).
Hepatitis G virus (HGV) or GBV-C, a flavivirus agent, has recently been 
identified as one of the cause of non-A to E hepatitis and often found to be associated with 
HBV and HCV infections (reviewed in Karayiannis and Thomas, 1996), was also 
implicated as a causal agent for fulminant non-A-E hepatitis. This was reported in FHF 
cases from Japan (Yoshiba et al,. 1995) and Germany (Heringlake et al., 1996). 
However, this was not confirmed by another group in Japan (Kuroki et al., 1996) and 
found to be transmitted in FHF cases during blood transfusion after the onset of disease 
(Haydon et al., 1997).
FHF due to non-viral agents has often been reported (Bernuau et a l, 1986a), due 
to drugs or toxins or (such as acetaminophen and mushroom toxins). The toxic effect of 
Amanita mushroom poisoning is mediated by a-amanitin in Western countries. Drugs like 
halothane, isoniazid, valporic acid and tetracycline have also been reported to cause FHF. 
Certain conditions such as cardiovascular disease, where dismption of blood flow to the 
liver can result in acute necrosis. Some metabolic disease such as Reye's syndrome or 
Wilson's disease may also present as FHF.
1.3.2 CLINICAL FEATURES
i) Encephalopathy
Hepatic encephalopathy is the most important criterion for the diagnosis of 
fulminant or acute hepatic failure (Trey and Davidson, 1970). Encephalopathy is a 
reversible clinical state that indicates the residual liver function has fallen below a critical
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threshold. It is caused, at least in part, by the accumulation of substances that are 
normally cleared by the liver. In FHF, encephalopathy is clinically graded from grade 0 to 
IV on the basis of severity of the disease (Table 1.1). The grades of encephalopathy are 
used to assess the severity of hepatic failure. Patients who do not develop encephalopathy 
beyond grade II have a good prognosis. In viral FHF, duration of jaundice more than 7 
days before the onset of encephalopathy indicates a poor prognosis (O'Grady et al.,
1989). A greater rate of survival was seen in patients who developed encephalopathy 
within 7 days of onset of jaundice, despite the progression to grade IV (O'Grady et al., 
1993), while only 7 percent of patients survived who developed encephalopathy between 
8 to 28 days after the onset of jaundice.
Table 1.1
Grade Clinical features
0 Not encephalopathic
I Mild or episodic drowsiness, impaired intellect and concentration
but reusable and coherent.
II Increased drowsiness with confusion and disorientation but
reusable and conversant.
III Very drowsy, disoriented, responds to simple verbal commands
but often agitated and aggressive.
IV Unresponsiveness to verbal commands but may move on painful
stimulus.
Table 1.1 Clinical features of the grades of hepatic encephalopathy (Table taken from 
Harrison et al., 1993).
The pathogenesis of hepatic encephalopathy is not well understood. A number of 
substances have been suggested to play a role. Accumulation of toxic substances are 
thought to impair neuronal function and damage the blood-brain barrier. Increased gamma 
aminobutyric acid (GABA) neurotransmission has been implicated in the pathogenesis 
(Jones et al., 1987), although GABA receptor number and affinity were found to be 
normal. A number of other substances such as ammonia, mercaptans and medium-chain 
fatty acids have been proposed to have a toxic effect.
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ii) Coagulopathy
Since the liver is involved in producing the majority of the clotting factors, it is not 
surprising that blood coagulation disturbance is one of the major complications of FHF; 
levels fall rapidly at the onset (Lechner et al, 1977). Interrelated clotting abnormalities 
may occur reduced synthesis of clotting factors, consumption of clotting factors, 
activation of fibrinolysis and platelet abnormalities. The commonly used assay to assess 
liver disease is the prothrombin time (PT), which measures factors I, II, V, VII and X (all 
medium in the liver). A prothrombin time greater than 50s indicates a poor prognosis 
(O'Grady et al., 1989).
Abnormalities in platelet counts, morphology and function have all been described 
in FHF (O'Grady et al, 1986). The platelet count usually declines progressively during 
the course of illness. Counts less than 100 000x109/L were found in about 70 percent of 
the cases. Mean platelet counts were lower in patients who died than in survivors. 
Adhesion abnormalities of platelets have also been reported (O'Grady et al., 1986). 
Abnormal platelet adhesion causes damage of vascular endothelium by interaction with 
platelet glycoproteins, and conformational changes occur. As a result, more platelets 
aggregate at the site of injury, activating and binding with coagulation factors.
iii) Cerebral oedema
Fulminant hepatitis patients who progress to grade IV encephalopathy have a 75 to 
80 percent chance of developing cerebral oedema and intracranial hypertension; this is still 
the major cause of death (O'Grady et al., 1989). Increased intracranial pressure could 
result from expansion of either the cerebrospinal fluid (CSF), blood volume or blood 
tissue by 25, 5 and 70 percent respectively (Blei, 1991).
Two pathogenetic mechanisms for cerebral oedema have been suggested. In 
vasogenic oedema, a breakdown of the blood-brain barrier allows leakage of plasma 
contents through the capillary endothelium; in cytotoxic (cellular) oedema, net cellular 
water accumulation occurs as a result of impaired osmoregulation (Blei, 1991).
iv) Other features
Severe circulatory disturbance is characteristic of FHF. There is a low systemic 
vascular resistance and mean arterial pressure is maintained by a compensatory increase in 
cardiac output (Rueff and Benhamou, 1973). Patients who progress to grade IV 
encephalopathy sometimes have pulmonary complications. This is not a serious problem 
in FHF unless accompanied by a high incidence of lung infection. Renal failure requiring 
dialysis occurs in about 30 percent of the patients with grade IV encephalopathy (O'Grady 
et al., 1988). Bacterial infection is found in about 80 percent of cases (Rolando et al.,
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1990); the prevalent organisms are staphylococci, streptococci and coliform bacteria 
(Rolando et al., 1990).
1.3.3 FULMINANT HEPATITIS B
HBV is one of the major causes of FHF throughout the world, but the incidence 
varies geographically. In most developed countries, the incidence has decreased in concert 
with the increasing awareness of the blood borne viruses and vaccination of high risk 
individuals. Hepatic failure due to HBV accounts for 45 percent of FHF cases in Paris, 
42 percent in Spain, and approximately 20 percent of cases in the United States (reviewed 
in Norman et al., 1997). The incidence of post transfusion fulminant hepatitis B has 
decreased since screening of HBsAg among the blood donor population (Gimson et al., 
1983). Females appear more likely to be affected than heterosexual males, but whether 
homosexual males are at risk of developing fulminant hepatitis B is uncertain (Bemuau et 
al., 1986b). Clustering of cases of fulminant hepatitis B has been reported in groups of 
intravenous drug-abusers and their sexual contacts.
Most of the early studies analysed differences between prognostic factors in 
survivors and non-survivors. In one study (Bernuau et al., 1986b), 115 FHB patients, all 
of twelve factors were found to be different in the two groups. Lower mean age, 
increased coagulation factor V and presence of detectable levels of anti-HBs were found 
in the patients who survived. In another study (Tygstrup et al, 1986), those between 30 
to 50 years had a better chance of survival. Sex of the patients had little influence on 
survival rates, though, in other studies, females were found to have a higher fatality rate 
(Bernuau et al, 1986b).
i) Pathogenesis: early studies
FHB used to have shown abnormally rapid clearance of HBsAg and HBeAg and
absence of detectable HBV DNA with early appearance of anti-HBs (Woolf et al., 1976;
Gimson et al, 1983a; Brechot et al, 1984), suggesting that the disease results from an
excess immune response to the virus rather than a direct cytopathic effect. Early
appearance of antibodies, indicating the rapid clearance of their respective antigens, was
due to enhanced antibody production. In addition, there was a higher concentration of
anti-HBc IgM in patients with FHB compared to acute self-limiting infection (Gimson et 
al, 1983a). This brisk immune response was believed to be responsible for 
pathogenicity. Aggregation of excessive HBsAg and anti-HBs complexes was revealed 
using an electron microscope (Woolf et al, 1976). These were believed to be responsible 
for blockage of hepatic sinusoids with ensuing ischaemic necrosis of liver cells. The high 
mortality rate in FHB is due to a lack of sufficient and rapid liver cell regeneration.
As most of the FHB cases have a very low level of serum HBsAg and HBeAg
and undetectable levels of viral DNA and as HBsAg and HBeAg could not be detected in
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the liver tissue, their role in disease pathogenicity remains unclear. In one study, survivals 
were significantly associated with the absence of serum HBsAg and presence of anti-HBs 
(Bernuau et al., 1986b); however, this was not confirmed by others (O'Grady et al.,
1990). Persistence of HBsAg and pre-S2 antigens and absence of respective antibodies 
were found to be associated with a fatal outcome in four of 5 cases indicating continuing 
viral replication and hepatocyte damage (Brahm et al., 1991). In contrast, early 
appearance of antibodies, including anti-pre-S2, was found to be associated with clinical 
recovery, therefore indicating that the early appearance of antibodies may result in a 
balance between massive liver cell necrosis, early cessation of replication and liver cell 
regeneration. FHB is also found in infections without any known viral markers. Several 
such cases have been reported where HBV was detected in 50 percent of the cases using 
polymerase chain reaction in absence of any other serological markers (Wright et al.,
1992).
Spontaneous or drug induced reactivation of chronic HBV infection leading to 
FHF can also occur (Yoshiba et al., 1992; Meyer et al., 1993). Mayer et al. (1993) 
described two cases where chronic infection spontaneously reactivated to FHF, and 
Yoshiba et al. (1992) described three HBeAg-negative chronic carriers who developed a 
fulminant course after intensive chemotherapy for non-Hodgkin's lymphoma.
The role of viral heterogeneity in the development of FHF has also been 
highlighted: an outbreak among two groups of intravenous drug-abusers and their sexual 
contacts implicated the presence of a viral factors. Transmission of HBeAg negative virus 
to two successive female sex partners of two unrelated, anti-HBe positive males with 
subsequent development of FHB (Fagan et al, 1986) indicates an increased virulence of 
HBeAg negative strains. Similarly, common source outbreaks (Oren et al., 1989) support 
the involvement of a more infective strain (this is discussed later in this section).
Co-infection or super-infection of HBV and HDV produces a more severe disease 
in experimental animals (Rizzetto et al., 1980). Several groups have reported such co- 
infection in severe and fulminant cases of HBV (Shattock et al., 1985; Bensabeth et al., 
1987). In one study, HDV super-infection was detected in 74 percent of the FHB cases 
(Bensabath et al., 1987). HDV super-infections tend to occur even more frequently 
among intravenous drug-abusers, for example, accounting for approximately 91 percent 
of the cases (Lattau et al., 1987).
ii) Pre-core variants and FHB
Following the development of more sensitive techniques in molecular biology and 
the subsequent discovery of the pre-core variant (A1896) (Carman et al., 1989; Brunetto et 
al., 1989), a number of studies were undertaken to delineate the association of A ]896 with 
FHB. HBV strains, with such mutations, have been identified in FHB patients who 
acquired HBV in various ways: through community transmission (Carman et al., 1991;
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Omata et al., 1991), intra-spouse transmission (Yotsumoto et a l, 1992), outbreaks 
(Liang et al., 1991), accidental and post-transfusion transmission (Kosaka et al., 1991; 
Kojima et al, 1991) and perinatal mother to infant transmission (Terazawa et al, 1991). 
Most of these patients were HBeAg negative and anti-HBe positive and sometimes 
negative for both the HBe markers. In the study by Omata et a l (1991), sequence was 
available from seven of 9 FHB patients; all 7 were anti-HBe positive and were infected 
with A 1896. In another study (Yotsumoto et al, 1991), three FHB cases resulted from 
three anti-HBe positive carriers who transmitted A ]896 to their spouses and caused a fatal 
outcome in two of the three cases. Interestingly, in all cases of FHB patients and their 
contacts, 100 percent of clones tested were found to contain the variant strain. A 
nosocomial outbreak was reported from Haifa, Israel (Oren et a l, 1989) where five 
individuals were infected from a common source: all five died from hepatic failure within 
a short period. Sequence analysis of pre-core region showed that all patients and the 
contact contained A]896 (Liang et al, 1991). Perinatal transmission of pre-core variant 
from mother to their infants has an increased likelihood of developing a fulminant course 
(Delaplane et a l, 1983). Perinatal transmission of HBV from HBeAg positive mothers 
leads to development of chronic HBV carriage in 90 percent of cases (Beasely et a l, 
1983). However, vertical transmission of HBV from a HBeAg negative, anti-HBe 
positive mother seldom gives rise to a chronic state (Raimondo et al, 1993), but either a 
self-limited acute course or FHB develops with a high mortality. This is believed to be 
due to absence of HBeAg, which would otherwise induce tolerance of fatal Th cells 
(Milich et al, 1990). Genetic heterogeneity in the mother's serum may also play a role in 
the course of infection in the infant. In most FHB cases, only A )896 was selected 
(Raimondo et al, 1993) upon transmission from mothers who were infected with a mixed 
population of A1896 and G1896 strains (Terazawa et al, 1991). The presence of A)896 in the 
infant was thought to be associated with immune pressure on the virus (Raimondo et a l,
1993).
In all of these studies, cases with A 1896 strain were found to cause more severe 
disease and were considered to be one of the major factors associated with the 
development of FHB. However, the mechanisms of pathogenicity by which the variant 
strain causes a more severe clinical course is not well explained and most importantly, not 
all the FHB cases were associated with A,896.
In most of the early FHB studies, the massive hepatocellular injury was thought to 
be due to enhanced antibody responses with early clearance of virus. Excess production 
of immune complex might result in blockage of hepatic sinusoids and ischaemic injury. 
However, after the mapping of T cell epitopes on HBV core and surface antigens, it was 
suggested that T cells play the key role in clearance of virus infected cells and HBeAg and 
HBeAg have been implicated as the target of CTL (discussed in section 1.2). One 
explanation for A ]896 pathogenesis proposes that if HBeAg epitopes, produced by the
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variant strain, are expressed on the hepatocyte membrane (Schlicht et al., 1989) in the 
absence of circulating HBeAg there may be a sttronger immunological attack against 
HBeAg, resulting in severe hepatic injury (Omata eit al, 1991; Carman et al, 1993a). But 
this does not explain how a non-variant strain causes FHB. It is not clear from most of 
the studies whether the patients were infected initiallly with AJ896 or mixed populations of 
A189 6and G1896. If they were not, it may be that an enhanced immune response is directed 
against an HBeAg producing strain, leading to extensive hepatocyte destruction and 
selection of the variant strain. However, during FHB, there is probably insufficient time 
for a variant to evolve. Thus, this could be explained by the fact that, in most of the cases 
associated with pre-core variants, the contacts were HBeAg negative and anti-HBe 
positive and the patients had a short duration of jaundice prior to onset of encephalopathy 
(Kosaka et al, 1991; Liang et al., 1991; Yotsum<oto et al, 1991). Other explanations 
suggested that the truncated peptide, derived from the pre-core region with a stop codon, 
may act as an immunological target or that the mutant strain is directly cytopathic to the 
hepatocytes (Omata et al., 1991). There is no direct evidence for this; however, in vitro, 
deleted pre-core sequence resulted in an increased production of HBeAg (Roossink et al., 
1986).
Pre-core variant was not found to be prevalent in all cases of FHB (Carman et a l,
1991) and studies from France (Feray et al., 1993) and the USA (Laskus et al, 1993) did 
not find any significant association of A1896 with fulminant hepatitis. This indicated that 
the host's enhanced immune response to viral antigens was mainly responsible for the 
development of more severe disease. It is noteworthy that, in the early study by Feray et 
al. (1993); one of 10 patients had the variant strain (A]896); however, 5 others had either 
HCV or HDV co-infection, indicating that other factors may have contributed to the 
severity of the disease. Although in the first report from the USA, Laskus et al. (1993) 
reported the presence of A18% in 2 of 37 cases, the other study by Liang et a l (1994) 
reported 17 of 28 cases containing A 1896, either alone or with G 1896. One of the aims of 
our study was to resolve this issue once and for all.
AIM OF THIS STUDY
The pathogenicity of FHB is not well understood. The pre-core variant A1896 has 
been clearly shown to have an association with FHB, but this was not reported in all 
studies. Moreover, the presence of this variant strain in chronic carriers supports the view 
that an intense immune response of host to the viral antigens plays the key role in the 
massive destruction of hepatocytes. The main aim of my thesis was to find a viral 
factor(s) associated with FHB . When the study was initially undertaken, no reports were 
found on the sequence analyses of full-length FHBV genome. However, in late 1993 
there was a report in which an FHBV strain from an infant, (which had caused the death 
of two paediatricians) was transmitted to chimpanzees (Ogata et al., 1993). The
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chimpanzees developed severe hepatitis. The sequence analysis from the source infant and 
the animals revealed identical sequences. In addition, there was a significant number of 
variations which appeared throughout the genome, some of which were in the Enh-I/XP 
and Enh-II/CP regions.
I performed three different analysis with FHBV cases. Firstly, sequence analyses 
of complete FHBV genomes to identify variants which could be linked with FHB; of 
particular interest would be the analysis of sequences in the cis-acting regulatory regions 
and the core gene as theses areas were found to be functionally important in a previous 
study. All but one of our FHBV samples were collected from FHB patients admitted at 
King s College Hospital London, over 10 years. None of the cases were linked and some 
of them were infected from different geographical areas.
Secondly, to compare the FHBV sequences with non-FHBV and to determine if 
there is a specific lineage among the unrelated FHBV cases.
The massive hepatocellular destruction may be due to enhanced viral replication 
and extensive production of replicative intermediates. The third aim was to perform 
functional analysis of some selected FHBV cases by transcription assay, transcription 
factor binding assay and to examine the in vitro distribution of expressed HBeAg.
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Chapter-2 Materials and Methods
2.1 MATERIALS
2.1.1 PATIENTS
A full lists of patients is given in Tables 2.1 and 2.2.
2.1.2 REAGENTS, SOLUTIONS AND CHEMICALS
Source 
Novagen 
Dr. Walter 
Prof. H Will 
Dr. C Trautwein 
Dr. C Trautwein
i) Plasmids
pT7-blue
pBLt55
pRK5
pBL
pSV
ii) Tissue culture systems
HepG2 cells: human hepatoblastoma cells, originally established from a 15 years
old male Caucasian. The cells produce a wide range of proteins, including factors
prothrombin, anti thrombin III, a-foetoprotein, complement, C3 activator and fibrinogen. 
Grown in Dulbecco's modified Eagles medium (DMEM), supplemented with 10% foetal 
calf serum, 100IU penicillin/100 IU streptomycin and 2 mM glutamine.
HeLa cells: human cervix carcinoma cells line. Epithelium like cell line derived
from human cervical tissue. Grown in the medium as above, supplemented with 5 percent 
foetal calf serum.
Huh7 cells human hepatoblastoma cells
COS7 cells: monkey kidney cells, Originally derived from CV-1, an African 
monkey kidney cell line, Transformed by an origin defective mutant of SV-40. Grown in 
the medium as mentioned above for HepG2 cells.
iii) Reagents and media for tissue culture
DMEM
Foetal Calf serum
Glutamine
Penicillin /Streptomycin
PBS A 170 mM NaOH, 34 mM KC1, 1 mM Na2HP04,
2 mM KH2P04, pH 7.2.
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Trypsin 0.25% trypsin dissolved in Tris-saline
Versene 600 mM EDTA in PBS A, 0.0015% (w/v) phenol
red.
iv) Enzymes
Restriction enzymes were purchased from Boehringer Mannheim or New England 
Biolabs. RNaseA (Ribonuclease A) and lysozyme were obtained from Sigma Chemicals 
Co Ltd. T4 polynucleotide kinase, T4 DNA ligase, Proteinase K, Taq polymerase used 
for PCR purchased from Boehringer Mannheim.
v) Commonly used chemicals
All the reagents and chemicals were purchased from BDH Chemicals, UK or from 
Sigma Chemical Co. unless otherwise mentioned in this section or in the methods section.
Manufacturer Chemicals
Beecham Research 
Bio-Rad
Boehringer Mannheim 
Prolabo
Ampicillin
TEMED, Amonium persulphate
Protease inhibitor, PCR reagents, Taq DNA
polymerase
Boric acid, chloroform, ethanol, glacial acetic acid, 
glycerol, hydrochloric acid, isopropanol, methanol
vi) Reagents and buffers for PCR, DNA sequencing and cloning
lOx PCR buffer 
lOx agarose gel- 
loading buffer 
lOx dNTPs 
lOxTBE
lOxTAE
lOxTE
lOx T4 kinase buffer
1 Ox ligase buffer
200 mM Tris-HCl (pH 8.4), 500 mM KC1 
lxTBE, 1% SDS, 50% glycerol 1 mg/ml 
bromophenol blue
100 mM of each dATP, dGTP, dCTP, dTTP 
89 mM Tris-HCl (pH 8.0), 89 mM 
boric acid, 1 mM EDTA 
0.2 M Tris, 50 mM EDTA (pH 8.0), pH 
adjusted to 8.0 with acetic acid 
0.1 M Tris-HCl (pH 8.0), 10 mM EDTA 
0.5 M Tris-HCl (pH 7.6), 0.1M MgCL2, 50 mM 
DTT, 1 mM spermidine-HCl, 1 mM EDTA 
(pH 8.0)
250 mM Tris HC1 (pH 7.6), 50 mM MgCl2,
5 mM DTT, 5 mM ATP, 25% PEG 8000
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vii) Reagents and solutions for small scale plasmid preparation
Solution I 25 mM Tris HC1 pH 8.0, 10 mM EDTA pH
8.0, 50 mM glucose.
Solution II 0.2 mM NaOH, 1 % (w/v) SDS
Solution III 3 M K-acetate, 5 M acetic acid
STET buffer 50 mM Tris HC1 pH 8.0, 50 mM EDTA pH
8;0, 0.5% triton X-100, 8% sucrose.
viii) Reagents and solutions for large scale plasmid preparation
Buffer PI
Buffer P2 
Buffer P3 
Buffer QBT
Buffer QC 
Buffer QF
50 mM Tris HC1 pH 8.0, 10 mM EDTA pH 8.0 
100 pg/ml RNaseA.
200 mM NaOH, 1% (w/v) SDS 
3 M K-acetate, pH 5.5
750 mM NaCl, 50 mM MOPS, 15% ethanol, 
pH 7.0, 0.15% triton X-100 
1 M NaCl, 50 mM MOPS, 15% ethanol, pH 7.0 
1.25 M NaCl, 50 mM Tris HC1, 15% ethanol, 
pH 8.5
ix) Reagents and solutions for transfection
CaCl2
2x HEBS buffer
2x BBS buffer
PBS/triton X-100 
PBS/Tween-20
0.25 M CaCl2, made from 1 M stock
280 mM NaCl, 10 mM KC1, 1.5 mM Na2HP04.
2H20, 12 mM Dextrose, 50 mM HEPES, 
pH 7.05
50 mM BES, 1.5 mM N a^O , pH 6.5, 280 mM 
NaCl
PBS-A with 0.1% (v/v) triton X-100 
PBS-A with Tween 20
x) Reagents and buffers for luciferase and (3-gal assay
5x extraction buffer 125 mM Tris Phosphate pH 7.8, 10 mM EDTA,
10 mM DTT, 50% glycerol, 5% triton X-100 
Measuring buffer 25 mM glycyl glycerine, 15 mM M gS04,
5 mM ATP
Luciferin 250 pM in H20 , made from 25 mM stock
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5x cell lysis buffer 
Luciferase assay reagent
xi) Reagents and solutions
NPBT
NPB/sucrose 
Dignam C
lOx annealing buffer
5x binding buffer
lOx proteinase 
inhibitor cocktail
Dialysis buffer
125 mM Tris Phosphate pH 7.8, lOmM 
DTT, 50% (Promega) glycerol, 5% triton X-100 
20 mM tricine,1.07 mM (MgC03)4Mg(0H)2 5H20 , 
2.67 mM MgS04, 0.1 mM EDTA, 33.3 mM DTT, 
270 pM coenzyme A, 470 pM luciferin, 530 pM 
ATP, pH 7.8
for gel shift analysis
10 mM Tris-Cl pH 7.4, 2 mM MgCl2, 140 mM 
NaCl, 0.5 mM DTT (freshly added), 0.5 mM 
PMSF, (freshly added), and 0.1% (v/v) triton X- 
100 (freshly added).
As above with 50% (w/v) sucrose but excluding 
triton X-100.
20 mM HEPES pH 7.9, 25% (v/v) glycerol,
420 mM NaCl, 1.5 mM MgCl2. 0.2 mM EDTA,
0.5 mM DTT (freshly added), 0.5 mM PMSF 
(freshly added).
200 mM Tris-Cl pH 7.6, 100 mM MgCl2,
500 mM NaCl
125 mM HEPES pH 7.6, 25 mM MgCl2,
170 mM KC1
20 mM DTT, 2 mM PMSF
25 mM HEPES pH 7.6, 0.1 mM EDTA, 40 mM 
KC1, 11.4% (v/v) glycerine
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2.2 METHODS
2.2.1 SEQUENCE ANALYSES OF FHBY GENOME
i) Extraction of FHBV DNA from serum
Digestion of serum and extraction of DNA: Sera from FHBV were 
digested using the proteinase K method. Twenty five pi of serum were mixed with lx 
SDE buffer, (25 mM NaOAc, 2.5 mM EDTA pH 8.0), 1 mg/ml proteinase K, 0.65% 
SDS and 10 ng tRNA (transfer RNA) and incubated at 37°C overnight. A negative serum 
control was used after every two of the patient's sera. DNA from proteinase K digested 
serum was extracted using phenol/chloroform method. An equal volume of tris-saturated 
phenol was added to the digested serum, vortexed, and centrifuged for 5 minutes at 
13,000 rpm on a bench top microfuge. The upper aqueous layer was removed and added 
to equal volume of chloroform, vortexed and spun as above. The DNA was precipitated 
from the aqueous layer by the addition of two and a half volumes of 100% ethanol 
(ETOH) and one tenth volume of NaOAc (pH 5.2). DNA was kept at -70° C for a 
minimum of 30 mins and precipitated by spinning at full speed for 20 minutes (min), the 
pellet was washed twice with chilled 70% ethanol, dried under vacuum for 20 mins and 
finally resuspended in 12-15 pi of distilled water (dH20). The DNA was stored at -20°C 
until used.
ii) PCR amplification of extracted DNA
a) Primers: A range of primers were designed and used for PCR amplification 
and sequencing across the genomes (Table 2.3). Primers were synthesised in-house on an 
Applied Biosystems machine. Oligonucleotides were removed from the column with 1.5 
ml ammonia solution, deprotected in a 55°C water bath for at least 5 hrs and dried under 
vacuum overnight (O/N). The oligonucleotides were dissolved in 100-200 pi dH20 . The 
optical density (OD) was taken at 260 and 280 nm UV wavelength to measure the 
concentration. A 50 pmol/pl aliquot was made and stored at-20°C.
b) Polymerase chain reaction (PCR): DNA was amplified in two reaction 
rounds of the PCR in a 50 pi reaction volume. 5 pi of extracted serum DNA was mixed 
with 1.5 pi of dNTPs (250 pM of each), 1.5 pi of 15 mM of MgCl2, 5 pi of 10X PCR 
buffer, 25 pmol of each sense and antisense primer and 1 unit of DNA taq polymerase. 
To avoid evaporation, approximately 30 pi of light weight mineral oil (Sigma) was 
layered on the reaction mix. The PCR reaction was carried out in a 0.5 ml eppendorf tube 
using a Biometra Trio Thermoblock (Biometra, UK). After initial denaturation at 94°C for 
4 min, the first round PCR program used was as follows:
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denaturation
annealing
extension 72°C for 1 min 30 secs 
5 cycles
94°C for 1 min 
55°C for 1 min
denaturation
annealing
extension 72°C for 1 min 30 secs
90°C for 1 min 
55°C for 1 min
35 cycles
Followed by a further extension at 72°C for 5 min. 1 pi of first round product was 
nested or hemi-nested using 25 pmol of sense and antisense inner primer. The number of 
cycles was reduced to 25 instead of 35 in the second stage.
c) Agarose gel electrophoresis: DNA fragments generated by PCR 
amplification were resolved by nondenaturing agarose gel electrophoresis. Agarose gels 
were made using either lxTBE (Tris, boric acid, EDTA) or lxTAE (Tris, acetic acid, 
EDTA) buffer. One per cent agarose gel containing ethidium bromide (EtBr) at a final 
concentration of 0.3 pg/ml of gel was used to analyse PCR amplified DNA. Five pi of 
amplified DNA was mixed with 2 pi amount of gel loading dye and was run at 80-100 V. 
Appropriate size markers were always run alongside the samples. Following 
electrophoresis, DNA was viewed under short-wave UV light and a picture was taken 
using the Imager (Appligene) or a polaroid camera.
iii) Sequencing of DNA
a) Purification of PCR product:
a.i) DNA purification using Geneclean: DNA purification was performed using 
the Geneclean kit (Bio lab 101 Inc, CA, USA) either directly from the PCR product or 
from DNA in an agarose gel slice. A 3x volume of Nal and 5 pi of glass milk was added 
to a 50 pi of the PCR product (or adjusted to 50 pi with TE buffer when a lesser volume 
was taken) in a 1.5 ml eppendorf tube. This was vortexed and incubated at room 
temperature R/T for at least 5 mins with occasional vortexing. The mix was spun for 10- 
15 seconds at 13,000 rpm in a bench-top microfuge, supernatant was discarded and the 
pellet was washed 3x using New Wash buffer (provided in the kit). The pellet was dried 
and finally DNA was eluted in 50 pi of dH20  by heating at 55°C for 3 mins and spinning 
for 1 min. When necessary, a second step elution was performed. To an agarose gel slice, 
3 volume of Nal and a half of volume of TBE modifier (when TBE gel was used) was 
added and heated up at 55°C until the gel melted. Glass milk was added and the DNA 
elution procedure was performed as above.
59
Chapter-2 Materials and Methods
a.ii) Phenol/ chloroform extraction: To purify DNA by phenol/chloroform 
extraction method, PCR product was run on 2% Nusieve gel in lx TBE, the band was 
excised and the gel was melted with 100 pi TE buffer at 65°C for 10 mins. The mix was 
washed 3x with tris-saturated phenol and twice with chloroform. The DNA was 
precipitated on dry ice using two and a half volumes of ETOH and one tenth volume of 
NaOAc, Following a 20 min spin, pellet was washed once with ice cold 70% ETOH, air 
dried and diluted in appropriate amount of dHzO.
a.iii) Dynabead separation: Streptavidin coated magnetic Dynabeads were used to 
purify DNA from PCR reaction when biotinylated primers were used. Commercial kit 
dynal (dT) (Dynal. Oslo, Norway.) was used and the method was followed according to 
the instruction of the manufacturer. Twenty pi (lOpg/pl) M-280 Streptavidin beads were 
washed twice with binding and washing buffer (B and W) and reconstituted in 40 pi 
volume. 40 pi of PCR product was added and bound to the beads during a 15 min 
incubation. A magnetic separator was used to separate the unbound DNA which was 
removed with a pipette. The beads were washed twice with B and W buffer and 8 pi of 
freshly prepared 0.1M NaOH was added for 10 mins to make single stranded DNA 
(ssDNA). Beads containing ssDNA were washed once with 0.1M NaOH, once with B 
and W buffer and once with TE buffer. Finally, beads containing ssDNA were adjusted to 
a volume of 20 pi and stored at 4°C until sequenced.
a.iv) Purification of product using QIAGEN kits: PCR product was purified using 
QIAquick gel extraction kit (QIAGEN ltd). DNA was run on a 1% agarose gel, the band 
containing DNA was excised and 3 volumes of buffer QX1 was added. The gel was 
melted by dissolving at 50°C for 10 mins. The melted gel was loaded onto a QIA spin 
column and spun for 1 min at maximum speed. The column was washed once with buffer 
PE and the DNA was eluted from the column with 10 mM Tris-HCl, pH 8.5.
b) DNA Sequencing
b.i) Dideoxy method: DNA was sequenced using Sequenase Version 2.0 kit 
(Amersham Life Science, Buckinghamshire, England) according to the manufacturer's 
instruction. Six pi (1-5 pg) purified DNA was annealed with 5-10 pmol (2 pi volume) of 
sequencing primer and 2 pi of 5x Sequenase reaction buffer. The DNA-primer annealing 
reaction was performed on a thermoblock using the program 95°C for 1 min, 65°C for 2 
min, 95°C for 45 sec and 37°C for 20-30 min. The annealed DNA was added to 3.5 pi 
labelling mix containing 2 pi of 1:8 (5x stock) dGTP labelling mix, lpl of 0.1 mM DTT 
and 0.5 pCi S35y ATP. The reaction was started by the addition of 2 pi of 1:8 sequenase 
T7 polymerase enzyme at 2°C for 2 mins (using a thermoblock). Then 3.5 pi of 
radiolabelled DNA was added to each of four tubes containing dideoxy termination mixes 
(ddA, ddT, ddG, or ddC), which was warmed to 37°C. The termination reaction was 
continued at 37°C for 5-10 mins and was stopped by adding 4 pi of stop solution.
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b.ii) Direct PCR product sequencing: A direct PCR product sequencing kit from 
the same manufacturer (Amersham Life Science, Buckinghamshire, England) was 
purchased and the methods followed according to manufacturer’s instruction. Typically, 5 
pi of PCR product from a single, bright band was treated with 1 pi of exonuclease and 1 
pi of shrimp alkaline phosphatase at 37°C for 15 min and 80°C for 15 min using a 
thermoblock, to remove short oligonucleotides and primers. 5-10 pmol (in 3 pi volume) 
of sequencing primer was added, heated to 100°C for 3 min and cooled down rapidly by 
chilling on ice. The sequencing reaction was carried out as above.
b.iii) Sequencing of M13 single stranded DNA: To make M13 single stranded 
DNA, PCR product was first cloned in plasmid pT7-blue (Novagen, AMS Biotechnology 
UK Ltd, Oxon, UK) (the method is described in section 2.2.3 of this chapter) and 
transformed in E.coli NM522 cells. 2 ml of exponential culture was infected with M13 
K07 helper phage and incubated for 1 hour at 37°C. 400 pi of this culture was transferred 
to 10 ml L-broth containing 70 pg/ml ampicillin and incubated O/N at 37°C with shaking.
1.5 ml of the culture was spun for 5 mins and the supernatant was added to 300 pi of 2.5 
M NaCl/20% PEG. The mixture was kept on ice for 20 min to precipitate the phage, 
centrifuged at high speed for 5 min to remove any trace of PEG and the pellet was 
resuspended to 50 pi of TE buffer. Phage DNA was extracted once with an equal volume 
of phenol/chloroform, purified using Geneclean kit and finally eluted in 20 pi of TE 
buffer. 7 pi phage DNA was used for sequencing. As phage DNA are single stranded, 
annealing was done at 65°C for two mins then followed by cooling to 37°C for 20-25 
mins. Sequencing reaction was performed as described above.
c) Sequencing gel: Two glass plates of uneven size were washed and wiped 
twice with 100% ETOH. The smaller one was treated with Repelcote (BDH, Poole, UK) 
which produces a siliconised surface. A 6% polyacrylamide/7M urea gel of 0.4 mm 
thickness was prepared from Sequagel 6 (National Diagnostics, Atlanta, Georgia, USA) 
according to manufacturer's instructions. After pre-electrophoresis with lx TBE for 20- 
30 min at 70W, the wells were washed and 3-4 pi of the sequencing reaction was loaded 
in each well in the order TCGA. Prior to loading, the sequencing reaction was denatured 
at 95°C for 2 min. Electrophoresis was carried out at 70W for 100 min (until the first blue 
dye reached the bottom of the gel ). For analysis of longer sequence, the gel was run up 
for as long as 300 min. On completion, the gel was removed from the apparatus, the 
plates were separated and the plate supporting the gel immersed for 10 min in a buffer 
containing 10% methanol and 10% acetic acid. This fixes the DNA into the gel and 
prevents diffusion of the bands. The gel was transferred to 3 MM Whatman filter paper, 
covered with cling film, dried under vacuum and autoradiographed against Kodak XS-1 
film.
d) Interpretation of sequencing data: Sequencing data were analysed using 
GCG package on computer. The sequences from Genbank and from study patients were
61
Chapter-2 Materials and Methods
aligned separately and a consensus was made for each. Sequence variations were 
determined from the consensus. Unique variants (for FHBV sequences) in this study 
were defined as those variants which did not occur in the Genbank data set nor in non- 
FHB cases, but only in FHB cases. Rare variants were defined as those variants which 
occurred rarely (once or twice) in the Genbank data set but occurred in larger numbers in 
FHBV sequences.
2.2.2 PHYLOGENETIC ANALYSIS
i) Phylogenetic trees
Core and X gene sequences were aligned with the ClustalW programme originally 
devised by Thomson et. al. (1994) and phylogenetic trees were constructed using a 
maximum likelihood method (program fast DNAml). The maximum likelihood 
transition:transversion ratio (Ts/Tv) and relative rate test of evolution for the three codon 
position was estimated using a likelihood program (SPOT). For the 191 core gene 
sequences, the Ts/Tv was determined to be 1.24 with the relative rates of evolution as 
0.87:0.62:1.51 at codon positions 1, 2 and 3 respectively. For the 114 X gene sequences 
the Ts/Tv ratio and the codon-specific relative rate test of evolution were found to be 1.28 
and 1.49:1.04:0.50. In all cases, unrooted phylogenetic trees were constructed and then 
midpoint rooted for clarity.
ii) Relative rate test of evolution
In order to determine whether there is any difference in the rate of evolution 
between FHBV and non-FHBV sequences, a relative rate test was undertaken. Distance 
between FHBV sequence (a) and their nearest non-FHBV neighbour (Z?)was compared to 
their nearest non-FHBV outgroup sequences (c) using the DNADIST (for nucleotide) and 
PROTDIST (for amino acid) programs within the PHYLIP package (Felsenstein, 1993). 
Thirteen and 14 comparisons were made for the X and core gene respectively. Tests were 
also performed for the antigenic regions in the core genes as defined in Carman et al 
(1995a) and according to the functional subdivisions in X identified in Yuh et al. (1992). 
Analysis at the protein level was limited statistically to the complex X and core genes and 
the combined antigenic and non-antigenic regions in core. Relative rate tests were also 
performed on FHBV sequences with and without the A1896 pre-core stop codon variant (9 
and 7 comparisons, respectively) and on a set of non-fulminant A]896 cases (9 
comparisons). In the tests, examining the effects of the A )896 variants, sequences from 
G1896 chronic hepatitis B virus cases acted as sequence b and c. In all cases the Wilcoxon 
Signed Rank Test was used to test the significance of any differences in evolutionary rate.
Finally, variants were divided into those that altered the encoded amino acid 
(nonsynonymous changes) and those that did not (synonymous changes) using the
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program INA (Ina, 1995) and compared between FHBV and non-FHBV cases. The 
relative rate of synonymous change is a useful indicator of the strength of natural 
selection.
iii) Analysis of clustering
A cluster is defined here as an uninterrupted phylogenetic lineage of 
epidemiologically unlinked FHBV sequences. We undertook an analysis to determine 
whether FHBV sequences form distinct clusters on the tree more than expected by 
chance. This was done by treating FHBV status as an additional character state, calculate 
the expected number of evolutionary steps, given the number of FHBV cases under a 
parsimony based model of evolutionary change (Carter et al., 1990), as implemented in 
the program FMAB.
2.2.3 MOLECULAR CLONING AND 
GENETIC MANIPULATION OF DNA
i) Preparation of insert and vector by restriction endonuclease digestion
Prior to digestion, the insert DNA was purified using Geneclean kit or 
phenol/chloroform extraction method. Restriction enzyme digestion of insert and vector 
DNA was carried out with the buffer and incubation temperature specified by the 
manufacturers. The number of units of enzyme added depended on the activity of enzyme 
and the amount of DNA being digested. Typically, 10 units of enzyme were added per pg 
of DNA. To dephosphorylate the restriction endonuclease digestion reaction, 1 unit of 
Calf Intestinal Phosphatase (CIP) per pg of DNA was added with CIP buffer and 
incubated at 37°C for 30 min. Digested DNA was run on 1% agarose gel with TBE 
buffer, visualised under UV, and the appropriate band was excised and purified using 
Geneclean or phenol/chloroform extraction method.
ii) Ligation of insert DNA and vector
The digested and purified vector and insert DNA were mixed in a ratio of 3 parts 
inserts to 1 part vector in a total volume of 15 pi containing lx ligation buffer (Life 
Technologies, Paisley, UK), and 1 unit of T4 DNA ligase and was incubated for 3-4 hr at 
16°C. The ligated DNA was either used immediately in a transformation reaction or was 
stored at -20°C until required.
iii) Transformation of E. coli
a) Preparation of competent cells : 10 ml of L-broth was inoculated with 10 
pi of glycerol stock of DH5-a bacteria and incubated in an orbital shaker at 37° overnight 
to produce a starter culture. 1.5 ml of this culture was used to inoculate 100 ml of L-broth 
which was grown in a shaker for approximately 2-3 hr or until the culture reached a
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density giving an OD600 0.2-0.3. The bacterial cells were transferred to two 50 ml Falcon 
tubes and spun at 3,000 rpm for 10 mins in a Sorvall RT 6000B centrifuge. Each cell 
pellet was resuspended in 20 ml of sterile, ice cold CaCl2 (0.1M) and incubated on ice for 
2 hr. The cells were then pelleted and resuspended in a total of 2 ml of CaCl2 (0.1M) and 
incubated on ice for at least 2 hr after which time they were ready for transformation 
Competent cells were also stored as a 15% glycerol stock in 1 ml aliquots at -70°C.
b) Transformation: 7.5 pi or 15 pi of ligation mix was incubated on ice with 
100 pi of competent DH5-a cells. After 40 min the cells were subjected to a 2 min heat 
shock in a42°C water bath and immediately placed on ice for 2-5 mins. 100 pi of room 
temperature L-broth was added to the mix and incubated in a shaker at 37°C for 1 hr. The 
cells were then pelleted, resuspended in 100 pi of fresh L-broth and plated onto LB agar 
plates containing 100 pg /ml ampicillin. If p galactosidase selection was used, 20 pi of X- 
gal (20 pg/pl in dimethyl formamide) and 56 pi of IPTG (100 mM in dH20 ) were initially 
spread onto the agar plate, and allowed to soak in for 30 mins prior to plating out the 
bacteria. The plates were dried at room temperature before incubation in an inverted 
position at 37°C overnight.
iv) Miniprep: small scale preparation of plasmid DNA
a) Alkaline lysis method: Minipreparation of plasmid DNA was done by 
alkaline lysis method as described by Shambrook et al. (1982). A single transformed 
bacterial colony was transferred into 3-5 ml of L-broth containing 100 pg/ml ampicillin 
and incubated at 37°C shaker for 16-18 hr. 1.5 ml of each culture was transferred into a
1.5 ml eppendorf tube and spun. The cell pellet was resuspended in 100 pi of solution I. 
After 5 min at room temperature, 200 pi of freshly made solution II was added, gently 
mixed 5-6 times and incubated on ice. 150 pi of solution III was added after 5 min; the 
tube was inverted and vortexed for 10 second. To extract the DNA, 150 pi of 
phenol/chloroform was added, vortexed and spun for 5-7 mins on a bench top microfuge. 
The upper clear phase was transferred to a fresh 1.5 ml eppendorf and the DNA was 
precipitated with two volume of 100% ETOH. The pellet was washed with 70% ETOH 
and air dried at room temperature. Finally, DNA was resuspended in 50 pi TE containing 
20 pg/ml RNaseA and incubated at 37°C for 30 mins.
b) STET prep method: 5 ml of saturated overnight bacterial culture was 
pelleted for 1-2 mins at 13,000 rpm. Supernatant was removed and the pellet was 
resuspended in residual medium. 300 pi of STET buffer containing 10 pi lysozyme (from 
10 mg/ml stock)was added and boiled at 95°C for exactly 1 min. The denatured cell 
suspension was spun for 20 mins at 15,300 rpm at 4°C, the pellet was removed with a 
tooth pick and 400 pi isopropanol was added to the supernatant. After 10-15 mins, DNA 
was precipitated by spinning at 4°C for 15 mins at 15,300rpm. 50 pi TE containing 
RNaseA (20 pg/ml) was added to the air-dried pellet.
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v) Restriction enzyme digestion of miniprep DNA
Digestion was carried out using the buffer and incubation temperature specified by 
the manufacturer. For miniprep DNA, typically 2 units of each enzyme was used per 
reaction containing 10 gl of miniprep DNA in a total of 20 gl volume. DNA was digested 
for 2-3 hr and 5 gl of digested product was run on a 1 % agarose gel containing EtBr and 
the insert was visualised under UV. As a digestion control, plasmid without insert was 
also digested with each enzyme, and run on the gel along with digested miniprep and 
undigested plasmid DNA.
vi) Large scale preparation of plasmid DNA
The QIAGEN midiprep kit was used for large scale preparation of plasmid 
following the manufacturer's instruction. Either a single large colony from L-broth agar 
plate or 10 gl of glycerol stock was inoculated into 10 ml of L-broth (Luria broth) 
containing 1 gg/ml ampicillin and grown in a shaker at 37°C for 3-4 hr to produce a starter 
culture. One ml of this broth was transferred to 100ml of L-broth containing 100gg/ ml 
ampicillin in a 200 ml flask and incubated at 37°C overnight. Typically, 25-30 ml of 
culture was spun at 3,000 rpm for 10 mins in a Beckman RC6000 centrifuge. Cell pellet 
was resuspended in 4 ml of buffer PI, 4 ml of buffer P2 was added, mixed gently and 
incubated at R/T. After 5 min, 4 ml of buffer P3 was added, mixed gently 12-15 times 
and incubated on ice for 15 min. The mixture was transferred in a tube in a SS-34 rotor 
and spun at 15,000 rpm for 30 mins in a Sorval centrifuge (RC 5B, Du Pont). The 
supernatant was passed through a QIAGEN midi column which had been previously 
equilibrated with buffer QBT. The column was washed 2x with wash buffer QC and the 
DNA was eluted with 5 ml of elution buffer QF. DNA was precipitated by the addition of 
0.7x volume of isopropanol, incubated at room temperature for 5 min and spun for 35 
min at 11,000 rpm in an SM-24 rotor in a Sorval centrifuge. After a 70% ETOH wash, 
the DNA pellet was resuspended in 100 gl of TE.
Plasmid was purified in large-scale using Hybaid recovery™ plasmid midiprep kit 
(HYBAID, Middlesex, UK) according to manufacturer's instructions. A saturated 
overnight culture was spun, pellet was resuspended in 500 gl dH20  and transferred to a
1.5 ml eppendorf. The cell suspension was centrifuged again and the pellet was 
resuspended in 200 gl pre-lysis solution. 400 gl of alkaline solution was added, mixed 
gently and incubated at room temperature for 5 mins. To the mix, 300 gl ice-cold 
neutralising solution was added and vortexed for 5 seconds at full speed. The suspension 
was incubated on ice for 5 min, spun for 5 mins and the supernatant was added to 1.2 ml 
of binding buffer. The DNA/binding buffer complex was settled at room temperature for 
2-5 min, supernatant was discarded and the complex was transferred to a spin filter, spun
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for 2-5 min and washed once with washing buffer. Finally DNA was eluted in 350 pi 
dH20  or TE.
vii) Sequencing of cloned DNA
8 jllI of plasmid DNA was mixed with 2 p i  of 2M NaOH and incubated at room 
temperature for 10 min to make single stranded DNA. 7 pi of dH20 , 3 pi of 3M NaOAc 
and 50 pi of 100% ethanol was added to the mix which was incubated on dry ice for at 
least 20 min. DNA was precipitated by spinning at 13,000 rpm for 20 min and the pellet 
was washed with ice cold 70% ETOH, dried and resuspended in 6-7 pi of dH20 . The 
DNA was then annealed with appropriate primers and sequenced as described before 
(Table 2.3).
2.2.4 TRANSFECTION
i) Tissue culture
Cells were grown in a medium (80 cm2) or large (175 cm2) tissue culture flask 
until confluent. To split cells, the cells were washed with versene and then trypsinised 
with a solution of trypsin and versene (1:4 ratio) for 5 mins at 37°C. Cells were 
resuspended in 20 ml of DME (Life Technologies, Paisley, UK.) medium (DMEM) 
containing 10% FCS (foetal calf serum), 2 mM glutamine, 100 IU/pl penicillin and 100 
IU/pl streptomycin, and triturated using a fine tip plastic pasteur pastette and seeded to 
new plates and flasks containing DMEM and grown in a 5% C 02 incubator at 37°C. 
Flasks were seeded at 1:10 dilution and 35 mm plates were seeded at 3xl05 cells per plate.
ii) Transfection
Cells were transfected using calcium phosphate method when they were 50-60% 
confluent. Typically, for a 60 mm plate, 150 pi of 0.25M CaCl2 containing 5 pg plasmid 
DNA was prepared and 150 pi of 2x HEBS (HEPES buffered saline) buffer was added 
slowly, dropwise to the DNA/ CaCl2 solution to allow a CaP04 precipitate to form a 
CaP04 /DNA complex. The mixture was incubated at room temperature for 30 mins to 2 
hr and then added dropwise across the plate. After 8-16 hr, the medium was changed and 
incubated at 37°C in 5% C 02 for further 24-48 hr until the cells were harvested.
As an alternative method, 2x BBS (BES buffer saline) buffer was used instead of 
HEBS. After transfection, the plates were incubated in 3% C 02 until the medium was 
changed at 8-16 hr when the plates were transferred to the 5% C 02 incubator.
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2.2.5 FUNCTIONAL ANALYSIS
i) Expression of core protein by immunofluorescence
a) Construction of plasmids: Core gene was expressed both with its 
homologous promoter and also using a heterologous promoter. To construct plasmid with 
its homologous promoter, an area spanning nt 1549-2458 containing the negative 
regulatory elements (NRE), the core upstream regulatory sequence (CURS), the basal 
core promoter (BCP), enhancer II (Enhll) and the core gene was generated by PCR 
amplificaton. The primers used were C9y and C2y with Xho 1 and Pst 1 restriction site 
respectively as outer sense and antisense primers and nested with C8y and C4y as inner 
sense and antisense primers with the same restriction sites (Table 2.3). The DNA 
fragment was cloned into vector pT7-blue (Novagen, AMS biotechnology, Oxon, UK 
Ltd.). The Xho-1 and Pst-1 digested product was excised from the gel, purified and 
recloned into pKLt-55 vector whose own promoter had been removed.
To study the effect of core protein sequence variability on intracellular distribution 
without any effect from its homologous promoter, a DNA fragment of ntl 818-2458, 
containing core gene only was generated by PCR from the clone with homologous 
promoter using the primers C5e and C4b with Eco R1 and Hind III restriction site and 
cloned into vector pRK-5. This vector contains the SV40 origin of replication and CMV 
early promoter.
b) Immunofluorescence: Intracellular distribution of core protein was 
performed by standard immunofluorescence technique. 5 pg plasmid DNA was 
transfected onto cells on a coverslip in a 35 mm dish.. 48-72 hr after transfection, the 
cells were harvested. The cell monolayer was washed 3x with PBS-A and fixed with 
paraformaldehyde (PFA) for 10-15 min at R/T. Cells were washed again 3x with PBS-A 
and permeabilised for 10 min with 0.1% triton X-100 in PBS. Cells were washed again 
twice with PBS-A, twice with 0.05% Tween 20 in PBS-A and labelled with 30 pi of anti­
core polyclonal rabbit antibody (Zymed, CA, USA) on each coverslip. The dish 
containing the coverslip was incubated in a moist box for 1 hr at R/T in the dark, washed 
twice with PBS-A, twice with PBS-tween 20 and incubated with 30 pi of FITC-labelled 
mouse anti-rabbit IgG for 30 min at R/T in dark. After 3 washes with PBS-A, the 
coverslip was dried and mounted on glass slides with 5 pi Citifluor, a glycerol/PBS 
solution (University of Canterbury, Kent, UK). Cells were viewed using a Nikon 
Microphot-SA fluorescence microscope with appropriate filters; pictures were taken using 
Kodak Film.
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ii) Transcription analysis by luciferase assay
a) Construction of plasmid: Plasmid constructs were based on pBL vector 
which includes the luciferase gene. The plasmid was derived form P-bluescript vector 
whose own promoter site was removed (Figure 2.3). A DNA fragment of 400 nt (ntl549- 
1974) which includes NRE, CURS, BCP, enhancer II and approximately 100 bases from 
the beginning of the core gene was generated by PCR. The primers C8m and BC-3 with 
BamH I  and Pst I  resriction sites respectively were used as sense and antisense and 
cloned into the pBL vector upstream of the luciferase gene.
b) Luciferase assay: Luciferase assay was performed according to the method 
described by Wood, (1991). Typically, 10 pg of plasmid DNA was transfected into two 
60 mm plates containing 50-60% confluent Huh7 or HepG2 cells by standard transfection 
method. To overcome the effect of variable transfection efficiency, each plate was 
cotransfected with 0.2 pg pSV vector containing p-galactosidase gene. 72 hr after 
transfection, cells were harvested for the assay. Cell lysates were made according to the 
method described by Wood, (1991). Cells were washed 2 times with PBS; 350 pi cell 
extraction buffer was added to each plate, incubated at room temperature for 10-15 min 
and the cell lysates were transferred to an eppendorf. Cell lysate were spun at 13,000 rpm 
for 2 min to precipitate the cell debris; supernatants were removed to a fresh eppendorf 
and used immediately for the assay or stored at-20°C.
The assay was done by adding 50 pi cell lysate to 350 pi measuring buffer 
containing 530 pM freshly added ATP in a Starstedt tube; (two tubes were taken for each 
plate) shaken quickly and measured in the luminometer (Lumac, model LB-95001, 
Beathold, Hannover, Germany) in which 100 pi luciferin (25 pM) was injected 
automatically.
Alternatively, the assay was done by using the Promega luciferase kit (Promega, 
Madison, USA) according to manufacturer's instructions. Typically, 250 pi of lysis 
buffer was used to make a cell lysate and 50 pi cell lysate was mixed with 100 pi assay 
buffer containing 470 pM luciferin and measured in a luminometer.
p-galactosidase assay was performed using the same cell extracts. 50 pi cell extract 
was added to 350 pi of (3-gal assay buffer containing lmg/ml ONPG, and incubated at 
37°C until pale yellow colour developed. The OD at 405 nm was measured. The 
luciferase value of each experiment was calculated by dividing the mean unadjusted 
luciferase value by the mean (3-gal value and the luciferase value for each construct was 
the mean value of all experiments.
For each construct, both luciferase and P-galactosidase assays were performed at 
least 3 times; for each assay, duplicate plates were used and, for each plate, duplicate 
measurements were taken.
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iii) Mobility shift assay
a) Preparing nuclear extracts: Nuclear extracts were made from Huh7 and 
HeLa cells. Cells were grown for five days in 5% C02 incubator at 37°C. The method 
followed was originally described by Dignam et al. (1983). Cells were washed twice with 
ice cold PBS, scraped with a cell scraper and taken into a 1.5 ml eppendorf tube. Cells 
were spun at 4,000 rpm for 5 mins on a bench top microfuge at 4° C. Two hundred pi of 
NEBT buffer was added to approximately 106 cells, mixed quickly and incubated on ice 
for 3-5 min to lyse the cells. The cell lysates were then layered on equal volume of NPB 
buffer containing 50% sucrose to separate nuclei from the cytoplasmic fraction. Nuclei 
were then pelleted by spinning at 13,000 rpm for 12 mins at 4°C and resuspended in 50 pi 
of buffer Dignam C and rotated gently for 30 mins to 1 hr at 4°C to lyse the nuclei. The 
lysate was then spun at 13,000 rpm for 12 min at 4°C and the supernatant containing 
nuclear extract was snap-frozen in liquid nitrogen and stored at -70°C until required.
b) Estimation of protein: The amount of protein in nuclear extract was 
estimated by Bradford assay. The Bradford (Bio Rad, Hemel Hempstead, UK) solution 
was diluted at a 1:5 ratio in dH20  and into 500 pi of this solution, 2,4 and 10 pg BSA 
(New England Biolab, Hertfordshire, UK) and 10 pi of nuclear extract were added. QD 
was taken at 595 nm and the amount of protein in the nuclear extract was calculated.
c) Annealing of oligonucleotides: Complementary oligonucleotide pairs 
corresponding to the variant HBV sequences were made either using in-house oligo 
synthesiser or purchased from Oligold (Table 2.4) (Eurogentec, Seraing, Belgium). The 
oligonucleotides were removed from the column, deprotected and dried as described in 
section 2.2.1. 50 pg of each sense and antisense oligonucleotide were annealed with 
annealing buffer (20 mM tris pH 7.6, 10 mM MgCl2, 50 mM NaCl) in 260 pi volume at 
70°C for 5 mins and cooled down very slowly. Annealed oligos were radiolabelled or 
stored at 4°C until used.
d) Labelling of oligonucleotides: 250 ng of annealed oligonucleotide was 
labelled with 10 units of T4-polynucleotide kinase (New England Biolab, Hertfordshire, 
UK) and 40pCi 32Py ATP (in 20 pi volume) at 37°C for 30-45 mins. Radiolabelled 
oligonucleotides were purified from unincorporated 32P using a Sephadex G-50 spin 
column (Pharmacia, Uppsala, Sweden). Before use, the column was washed twice with 
lx TE buffer by spinning at 500g for 4 min. Labelled oligonucleotides were diluted to a 
volume of 70 pi, placed onto the Sephadex bed and eluted by spinning at 500g for 4 min. 
The radiolabelled oligonucleotides were stored at -20°C.
e) Gel-shift assay: 30,000-50,000 cpm of radiolabelled oligonucleotides were 
mixed with 4 pi of 5x binding buffer, 2 pi of proteinase inhibitor cocktail, 1 pg poly 
dldC, and 2 pg BSA in a total volume of 10 pi and incubated on ice. The labelled 
oligonucleotide was then added to 10 pi dialysis buffer containing 0, 1 and 3 pg of
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nuclear extract. The reaction mix was incubated at R/T for 15-20 min and shift was 
analysed by electrophoresis on a 6% polyacrylamide nondenaturing gel. Two pi of 20% 
Ficoll was added prior to loading. The gel was fixed in gel fixing buffer containing 10% 
methanol and 10% acetic acid and dried under vacuum. The dried gel was exposed 
overnight using a Kodak XS-1 film.
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Table 2.3 List of primers for PCR and sequencing
Fragment Primer Sequence Restriction
site
sense/antisense
inner/outer
Nucleotide
position
Primers for PCR
1 Gl C CGG ATCCCC ACCGTG AACGC 
CCA
Bam HI sense, outer 1615-1630
G2 CGGGATCCTGCCCAAGGTCTT
ACATAAG
Bam HI sense, inner 1639-1658
C2N CCCC/AGTAAAGTTC/TCCG/CA
CCTT
- antisense, outer 2475-2495
C4 GAGAATTCTACTAACATTGAG
ATTCCCG
Eco R1 antisense, inner 2441-2460
2 19A TATCAACACTTCCGGAA/GACT - sense 2319-2338
21A GAGAATTCCTGAGCCTGAGGG
CTCCAC
Eco R1 antisense, outer 3082-3099
22A CTCCAACTGA/GTGA/GTCGGG - antisense, inner 2972-2990
3 23A CGGATCCGCCTCATTTGC/TGG
GTCAC
Bam HI sense 2809-2826
26 GAGAATTCGGTATTGAGAGGA
TTCTTG
Eco R1 antisense 222-240
4 SI CCTGCTGGTGGCTCCAGTTC - sense, outer 56-75
S6 CGGGATCCGAGGACTGGGGAC
CCTG
Bam HI sense, inner 130-146
S2 TG AC ATACTTTCC AATC AAT A - antisense, outer 972-992
S7 GAGAATTCTTAGGGTTTAAATG 
TATACC
Eco R1 antisense, inner 823-842
5 S4 GTATGTTGCCCGTTTGTCCTC - sense, outer 459-479
12A GGGCC A AGTCTGT AC A A/GC AT 
C
sense, inner 758-778
14 GAGAATTCTAG/AACAAAGGA
CGTCCCGCG
Eco R1 antisense 1408-1427
6 01 GCCTGTTTTGCTCGCAGC - sense 1288-1305
0 2 CACCACCCCCAACACCTC - antisense 1734-1752
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Table 2.3 List of primers (continued)
Primers used for making plasmid constructs
C9y CGAGCTCGAGACCACGGGGCGCAC Xho 1 sense, outer 1516-1539
CTCTCTTTAC
C8y CGAGCTCGAGGTCTGTGCCTTCTCA Xho 1 sense, inner 1549-1571
TCTGCC
C2y GACCTGCAGCCCA/CGTAAAGTTTC Pst 1 antisense, outer 2476-2495
CC/GACCTT
C4y G ACCTGC AGCCTT ATG AGTCC AAGG Pst 1 antisense, inner 2459-2479
G/AATA
C8m TCGACGGATCCGTCTGTGCCTTCTC Bam HI sense 1549-1571
ATCTGC
BC3 GCATTCTGCAGGAAAGAAGTCAGAA Pst 1 antisense 1956-1974
GGCAA
C5e AGTCGAATTCCA/CCCTCTGCCTAA EcoR 1 sense 1828-1845
CATCTC
C4h GG AC AGA AGCTTCCTT ATG AGTCC A Hind III antisense 2459-2479
AGGG/ATA
Primers for sequencing
BC1 GAAAGAAGTCAGAAGGCAA - antisense 1956-1974
C a CATACA/TGCACTCAGGCAAGC - sense 2055-2073
KC1 GCGAATCCACACTCCA/GAAAGA - antisense 2261-2271
S8 GAAGATGAGGCATAGCAGC - antisense 415-434
S3 AATGGCTCTAGTAAACTGAGCC - antisense 669-690
16r CTGCGAGAGCAAAACAAGC - antisense 1288-1304
14r GCGGGACGTCCTTTGTC/TTA - sense 1408-1427
C l CAC/AACAGTCTTTGAAGTAT/GG - antisense 1702-1721
Sir GAACTGGAGCCACCAGCAGG - antisense 56-75
21r TGGAGCCCTCAGGCTCAG - sense 3082-3099
Table 2.3 shows the primers used for PCR, sequencing and cloning. 6 overlapping 
fragments of PCR products were generated to sequence full-length genome. The 
underlined nts denote restriction sites. sense= sense strand, antisense= antisense strand, 
inner= primers used in nested PCR, outer= primers used in 1st round.
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Table 2.4 Sense strand oligonucleotides used for gel shift
OL-wt 1742
OL-CHBV-2
OL-FHBV-4
OL-FHBV-14
OL-FHBV-5
OL-FHBV-1
OL-FHBV-15
GGGGGAGGAGATTAGGTTAAAGGTCTTTGTATTAGGAGGCT 1783
------------------- C------A----- T-A -T-A — C--------------------
------------------- C------A----- T-A -T-A --------------------------
------------------- C------A----- T-A -T-A --------------------------
 T C----------------
O L -ew .l 1031 CACAATGTGGTTATCCTGCGTTAATGCCCTTGTATG 1066 
O L -em .l  T-------------- T------------
OL-ew 2 1231 CGCATGCGTGGAACCTTTGTGGCTCCTCTGCCGATC 1266
OL-em.2  TC-----------------------------
OL-lt.wt 1783 GTAGGCATAAATTGGTCTGCGCACCAGCACCATGC
OL-lt.in ----------------------------------------------- A--------------
AACTTTTTCACCTCTGCCTAA-TCAC 1842 
 A------
Table 2.4 shows the oligonucleotide sequences used for gel shift analysis. Only sense 
strands are shown here. Nucleotide positions of 5' and 3' ends, numbered from Eco R1 
site.
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Chapter-3 Results
The aim of this study was to determine whether viral factors are associated with 
the development of FHB. The study was divided into three parts. The first part was to 
sequence FHBV DNA extracted from patients' sera. This was followed by phylogenetic 
analyses of FHBV sequences to determine whether they are within particular lineages. 
The third part involved functional analyses of some selected FHBV cases. The first 
section of this chapter consists of sequence analyses of FHBV genomes. In the second 
section, the sequence data for core and X genes alone of FHBV cases were analysed 
compared to 161 and 86 core and X genes respectively from non-FHB cases. These 
analyses were carried out in collaboration with the Wellcome Centre for the Epidemiology 
of Infectious Diseases at Oxford University. The results in the third section include 
transcription analyses, nuclear factor binding assays and core protein expression and 
distribution in selected cases.
3.1 SEQUENCE ANALYSES OF FHBV GENOMES
Twenty one patients were included. Sixteen were FHBV, 3 were contacts of 
FHBV cases and 2 had self-limited acute infection. Of these 21 patients, sequencing was 
performed across the full length genome for 8. These 8 comprised 5 FHB Vs, 2 
symptomless carrier contacts, and 1 contact with acute hepatitis who was the source of 
infection to her sibling (FHBV-6). For 10 patients, sequences were generated from the 
begining of Enh-I to the end of the core gene. For the remaining 3 patients, the genome 
was sequenced from the begining of Enh-II to the end of the core gene. In summary, the 
following sequences were generated from a total of 21 patients:
Full genome 8 patients
Enh-I/X promoter, X gene, Enh-H/BCP, core gene 10 patients
Enh-II/BCP, core gene 3 patients
This section discusses the detailed sequence analysis of the above mentioned 
regions for the 21 study patients and compares these with 11 published sequences from 
three recent studies on FHB cases (Ogata et al., 1993; Hasegawa et al., 1994, Stemeck et 
al., 1996). The phylogenetic section includes analysis of variants in the X and core gene, 
so there is some repetition. Other studies (Yotsumoto et al., 1991; Karayiannis et a l, 
1995) have shown that FHB patients and their contacts have identical or nearly identical 
sequences; therefore, they are considered here as FHB cases.
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i) Nucleotide variants clustered in four positions of Enh-I region
Sequencing data were available in the Enh-I and X promoter regions from 18 
cases. Fourteen of them were FHB, 3 were contacts and 1 was an acute hepatitis case. 
Table 3.1 shows the distribution of nucleotide variation in the Enh-I and X promoter 
region in 17 FHB cases in this study in comparison with 11 other FHB cases from three 
other groups and also non-FHB cases in this study (1 case) and from Genbank (22 
cases). Most of the variants in this region were found to be unique to one case and absent 
in the others and were distributed throughout the entire Enh-1 and X promoter region. 
However, a significant number of patients had variants in four nucleotide positions. 
T/C]050G was found in 10 of our 17 FHB cases, but not in the acute case studied at the 
same time. This variant was also seen in 2 of 11 other FHB cases but occurs only once in 
22 non-FHB sequences in Genbank. TI059C was seen in 10 of our 17 FHB cases, 7 of 11 
FHB cases reported previously and was seen in only 1 of 22 Genbank non-FHBV 
sequences. Clustering of variants was also seen at positions 1249 and 1250. At nt 1249, 
common HBV sequences contain either a G or a C. Ten of our 17 FHB cases showed 
T 1249. In addition, T1250C was observed in 12 of our 17 FHB cases. These substitutions 
were also observed in other reported FHB cases (5 and 6 of 11 cases respectively). T 1249 
was also found in 1 of 22 non-FHB cases. It is to be noted that 10 out of 12 cases C ]250 
appeared with T1249; whereas in two other cases, it appeared with G ]249 or C 1249. 
Interestingly, these substitutions are found in the basal X promoter or accessory module 
of Enh-I (Trujillo et al., 1991) but not in the liver specific basal module where most of the 
nuclear factors bind. Occurrence of variation in the basal X promoter region may be 
significant. The second section of this chapter provides further detail.
ii) Higher number of variants in Enh-II/CP are found in the FHB cases
Sequence analysis of the Enh-II/CP complex was available for all 21 of my 
patients. Table 3.2 shows the distribution of variants compared to the other 11 reported 
FHB cases and the 22 non-FHB sequences. A specific variant that was common to all 
fulminant cases could not be identified. However, some of the variants occurred more 
commonly in FHB cases than in non-FHB cases. The most common variants found were 
T ]676? G1754, A)757, T1762, A1764 and T1766. Most of these variants are also observed in 22 
non-FHB sequences obtained from Genbank data, but the number of occurrences are 
lower than in fulminant cases. T )676 occurs in 12 of 19 FHB cases analysed here, but is 
not seen in either of the two acute cases and is seen in only 1 of 22 non-fulminant 
Genbank sequences. Eight of 11 FHB cases from other studies also contained this 
variant. T 1754G was found in 6 cases in this study and also in one case in a previously 
reported study, but is absent in the Genbank data.
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A G to A conversion at nt 1757 (A1757) was also observed in 6 of 19 FHB cases in this 
study and 7 of 11 cases in other studies, but seen in 2 of 22 non-FHB cases and was not 
in the acute cases. The association of T1676 and A1757 with FHB is a matter of little debate. 
In one study they are mostly found to be associated with genotype D and therefore not 
believed to have a major contribution in the development of FHB (Bollyky et al., 1997, 
submitted). However another recent study by Stemeck et al. (1996) it was reported that 
T 1676 and A1757 are not genotype D specific and they occurred rather infrequently in 35 
non-fulminant cases in Genbank (17 and 14 percent cases respectively).
Two other frequently described variants in the BCP are T,762 and A ]764. These 
variants were found in 5 of 19 cases at each position in our study and also occurred in 4 
of 11 and 5 of 11 fulminant cases respectively in other studies. However, they are also 
seen in non-fulminant cases (4/22 for each variant) showing that these are not unique to 
FHBV sequences. Later analyses (section 2 and 3 of this chapter) suggest that presence of 
these two variants is significant when they appear in combination with one or more other 
variants in the same region. In two of the cases in our study, these variants were observed 
in the form of mixed populations (FHBV-4 and 5); in two other cases G ]764T or G1764T/A 
were observed (FHBV-8 and FHBV-14). There are two other variants, T ]766 and A 1768, 
which were reported to be mostly associated with FHB cases, and these were also seen in 
my study. A variant at nt 1766 was found in 5 of 19 FHB cases. In two cases it was seen 
as a mixture of C/T, in one, a mixture of C/G, and in another case as a G. Similarly, T 1768 
is also found in mixed or non-mixed form in a total of 3 cases. These two variants were 
also seen in the other 11 reported FHB cases (2 and 1 cases respectively). A recent study 
(Baumert et al., 1996) showed that these two variants are associated with high replication 
efficiency which is due to higher rate of encapsidation of pregenomic RNA, even though 
they are approximately 75 nt upstream of e. In the present study, it was shown that these 
two variants are associated with a higher rate of transcription (section 3.3 of this chapter).
Other variants unique to a particular case were distributed throughout the entire 
enhancer-II and core promoter region. A T to C substitution at nt 1703, at nt 1773 and at 
nt 1821 were seen in 2, 3 and 2 cases respectively. A C to T or C at nt 1653, A to C at nt 
1752, T to A or T at nt 1809, A to C at nt 1819 were also seen in one or two cases. 
Although they do not occur in high numbers, these are unique to FHB cases presented 
here or elsewhere.
The pre-core variant, A1896, was also observed in 9 of 19 cases. This is the most 
common variant previously found to be associated with both severe anti-HBe positive 
chronic disease and fulminant hepatitis. A 1896 was also seen in 6 of 11 other previously 
reported fulminant cases. Here, in 5 of 9 A]896-FHB cases, the variant was the dominant 
population; in 4 cases it was mixed. Nonetheless, appearance of A]896 is strongly 
correlated with HBeAg negative status of the patients, all but one being HBeAg negative
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on admission (Table 3.8). Another variant, A 1899, was also seen in 5 of 19 cases but 
always with A]896.
Two of our cases had an insertion at nt 1838, just after the X ORF. Case CHBV-1 
was a HBeAg negative, anti-HBe positive carrier, pre-core sequence contained G ]896 and 
an A insertion at nt 1838 which prevented production of HBeAg. FHB-15 had an AC 
insertion at the same position despite the presence of A1896.
Most of the variants clustered in the BCP are in the binding sites of most of the 
nuclear factors (Figure 1.4).
iii) X protein has aberrant occurrence of cysteine, serine and methionine 
residues
Table 3.3 shows the substitution of amino acids in the X protein. As X protein 
overlaps with the Enh-II/CP complex, some of the nucleotide changes in this region led to 
aa changes in the X protein. The rate of aa substitution in the X protein compared to non- 
FHB is described in the second section. Amino acid substitutions were observed in a total 
of 21 positions of the X gene in 18 of the fulminant cases in this study. Many of these are 
unique variants, seen in only one or two cases and not seen in any of the non-FHBV 
cases. However, in the X protein there is no particular variant which was common to all 
fulminant cases, but a significant number of cases showed aa substituted to cysteine, 
serine and to methionine. A substitution of Arg26Cys was observed in 9 of 18 FHB cases 
in this study and 5 of 11 FHB cases in other studies. A similar change was observed in 1 
of 22 non-FHB Genbank cases, but not in our acute case. The presence of cysteine was 
also seen at aa 6 in one patient and at aa 72 in another. Cysteines are highly conserved in 
X protein and the presence of additional cysteine residues may play an important role in 
determining its tertiary structure. Similarly, Ile88Met and Ilel27Met substitution occurred 
in 5 of 17 and at 6 of 17 FHB cases respectively in this study. Leul30Met substitution 
was also seen in 6 of 17 FHB cases, confirmed in other studies where this appeared in 2 
of 11, 3 of 11 and 4 of 11 FHB cases respectively. In Genbank non-FHB sequences, 
Leul30Met was seen in only 4 of 22 cases. The impact of the presence of aberrant 
methionine residues in the X protein is not known but their appearance in greater numbers 
in FHB cases may be significant. Substitution of Pro/Leu33Ser was found in 7 of 17 
FHB cases in this study and 9 of 11 FHB cases in other studies. Serine substitution was 
also found at aa 44 (1/17 cases), aa 136 (1/17 cases) and at aa 147 (2/17 cases) (overall in 
3 FHB cases). Again the presence of higher number of serine residues may contribute to 
the transactivation function of the X protein or it may be genotype D specific, as most of 
the cases in our study belong to genotype D. Other aa substitutions were also found in the 
X protein, some of them unique to a particular case (Table 3.3).
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iv) Rate of nucleotide and amino acid substitution in pre-S/S regions is  
low
The S and polymerase ORFs were sequenced for eight patients in this study. 
Variations in nucleotide and the predicted amino acid changes in these 8 cases was 
compared with the data available for another 11 FHB and 22 non-FHB cases found in the 
GenBank. As can be seen from table 3.4, only a few nucleotide changes occurred in the 
pre-S regions in each case. Four cases in this study did not show any variation. Two of 
the 8 cases had 2 variations in each, and one had just one. Surprisingly, one contact case 
(CHBV-1), showed 11 variants in pre-S, all clustered between nt 92-111. As this area is 
not in any of the surface promoter regions, their functional impact is not known. These 
variations were not detected in any of the 11 FHB cases or in 22 non-FHB sequences. A 
similar low rate of amino acid substitution was found. Five cases did not show any 
substitution, one case had one substitution, and another had two. Case CHBV-1, who 
had 11 nucleotide changes, showed 7 amino acid substitution.
When variability in the HBsAg was compared with the other 11 FHBV and 22 
non-FHB (Table 3. 5), no significant clustering pattern was seen. Most of the nt variants 
were unique to a particular case and some occurred twice. But two variants (T]90 and T526) 
occurred in three of the FHB cases and in one non-FHB case. None of the variants except 
T346 identified in this region were reported before in FHB cases. T346 was found in one 
case in this study and in 3 other FHB cases (Sterneck et al., 1996). In HBsAg, the 
contact case CHBV-2 showed the most variation; 7 of the 19 unique variants were found 
in this one case. Most of these nucleotide changes did not lead to predicted amino acid 
changes. Amino acid variability was low with a range of 1 to 3 substitution for each case; 
FHBV-16 was invariant. This is consistent with other studies; the surface was less 
variable than any other region and no significant clustering was observed. Metl25 (in the 
MHR) was seen in 3 of 8 FHBV cases in this study and 2 of 11 FHBV cases in the other 
three studies, but was also found in 1 of 22 non-FHBV cases.
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Table 3.5 Nucleotide variation in S gene
Nucleotide FHBV-3 FHBV-6 FH BV-9 FHBV-14 FHBV-16 AHBV-1 CHBV-1 CHBV-2 Other Genbank non-
position FHB V  (11) FHBV (22)
G  161 + - - - - -
T I90 + + + - - 1
2^02 + - - - - -
G  235 - - + + - -
^ 2 9 0 - - - - + -
r 298 - + - - - -
f  325 + - - - - -
^ 3 4 6 - - - - + 3 -
G 370 - + - - - -
^ 390 - - - - + -
0 3 9 . - - - + -
c 46 1 - + - - - -
T1 327 + +  - - - + - - 1
A 663 - - - - + -
c 709 - + - - - -
n
' “'742 - + - - - -
A 767 - - - - + -
c 770 - - - - + -
800 - - - - - -
Table 3.5 sh o w s nucleotide variation in the HBV S gene o f  8  fulminant cases in this s tu d y , 
com pared  with 1 1 FH B cases from  other 3 studies and 22 non-FH B  cases  from  G enbank . Variants 
were distributed  throughout the S gene. At 2 nt positions (190 and 527), variants were seen in 3 out 
o f  8  FHB cases and only 1 case from  22 non-FH B  (Genbank).
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Chapter-3 Results
v) Variants in polymerase protein are discrete
In the po lym erase protein, variation was found  to be m ore discrete than any other 
region and distributed throughout the entire region. As the P O R F  overlaps  the surface , 
Enh-I  and X-protein  region, som e o f  the changes in these regions also appear in the 
po lym erase  protein. As most o f  the X variants described above w ere at the C-terminal 
half, they did not lead to change in the polymerase protein . Table 3.7 sh o w s  the 
distribution o f  variants in the polym erase protein in 8  o f  the F H B V  cases.
Table 3.7 D istribution o f  variants in po lym erase  protein
Distribution o f  changes
F414 6^70F H B V -3 S42 D,75 G 373
F H B V - 6 F* 176 A-689
F H B V -9 A 429 Y 553
F H B V - 14 G 38 P 405 ^542
F H B V - 14 S 459
AHBV-1 S 95 S.397 ^689
CHBV-1 T 49 ^ 6 8  F 82 Y 117 C
C H B V -2 ^ 6 8 L 8| F 526
157 R 303 ^ 3 3 6  s340 h 341 a 383 h 384 d 466 L579
561 562 657 L 668
vi) HBe antigen status is correlated with disease progression
Tw elve o f  o u r  19 FHB cases had rapid disease p rogression ; 10 w ere H B eA g 
negative (the 2 exceptions being F H B V - 6  and FHBV-1 1). All 10 had a h igher num ber o f  
variants com pared  to H BeA g positive cases, particularly in the E n h -I I /B C P  com plex ,  X 
and core gene (Table 3.8). F H B V -6 , negative for both H B eA g and an ti-H B e, w as 
infected from her s ister (AHBV -1) by sharing a needle, AHBV-1 w as  H B eA g positive 
and anti-H B e negative. Both had G l896. FHBV-1 1 was H B eA g positive and anti-HBe 
negative, had G l896 and  is the only example o f  rapid d isease p rogression  despite the 
presence o f  an H B eA g-producing  strain. 4 o f  6  o ther H B eA g  positive FH B  cases 
(excluding  case A H B V -1 . as it was an acute contact case) had slow  disease p rog ress ion ,  
were less variable in the Enh-II/CP com plex, X and C gene and had a h igher fatality rate 
(5 o f  6  cases including F H B V -1  1 ). The only H B eA g positive survival was case FH B V -5  
w ho , a lthough H B eA g positive on adm ission , later seroconverted  to an ti-H B e, had both 
A 1896 and  G i896 and rapid  disease progression. Except for F H B V - 6 , 3 o ther FHB patients 
were both H B eA g and anti-HBe negative; two o f  them died and one received a liver 
transp lan t (case-FH B V -7). This last patient had very slow disease p rogression  and grade 
II-III com a when transplanted, so had no chance o f natural surv ival.  Other factors also 
seem ed to contribute to disease severity. Three o f  the patients were pregnant (two died 
and  one had a liver transplant) and two cases were coinfected with H D V , both o f  w hom  
died.
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Chapter-3 Results
vii) FHB patient has a heterogeneous population compared to her acute 
contact
Whole genome sequences were available from the acute /fulminant family pair. 
There was a considerable heterogeneity between the two cases. The sequence from 
AHBV-1 showed a single population of subtype ayw whereas, although FHBV-6 
contained same subtype ayw as the dominant population, she had another strain as a 
minority (Table 3.9). We are not certain about the subtype of this strain. This contradicts 
with the previous reports where source and contacts had identical sequences. This may be 
because, unlike other studies, the source had an acute self-limited disease.
Table 3.9 Genetic heterogeneity of a pair of fulminant (FHBV-6) and
acute contact (AHBV-1) cases.
nt position FHBV-6 AHBV-1 nt position FHBV-6 AHBV-1
S gene
10 C T 2200 C(A) C
275 T C 2212 C(T) C
505 A C 2215 T(A) T
Enh-I/XP 2221 T(C) T
926 A C 2224 C(T) C
1127 A C 2239 A(T) T
Enh-II/BCP 2242 C(T) C
1637 C G 2245 A T
1768 T(C) T 2246 T A
Core gene 2248 A(C) A
1956 T A 2251 A G
1978 A G 2260 G(C) G
1979 G A Polymerase gene
1997 C G 2554 T C
2160 G(A) G 2581 G C
2170 C(T) C 2826 C T
2176 T(C) T
2189 T(A) T
Table 3.9 shows the nucleotide variability of case FHBV-6 and its 
acute contact. Nucleotides in the ( ) denote the minority population 
observed on direct sequencing.
3.2 PHYLOGENETIC ANALYSES
For the phylogenetic study, 30 FHBV core gene sequences from 27 unlinked 
episode were analysed, of which 11 were obtained from GenBank sequence databases. 
For X gene, 26 FHBV sequences representing 25 unlinked episodes were analysed, of 
which 9 were obtained from the sequence databases. With respect to the non-FHBV 
sequences, 1 X and 2 core gene sequences were from this study and 159 core gene and 
86 X gene sequences were obtained from the sequence databases. This produces a total of 
191 core gene and 114 X gene sequences.
87
F i g u r e  3-1
5%  D ivergence
88
Figure 3.1 Clustering of FHBV sequences on the maximum likelihood tree of 
the X gene. For the 114 X gene sequences the Ts/Tv and the codon-specific 
relative rates of evolution were found to be 1.28 and 1.49:1.04:0.50 at codon 
positions 1, 2 and 3, respectively. Lineages which possess FHBV status are 
indicated. Horizontal branch lengths are drawn to scale. Clusters of sequences, 
as defined as FHBV lineages which have no intervening non-FHBV sequences, 
are numbered in bold. Genotype of each major branch is given.
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Figure 3.2 Clustering of FHBV sequences on the maximum likelihood tree of 
the core gene. For the 191 core gene sequences the Ts/Tv was determined to be 
1.24 with the relative rates of evolution as 0.87:0.62:1.51 at codon positions 1, 
2 and 3, respectively. Lineages which possess FHBV status are indicated. 
Horizontal branch lengths are drawn to scale. Clusters of sequences, as defined 
as FHBV lineages which have no intervening non-FHBV sequences, are 
numbered in bold. Genotype of each branch is given. As most of the patients in 
the cluster-1 belonged to UK, to overcome the epidemiological bias, removal of 
all UK cases from cluster-1 altered the P value but still significant (P= 10‘2)
Chapter-3 Results
i) Epidemiologically unlinked FHBV cases have genetic similarity
Figures 3.1 and 3.2 which show the phylogenetic trees of X and core genes 
respectively; and shows that FHBV sequences are clustered. For X gene, the distribution 
of the 25 independent FHBV sequences on the phylogenetic tree could be accounted for 
most parsimoniously by 14 unambiguous evolutionary steps, fewer than the minimum of 
21 expected under a random model of sequence evolution (P= O.lxlO'5). In the core gene, 
the 17 observed unambiguous evolutionary steps for the 27 independent FHBV 
sequences was again less than the 25 expected if these sequences were not clustered (P= 
0.4 x 10'7). This clustering reflects a high degree of genetic relatedness amongst FHBV 
sequences. Generally the same clusters were found in both genes indicating that the 
viruses themselves are related; however, sequences FHBV-19, FHBV-21 and FHBV-23 
occupied different positions on the X and core gene trees. Whether these discrepancies 
reflect recombination events, as was clear in the case of non-clustered FHBV sequences 
FHBV-25 and FHBV-26, or the effect of rapid evolution associated here with FHBV 
sequences was unclear.
ii) Clusters were linked to clinical outcome
Clustering FHBV sequences was strongly linked to mortality. Every cluster was 
uniform with respect to outcome (i.e. survival or death) with two exceptions, one being a 
liver transplant recipient while the other was pregnant and died. All FHB cases in 
individuals who were pregnant, HDV coinfected, or over 30 years of age were fatal, with 
the exception of those patients who received liver transplants. Clustering was also 
uniformly linked to the speed of onset of hepatic encephalopathy and clearance of HBsAg 
and HBV DNA, with two exceptions. The two patients who were coinfected with HDV 
were found in the same cluster.
iii) FHBV sequences were characterised by a different rate of nucleotide 
evolution
Relative to their non-FHBV phylogenetic neighbour, the FHBV sequences had a 
significantly higher rate of nucleotide substitution in both the X and core genes (Tables 
3.10 and 3.11 respectively). In the X gene, this increase was also significant at the amino 
acid level and localised to the BCP at both the nucleotide and amino acid levels, FHBV 
sequences also had a higher rate of synonymous changes in the X gene, indicating an 
elevated rate of background mutation. This relationship is also reflected in the codon 
position specific weighting ratio determined for the X gene phylogenetic tree, where first 
and second codon position changes occur at an elevated rate relative to third position 
changes. In the core gene, the elevated rate of evolution in FHBV sequences was 
significant at the nucleotide level for the whole gene and for the non-antigenic regions.
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Table 3.10 Relative rate tests for the X gene com paring  rates o f  evo lu tion  be tw een  
F H B V  and n o n -F H B V  sequences.
N ucleo tide  Sequence" A m ino acid sequences*
Region Region
Full sequence 0.024 Full sequence 0 . 050
1373-1631 0 .9 0 6 1 - 8 6 0 .2 5 5
(C U R S ) 1631-1742 0.678 (C U R S ) 87-12 0 .6 3 6
(B C P) 1742-1838 0.009 (B C P) 124-154 0.042
T able 3.10 All results are expressed as P -  the probability that F H B V  sequences  
are evolving faster than non-F H B V  sequences. Significant results are in bold 
type. *Nucleotides are num bered  from the unique EcoRl site. * Am ino acids are 
num bered  from the start o f  the X gene. C U R S  = Core U pstream  Regulatory 
Sequence ,  BCP = Basal Core Prom oter. Relative rate test results for 
sy n o n y m o u s  and nonsy n o n y m o u s  changes were significantly different only  for 
the num ber o f  synonym ous changes in the X gene between F H B V  and non- 
F H B V  sequences  (P = 0 .014).
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Table 3.11 Relative rates test for core gene
N ucleotide Sequence *
R egion FHBV g 18%f h b v a 1896 f h b v A  i896 non-FH BV
Full sequence (1901-2458) 0.045 0.022 0.009 0.018
R egion 1 (1963-2020) 0 .154 0 .787 0 .0 7 6 0 .715
C D 4 epitope (2050-2107) 0 .610 0.361 0 .9 4 4 0.036
A nti-H B e / e l  (2122-2161) 0.919 0.281 0.141 0.036
A nti-H B e /  e2 (2200-2251) 0 .724 0.281 0.014 0.281
A nti-H B e /  e3 (2290-2305) 0.787 1.000 0.022 0.181
A ntigenic regions 0108 0 .052 0.009 0.014
N on-antigenic regions 0.039 0.043 0.013 0.051
A m ino A cid Sequence
Region FHBV g i896 f h b v a 1896 f h b v A ]896 non-FH BV
Full sequence 0 .108 0.151 0.013 0.013
A ntigenic regions 0 .162 0.295 0.009 0.014
N on-antigenic regions 0.235 0 .052 0.024 0 .183
Table 3.11 shows relative rates tests for the core gene comparing rates of evolution 
in the complete FHBV dataset, A]896 FHBV variants, G 1896 FHBV variants, and 
non-FHBV A ]896 variants, all against G 1896 non-FHBV sequences. All results are 
expressed as P = the probability that FHBV sequences are evolving faster than non- 
FHBV sequences. Significant results are in bold type. *Nucleotides are numbered 
from the unique EcoRJ site. Relative rate tests for synonymous and 
nonsynonymous changes were not significantly different between FHBV and non- 
FHBV sequences in any areas tested.
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iv) No particular variant was associated with clusters of sequences
There was no single unique variant linked to all individual FHBV sequences or 
group of sequences. However, particular variants characterised FHBV sequences and 
clusters of sequences (Table 3.12). On the nucleotide level, these included variants in 
enhancer I, (which regulate transcriptional function of X promoter and also has a 
stimulatory affect on BCP), the NRE and CP/Enh-II complex. At the amino acid level, 
these included uncharacteristic patterns of otherwise highly conserved cysteine residues, 
which would be expected to play a central role in determining the tertiary structure of 
protein products of X, and aberrant methionine residues, which might be expected to alter 
levels of the three protein products thought to be coded by the X gene and thus affect on 
transcriptional transactivation of HBV.
v) Particular ‘m otifs’ or combinations of variants were associated with 
FHBV cases
The FHBV sequences possess particular motifs or combination of variants which 
distinguish them from non-FHBV sequences. The combination of either aberrant 
methionine residues, aberrant cysteine residues, or one of three identified nucleotide 
variants in Enh-I with any of a group of notable variants in the NRE, the BCP or the A]896 
pre-core variant was nearly exclusive to FHBV sequences (Table 3.13). T 1762 and A 1764 
characterised some clusters of FHBV sequences but were not by themselves 
disproportionately represented in FHB cases. However, where both these variants are 
present with either T 1766 or A1768, 3 of 4 examples were FHBV. With a single exception, 
whenever the A,896 variant was found with the aberrant cysteine and methionine residues 
in X protein or Enh-I variants described here, it was in a sequence associated with 
FHBV.
vi) A 1896 is linked to different patterns of evolution in FHBV and chronic 
sequences
In G 1896 FHBV sequences and in the complete FHBV dataset (A]896 plus G I896 
FHBV sequences), changes in the complete core gene and in non-antigenic regions 
accumulated faster than in non-FHBV sequences. A1896 FHBV sequences had 
significantly higher rates of nucleotide evolution than in G I896 non-FHBV sequences in 
the complete core gene and in both non-antigenic and antigenic regions, particularly 
within the anti-HBc/e2 and anti-HBc/e3 epitopes, as well as significantly higher rates of 
amino acid evolution in all areas tested. These results for A]896 FHBV also differed from 
the non-FHB A]896 controls which did not accumulate changes at a significantly increased 
rate in non-antigenic regions and differed in the specific antigenic regions affected
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Chapter-3 Results
Table 3.13 M otifs or com binations o f  variants, suggested  to play a role in FHBV and 
their occurrence in dataset.
* M otif
FHBV
prevalence
Non-FHBV
prevalence
A,x%only A |X % plus G 1896
1
4/13
0/32
2
8/13
0/32
3
8/13
1/32
total
(45)
1 1/13
1/32
4
4/26
1/88
5
8/26
0/88
6
13/26
4/88
7
1 1/26 
2/88
8
14/26
1/88
Total (114)  
21/26  
6/88
C luster-1 3/3 3/3 3/3 2/8 2/8 8/8 8/8 8/8
Cluster-2 - - - 1/2 1/2 - - -
Cluster-3 - - - 0/2 0/2 0/2 0 /2 0 /2
Cluster-4 0/2 0/2 1/2 0/2 0/2 0/2 0 /2 2/2
Cluster-5 - - - 0/2 0/2 2/2 1/2 2/2
Clusler-6 1/3 1/3 2/3 1/3 1/3 1/3 0/3 0/3
0/2 2/2 0/2 0/2 1/2 0/2 0/2 0 /2
0/2 2/2 2/2 0/2 2/2 2/2 2/2 2/2
Individual cases 0/2 0/2 0/2 0/3 0/3 0/3 0/3 0/3
Table 3.13 show s the motifs o f  each clusters and the num ber o f  cases show ing  each 
motif. Only sequences for which complete information was available for the areas in 
question are listed. From a total o f  I 14 sequences, 26 were FHBV (14 A l896 and 12 
G IS%) and  8 8  were non-FH B V  (31 A l896 and 57 G l896). C luster 3 and 3 sequences from 
individual cases did not show any motifs. M otifs in here defined as:
M otif  1= A i896 + aberrant cysteine residue in X protein.
M otif  2= A 1896 +  aberrant m ethionine residue in X protein.
M otif  3= A 1896 + enhancer-I nucleotide variant.
M otif  4=  BCP nucleotide variant + aberrant cysteine residue in X  protein.
M o tif  5= BCP nucleotide variant + aberrant methionine.
M o tif  6 = N RE nucleotide variant + aberrant cysteine residue in X protein.
M otif  7= N R E nucleotide variant + aberrant m ethionine residue in X protein.
M otif  8 = N R E nucleotide variant + enhancer-I nucleotide variant.
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3.3 FUNCTIONAL ANALYSES
i) Fulminant hepatitis B virus constructs have a higher transcription level
A sequence greater than 400 nt, containing the NRE, CURS, BCP, Enh II and the 
5’ end of the core gene, from a total of 20 patients was cloned into a luciferase-expressing 
vector. Eleven of 20 were FHB; 4 of them were HBeAg negative in the first available 
samples. Two were laboratory standard adw (HBV adw2 in Genbank; genotype A) and 
ayw (Xxhepav in Genbank; genotype D) subtype controls (both HBeAg producing) and 
the remaining 7 were CHB controls with well known clinical characteristics. Table 3.14 
shows the luciferase level correlated with variation in the cis acting and pre-core regions. 
Seven of 11 FHB cases, all with variation in the first two AT rich regions of the BCP 
(Figure 3.3) showed substantially higher luciferase activity compared to control adw 
which we considered as background or normal. Six of these 7 cases also had A]896 and 
one with GI896 sequence had an A insertion at 1838 and was therefore an HBeAg negative 
strain. Two of 11 cases (FHBV-8 and FHBV-9) had an intermediate level of luciferase 
level compared to control adw. For case FHBV-8, 2 clones were tested, one with A 1896 
and the other with G1896, but both had variant BCP regions. Both clones showed the same 
level of luciferase activity, but this was not consistent (higher standard deviation). Case 
FHBV-9 was G1896 and invariant in the BCP, but had a single variant in the CURS. The 
last 2 of the 11 FHB cases (FHBV-12 and FHBV-16) had normal luciferase activity and 
contained G1896 with almost identical variants in the CURS and BCP. Only one of these 
variants was in the third AT rich region and both sequences were invariant in the first two 
AT rich regions. Six of 7 control CHB cases showed normal luciferase production 
comparable to adw control. Three of 7 CHB controls had HBeAg-producing sequences 
(G,896); the remainder were Al896.
Turning to specific variants, of those in the BCP, T 1762 (in three) and A]764 (in 
five) were the most common in CHB (5 of 7 cases). These variants were also common in 
FHB cases that were associated with high luciferase expression, but were always 
accompanied by T 1766 and/or A 1768. This indicates that T 1762 and A 1764 alone are not 
sufficient to affect transcription in our system. However, T 1762 (without A ]764) with one 
other unique variant (AI826) appeared to be crucial in case FHBV-1. The only CHB 
control case which had intermediate luciferase activity (1-40) was HBeAg positive and 
contained a deletion in the BCP from nt 1754-1762 (Figure 3.3). The functional effect of 
combinations of non-unique variants was further seen in the linkage of variants at nts 
1727 and 1740. G1727 and Tl740 together were observed 4 times, but only in the group of 
7 high luciferase-producing FHB sequences. The control ayw subtype (con-ayw) had 
higher luciferase activity compared to adw and had considerable differences in the 
BCP/enhancer II complex, particularly at positions 1678, 1727, 1740 and 1773 
(Figure 3.3).
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Figure 3.3
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1-89
1-95
1-105
1-177
 T--------------XXXXXXXXX-A---A------
------------------------------ T---------------------------------------------------- c-
 T --------------------------------------------------------------------------------------------------------------------C -
------------------------------------------------ T -------------------------------------------------------- t _ a -------------------c _
-------------------- T------------------------T-A--------C-
C-------------------- t ------------------------- A--------C-
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4 177 6 (Enh-IIends)
Con-ayw AGGAGGCTGTAGGCATAAATTGGTCTGCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAA~TC
Con-adw  C----------------------------------------------------------
FHBV-1  A ------------------
FHBV-4--------------------------  T----------------
FHBV-5-------------------------- T----------------
FHBV8.1 ---------------------------------------------------------------------------
FHBV-8.5 ---------------------------------------------------------------------------
CHBV-1 -----------------------------------------------------------------------A 
FHBV-9 ---------------------------------------------------------------------------
FHBV-12  C--------------- T------------ C-----------------------
FHBV-14---------- C--------------- A-------
CHBV-2--------------------------  T----------------
FHBV-15 -----------------------------------------------------------------------AC--
FHBV-16  A--------------- T--T---------C-----------------------
I_40 ---------------------------------------------------------------------------
I _ 5 9  --------------------------------------------------------------------------------------------------------------------------------------------------
! — 6 9 ---------------------------------------------------------------------------
! — 8 9 ---------------------------------------------------------------------------
I _ 9 5 ------------------------------------------------------- T-------------------------------
1-105 ---------------------------------------------------------------------------
1 -1 7 1 ---------------------------------------------------------------------------
1 1849  (BCP ends) Genotype 1896  1899
Con-ayw ATCTCTTGT D G G
Co n -a d w ---------  A G G
FHBV-1------ ---------  D A G
FHBV-5------ ---------  D A A
FHBV-4------ ---------  D A A
FHBV-8.1 ----T---- D A A
FHBV-8. 5---- ---------  A G G
CHBV-1 ---------  A G G
FHBV-9------ ---------  A G G
FHBV-12----- ---------  D G G
FHBV-14 ----T---- D A A
CHBV-2 ---------  D A A
FHBV-15   D A G
FHBV-16----- ---------  A G G
1-40------------------  D G G
1-59------------------  D G G
1-69------------------  D G G
1-89------------------  D A A
1-95------------------  D A A
1-105------- ---------  D A A
1 - 1 7 7    D A G
Figure 3.3: Sequences from nt 1549 to 1974 w ere cloned into the vec to r pB L . Here, the sequence oi 
C U R S , B C P  and  Enh-II on ly  is show n  along w ith  the major nuclear factors  binding sites. C H B V -1  
and -2 are con tac ts  o f  FH B  cases. All I- num bers  denote  chronic carrier contro ls .  B C P = b asa l  core 
prom oter.  C U R S = c o re  ups tream  regulatory  s e q u e n c e V  =  insertion. X =  dele tion
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Chapter-3 Results
Con-ayw had A 1727 and C]740; a number of FHB and control CHB cases also contained 
A 1727, but always with T 1740. This is a remarkable parallel with our finding that 4 FHB 
cases had G ]727 and T1740 . T 1773 was found in 8/11 of the FHB cases with high or 
intermediate luciferase activity. Three FHB cases had T]678; 2 of them had high and 1 had 
intermediate luciferase activity. Con-ayw, the control with intermediate activity was the 
only control sequence to have T1678. In summary, although the BCP is generally variable, 
some unique variants, but more importantly, combinations of variants (’motifs'), were 
associated with high or intermediate transcriptional activity, nearly always in FHB cases.
ii) Luciferase activity correlates with disease progression
There was a correlation between high luciferase expression, rapidity of disease 
progression, and seroconversion to anti-HBe. All 7 FHB cases with high luciferase 
expressing sequences had rapid disease progression regardless of their eventual clinical 
outcome. In contrast, FHB cases with intermediate or normal luciferase expression had 
slow disease progression. There was a correlation between high luciferase expression and 
HBeAg status in FHB cases. Six of 7 FHB cases with high luciferase expression were 
HBeAg negative on admission and seroconverted to anti-HBe; the other 4 FHB cases 
(with intermediate or normal luciferase expression) were HBeAg positive on admission 
and 1 of them seroconverted to anti-HBe. In contrast, 4 of 7 HBeAg negative CHB cases 
had normal luciferase expression (and 3 had an intermediate level).
iii) BCP and enhancer I sequences from FHB have different nuclear factor 
binding patterns to non-FHB controls
To investigate the effect of BCP variation on binding of transcription factors 
derived from nuclear extracts, pairs of complementary oligonucleotides spanning nts 
1742-1783 from 6 FHB cases with variability in the BCP and from adw subtype (as a 
non-FHB control) were synthesised. As can be seen from Figure 3.3, the chosen 
oligonucleotides included most of the variants previously identified as linked to FHB. 
Figures 3.4s give the results of nuclear factor binding and figure 3.6 compares the 
sequence to cartoons of the banding patterns. The non-FHB sequence (OL-adw) shows 3 
clear complexes (Figure 3.4a), whereas all FHB sequences except one (FHBV-1), which 
had only one mutation (T]762), bound poorly, or not at all, with complexes II and III. 
Case FHBV-1 (Figure 3.4c) which showed a similar binding pattern compared to non- 
FHB control (OL-adw), had two bands in complex-II. In order to identify liver specific 
complexes, nuclear extracts from HeLa cells were made, and the binding assay repeated 
using oligonucleotides from 3 FHB and 1 control non-FHB cases. From figure 3.5b, it is 
clear that complexes II and III are not hepatocyte specific.
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Figure 3 :Nuclear factor binding pattern of ‘normal’ and variant oligonucleotides. 
Nuclear extracts were prepared from HuH7 cells. 0, 1 and 3 ug of nuclear extracts 
were mixed with 30,000 cpm 32p labelled oligonucleotides (oligos) and run on 6% 
polyacrylamide non-denaturing gel. Figure 3. A shows nuclear factors binding 
pattern of oligos from adw and CHBV-2. Figure 3.B and 3.C show nuclear factor 
binding pattern of 5 more variant oligos. In figure 3. D , 30,000 cpm 32p labelled 
oligonucleotide from FHBV-14 was mixed with 1x, 5x and 25x molar excess of 
unlabelled oligonucleotide as cold competitor (lanes 3,4 and 5), added to 3 ug 
nuclear extract and resolved on 6% polyacrylamide gel. lane 1=no nuclear extract, 
lane 2= no cold competitor.
Figure 3.5
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Figure 3.5: Shows the nuclear factor binding pattern of HuH7 and HeLa cells. 
Nuclear extracts were made from HuH7 cells and HeLa cells. 0, 1 and 3 ug of nuclear 
extracts were mixed with 30,000 cpm 32P labelled oligonucleotide and resolved on 6% 
polyacrylamide non denaturing gel. Figure 3.5(a) shows binding of oligonucleotide 
derived from con -adw  (OL-adw), CHBV-2,FHBV-14 and FHBV-4 with nuclear extracts 
from HuH7 . Figure 3.5 (b) shows sam e oligonucleotides binding with nuclear extract 
made from HeLa cells.
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Cases Luciferase Variations in the BCP 
value x106
C on-adw 1.50
FHBV-1
FHBV-4
11.51
8.81
^1762 A-1826
C 1 7 5 3  A1 7 5 7 T1 7 6 2  A1764)
T1766 A1 7 0 8  Tl810
Q. O- q_
E I  E0  R  0o  o  o
a
FHBV-5 10.25 C 1 753 A1757 T1762 A1764, 
T1766 Ai768T1810
FHBV-14 1 1 < 3 9 A1 7 5 7 T 1 7 6 4  Gl766 A1834 
T1845
CHBV-2
FHBV-15
9.68
7.98
Cl753 A-1757 T-|702 A1 7 6 4  
Ai7 6 8  C i77i T1810
Tl678 C i752 A 1 7 5 7 I
Figure 3.6 Cartoon representation of nuclear factor binding 
assay  showing luciferase values and variants in the BCP
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Figure 3.7
Complex-1
Complex-2
Complex-3
Free probe
OLew-1 OLem-1 OL ew-2 OL em-2
Figure 3.7: Oligonucleotides were made from normal C-|050 (OL ew-1), variant G1050  
(OL em-1), normal C-| 2 4 9 , T1250 (OL ew-2) and variant T1 2 4 9 , C-| 250 (OL em-2). 
Oligonucleotides were mixed with 0,1 and 3 ug of nuclear extracts from HuH7 cells and 
run on 6% polyacrylamide non-denaturing gel.
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T he B C P  variant oligonucleotides show ed  a similar pattern o f  b ind ing  to both nuclear 
extracts (F igure 3 .5b , lane 3, 4 and 5). A competitive experim ent using  unlabelled 
oligonucleotides as a cold competitor show ed  the specificity o f  the interactions (Figure 
3 .4 d ) .
A num ber o f  F H B  sequences had variants in Enh-I ,  particularly T 1050C, G P49C 
and  T i250. F our pairs  o f  o l igonucleo tides  with or w ithout Enh-I  variants w ere  synthesised  
(Table 2.4) and bo u n d  to nuclear extracts o f  H uH 7 cells. F igure 3.7 show s that variant 
G 1050 (oligonucleotide em -1) does not have any effect on the nuclear factor binding 
pattern , but variants T 1249 and C 1250 (o ligonucleo tide  em -2) , in contrast to G l249 and  T 1250 
(o ligonucleo tide  ew -2),  do  not give rise to com plex  3.
F inally , a nuclear factor binding assay was perform ed us ing  an oligonucleotide 
with an insertion o f  A at 1838 as detected in two patients (CHBV-1 and F H B V -1 5 ) .  N o  
difference was observed  in the b inding pattern (data not shown).
iv) Expression and distribution of core protein was not different in FHBV.
To investigate the pattern o f core protein and its intracellular distribution under  the 
control o f  the hom o lo g o u s  p rom oter,  an area spanning nt 1549-2458 from  13 patients (8 
FH B  or contacts o f  F H B , 4  C H B  and 1 A H B ) was cloned into vector pK L t5 5 .  C ore 
proteins were expressed  in H epG 2 cells and labelled with polyclonal anti-core rabbit IgG . 
T he influence o f  core protein sequence on intracellular distribution w as addressed  using 
core  nt 1818-2458 from  11 FH B, 4 C H B  and 1 A H B  cases in vector pR K 5 under control 
o f  the C M V  early prom oter.  The core proteins were expressed  in both C O S 7  and H ep G 2  
cells. H B cA g  distribution w as observed  in both cytoplasm  and nucleus and there w as no 
obvious difference in the level o f  H B cA g  expressed in FH B  and control cases. A similar 
level o f  expression  w as observed  using either hom ologous  or heterologous prom oters  
(F igure  3.8)
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3.8a H B cA g  express ion  in H epG 2  cells from  an FH B  case
« '  • 
•  *
m
•  f
♦  *
3 .8 b  H B cA g express ion  in H epG 2 cells from  a con tac t  case
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Figure 3.8 (continued)
w
3.8c H B cA g  expression  in H epG 2 cell from  a control carrier  case
3.8d H B cA g  expression  in H epG 2 cells  from  posit ive  control case.
F igure 3.8 show s H B cA g expression from  various p lasm id  constructs  w ith  
hom ologous  prom oter. The positive control contains heterologous 
prom oter.
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Chapter-4 Discussion
HBV infection is associated with a wide spectrum of liver injury, ranging from 
acute self-limited infection to an asymptomatic chronic carrier state, chronic hepatitis with 
or without progression to cirrhosis and fulminant hepatitis (FHB). FHB is a severe 
manifestation of acute hepatitis with a mortality rate of 50 percent. In early studies, a high 
mortality rate was reported with rapid clearance of viral antigens and appearance of 
respective antibodies (Brechot etal., 1984). Pathogenesis was believed to be due to over 
production of antigen-antibody complexes which eventually caused the blockage of liver 
sinusoids and resulted in ischaemic liver cell necrosis (Woolf et al., 1976).
Are FHBV strains genetically related?
In the phylogenetic study, we showed that FHBV sequences have substantial 
genetic similarity; sequences from epidemiologically unrelated FHBV cases were 
statistically clustered within particular viral lineages. For X gene, 26 cases from 25 
independent episodes had 14 evolutionary steps, which is fewer than the minimum of 21 
expected by a random model (P= O.lxlO'5). In the core gene, 17 evolutionary steps were 
observed in 30 cases from 27 unlinked episodes which would be 21 if the sequences were 
not clustered (P= 0.4xl0"7). This is conclusive evidence of a viral genetic basis to FHBV. 
Each cluster is associated with a particular variant 'motif or combinations of variants. We 
have also shown that variants out of their genotype context occur in HBV. In this study, 
we have shown that the Enh-II/CP complex of A1896 associated FHBV sequences has 
significantly increased transcriptional efficiency (see later).
The phylogenetic clustering of unlinked FHB cases, when FHB is itself a viral 
transmission dead end, would suggest that certain viral genetic contexts, such as those 
defined by strain and genotype identity, might either be particularly susceptible to 
acquiring specific FHB associated variants or already possess some elements of the FHB 
motif combinations. We propose that the symptomless contact who transmits HBV 
resulting in fulminant hepatitis has a heterogeneous population of HBV strains, or a 
quasispecies characteristic of quickly evolving viruses (Duarte et a l, 1994), some of 
which all posses the necessary elements required to cause FHB in a de novo infection by 
triggering a massive immune response in the presence of elevated rates of viral 
replication.
Are there specific unique variants associated with all FHBV?
In our study, no specific variants were identified which were common to all FHB 
cases. Recently, a number of studies on sequencing entire genomes from FHB cases have 
been reported. In two of these, (Ogata et al., 1993; Hasegawa et a l ,  1994), FHBV
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sequences showed a significantly higher number of nucleotide substitutions in all four 
open reading frames and also in the cis-acting regions. In our study we have shown that 
there are a number of unique variants found in some FHB cases, but not in others, and 
some variants were identified which occurred in significantly higher numbers in FHB 
cases when compared with non-FHB cases. The ds-acting regions were areas of especial 
interest as they regulate viral transcription. Variants in the Enh-II/CP have been reported 
in FHB (Ogata et a l, 1993) and chronic cases (Okamoto et al., 1994). Sixteen of the 19 
FHB cases in our study possessed notable variants in the Enh-II/CP complex. The two 
most common variants in the BCP were T]762 and A]764; both have been reported in FHB 
and chronic cases (Sato et al., 1995; Kurosaki et al., 1996) and can also appear 
occasionally after seroconversion to anti-HBe. However, in FHB cases these are linked to 
fatality (Laskus et al., 1995; Kaneka et al., 1995). Previous studies (Okamoto et al., 
1994; Sato et al., 1995) found that variation in the Enh-II/CP complex was associated 
with seroconversion to anti-HBe, so it was believed to contribute to downregulation of 
pre-core mRNA transcription. However, this has not been found in all anti-HBe positive 
cases (Kurosaki et a l,  1996) and has been reported from HBeAg positive chronic HBV 
cases (Okamoto et al,. 1994; Laskus et al., 1995); there was an association with lower 
levels of HBeAg production. In one study, it was found that these two variants in chronic 
patients has no effect on transcription (Nishizono et al., 1995). In our study, 6 of 7 cases 
with T ]762 andJ or A ]764 had A 1896 containing sequences, excepting case CHBV-1 who 
possessed G 1896 despite having one of these variants (Table 3.8). CHBV-1 had an A 
insertion at nt 1838 (within pre-core) resulting in a frame shift and was therefore HBeAg 
negative. Thus, for our patients, it seems that there is a correlation with core promoter 
variants and HBeAg negative phenotype.
Why are the motifs important?
The first novel concept to come from our study is that, individually, many of these 
variants are not unique to FHBV sequences but that their pathogenic significance lies in 
their interaction. The second novel concept is that there can be an interaction between 
protein and nucleotide variants. Twenty-one of 26 FHBV X gene sequences had a 
combination of: i) variants in the cA-acting region which regulates pregenomic and pre­
core mRNA synthesis; ii) the pre-core variant A ]896. and iii) one of the three alterations 
which might be expected to affect the synthesis and function of X gene products (aberrant 
methionine or cysteine residues or enhancer I variants). These combinations or motifs 
were nearly exclusive to FHBV sequences. The interactions between the nucleotide 
changes in ds-acting regulatory elements and aberrant cysteine and/or methionine residues 
(which may have altered the structure) of X protein can have functional effect (cluster 1 
and 5, chapter 3.2). Similar motifs were also found in A1896 and Enh-II/CP variants 
(cluster 6, chapter 3.2). We have shown that a specific combination of variants in Enh-
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II/CP resulted in an increase rate of transcription which was probably due to a protein- 
DNA interaction resulting in high transcription efficiency. In this study we have 
conclusively shown that unique variants in combination with 'normal' variants can cause 
abnormality; as we have shown in case FHBV-15 (discussed below).
We have also shown that the significantly higher rates of nucleotide evolution in 
the core and X genes and in the HBV genome as a whole, suggest that an increased rate 
of evolution is a hallmark of FHBV. The elevated rate of synonymous changes in X and 
in non-antigenic regions in the core gene are consistent with this interpretation.
What is the importance o f AI896 ?
There is no simple answer to this question. A]896 has been implicated in the 
development of FHB in some studies (Liang etal., 1991, Omata et a l,  1991). However, 
the HBeAg producing strain, G 1896, is also found in FHB cases (Carman et al., 1991a, 
Laskus et a l., 1993; Feray et al., 1993) and A ]896 has also been found as the dominant 
strain in patients with acute (Carman e ta l ,  1991b; Uchida et a l,  1993; Mphahlele et a l., 
1997) or chronic hepatitis (Carman et al., 1989; Brunetto et al., 1989; Okamoto et a l ,  
1990; Tong et al., 1990). Nine of 19 FHBV cases in our study harboured A 1896, the 
others being G 1896. Our data confirm that A ]896 is not invariably found in FHB patients. 
Presence of Aj896 was strongly correlated with the HBeAg status of our patients. Eight of 
9 patients containing A1896 were HBeAg negative and had seroconverted to anti-HBe. The 
only exception was case FHBV-5, who was HBeAg producing despite containing AI896.
Yet, there is an epidemiological association between HBeAg negative infection 
and FHF. HBeAg negative infection of all clinical types is strongly associated with the 
Aj896 variant. Transmission of A1896 from an anti-HBe carrier resulting in FHB has been 
documented after sexual exposure (Fagan etal., 1986), outbreaks from a common source 
(Liang et al., 1991), intrafamilial contact (Kosaka et al., 1991) and mother to infant 
transmission (Terazawa et al., 1991). Most of these studies reported rapid and severe 
liver failure with a fatal outcome. In our study, 12 of the 19 FHB cases were HBeAg 
negative on admission and 9 had rapid disease progression accompanied by the 
appearance of anti-HBe in most cases, regardless of clinical outcome. The mechanism of 
pathogenesis by an HBeAg negative variant is poorly understood. However, HBeAg is 
probably an immune modulator (Milich et al., 1990) and its absence in a naive host may 
be responsible for rapid hepatocyte destruction by CTL directed to HBcAg epitopes 
(Mondelli etal., 1987). Infants born to an anti-HBe positive mother seldom develop the 
chronic state, but either a self limited acute hepatitis or FHB (Beasley et al., 1983; 
Delaplane et al., 1983). Recently, transmission of a pure strain of A1896 to an adult 
resulting in acute infection and development of anti-HBe has been reported (Mphahlele et 
a l ,  1997). However, it is not clear from most FHB studies whether patients were
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exposed to a variant strain as opposed to a mixture of variant and normal strains. If they 
were not, then it may be that there was an initial massive response to the HBeAg 
producing strain (Carman et al, 1993a) leading to selection of the variant strain; or if they 
were initially exposed to the variant strain, than the absence of immune modulation may 
lead to immune elimination of hepatocytes expressing HBcAg epitopes on their 
membrane.
CD4+ Th cells play an important role in the clearance of virus during acute 
infection but are less active in chronic patients except during acute exacerbations (Ferrari 
et al, 1991; Penna et al, 1992). CD4+ cells recognise peptides presented by HLA class-II 
molecules and HBe and HBc Ags are cross-reactive at the T cell level (Milich et a l, 
1988). A recent study found that, in transgenic mice, HBe and HBc Ags elicited different 
subsets of Th cells (Milich et al, 1997); HBcAg was preferentially recognised by Thj 
cells, leading to enhanced cytokine activity with liver cell injury, whereas Th2 cells elicited 
by HBeAg were involved in secretion of anti-inflammatory cytokines and antibodies. 
Presence of both antigens thereby maintains a balance between antigen production and 
massive CTL response. On the other hand, the absence of an anti-inflammatory HBeAg- 
specific Th2 like response may increase the risk of an unchecked and aggressive 
HBeAg/HBcAg-specific Th, cell dominated response.
Although there is substantial evidence for the occurrence of A 1896 in chronic 
carriers, FHB is rare. This is probably because, in the course of chronic infection, a 
prolonged and imbalanced immune response leads to evolution of this variant, which 
upon transmission to a naive host may lead to FHB in a proportion of cases. Another 
explanation is that A1896 with other variants in the genome may be responsible for FHB. 
Transmission of A 1896 can also result in acute infection but it is rare (Mphahlele et al., 
1997). We show here that the diversity of A1896 associated illness can be explained by the 
presence of variants elsewhere in the genome.
So, what is the role of A I896?
Different cases of FHB are associated with distinct selective forces: FHBV 
sequences with A1896 were shown to have different patterns of evolution in the core gene 
compared to FHBV sequences without this variant. However, we have recently shown 
that transmission of the A1896 variant and, presumably HBeAg negative status, occurs on 
a significant scale, yet clearly does not often lead to FHB (Bollyky et a l, submitted). In 
this study we have conclusively shown that the combination of A 1896 with other FHBV- 
associated variants distinguishes A]896 CHB from A ]896 FHB cases. Lending further 
support to this hypothesis of non-equivalent effects of A 1896 in FHB and CHB cases, we 
have also shown here that A1896 FHBV sequences have different patterns of evolutionary 
change from A1896 CHBV sequences. This may be because a prolonged selective force in 
CHB is associated with evolution of A1896; there is also evidence that a proportion of A1896
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in CHB is due to superinfection by A]896 containing virus rather than emerging de novo  
from G1896 status during seroconversion (Bollyky et al., submitted).
Do the motifs have any functional effect?
Another novel concept of this study is that the multiple sequence motifs are 
associated with a common functional effect. One hypothesis to explain the massive liver 
cell injury in FHB is that altered binding of transcription factors leads to increased virus 
replication which, in predisposed individuals, induces an exaggerated immune response. 
We have shown clearly that m-acting regions from four phylogenetically linked clusters 
of FHB viral sequences (which are epidemiologically unrelated), have enhanced 
transcriptional activity in vitro. Further, this effect was confined to those FHB associated 
sequences containing variants in the BCP as well as A]896. The only exception to this rule 
was CHBV-1, a symptomless male contact implicated in causing FHB in successive 
wives (Fagan etal., 1986). His sequence also showed high luciferase expression despite 
having G1896 but this was accompanied by an A insertion at ntl838 and C ]862 which lies 
within the encapsidation signal and may have altered the RNA secondary structure. FHB 
cases with Gl896 sequences (clusters 3 and 7) had normal or intermediate luciferase levels. 
Two of these cases with normal transcriptional activity had variants in the BCP, one of 
which was in the third AT rich region (at ntl794); its effect on transcription is thus 
unknown, but is unlikely to be important. It is illuminating that A 1896 sequences from 
chronic carriers not associated with FHB cases had normal transcriptional activity, whilst 
A ]896 containing contacts of FHB cases had levels similar to A 1896 FHB cases. A1896 
containing chronic carrier controls also had variants in the BCP, commonly T ]762 and 
A 1764. However, in FHB cases these two variants were accompanied by T 1766, A]768 or 
both. In a recent study, based on sequence generated from a single patient, these latter 
two variants were found to be associated with an elevated rate of replication (Baumert et 
al., 1996). It is clear that the two most common variants in the BCP (T1762 and A1764) do 
not contribute to the level of transcription unless they occur in combination with other 
variants. This substantiates the conclusions from the phylogenetic analysis that there are 
multiple sequence motifs in FHB associated cases which have a common functional 
outcome and that A 1896 itself is not, per se, the major factor but is a marker for other 
variation within the cis -acting region of the genomes associated with it. As FHB as a 
clinical entity is rarely, if ever, transmitted, it must also be true that this increased 
transcriptional activity must be suppressed or otherwise offset in chronic carriers who 
have it.
Is sequence related to clinical outcome in FHB?
Motifs which characterise individual clusters of FHBV sequences correlate with 
distinct clinical features. The sequence cluster relationships were linked to death or
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survival in the absence of confounding prognostic factors such as pregnancy, coinfection 
with HDV or older age. A fatal outcome was associated with every FHBV sequence with 
either the T]762 or A]764 variants. In two other studies, 3 of 4 (Laskus et al., 1995) and 4 
of 5 (Kaneko et al., 1995) such cases were fatal. In our study, variants in these two 
positions occurred in 5 cases as the dominant population: the outcome in all cases was 
fatal. In a recent computer modelling study, these variants have been suggested to lead to 
alteration in RNA superstructure encompassing the e loop from which RNA is 
encapsidated (Kidd et al., 1996). They are also the part of the TATA-like regions 
involved in initiation of pre-core and pregenomic transcripts (Okamoto et al., 1994). A 
further novel, though related, concept to arise from this study is that specific variants can 
be linked to different clinical outcomes if they occur outside the usual genotype context. 
Every FHBV case associated with an aberrant C 1773 was fatal. Although this study was 
not designed to address this issue, particular genotypes may predispose patients to 
FHBV: 15 of 26 FHBV X gene sequences were genotype D.
Interestingly, there was a correlation between clinical parameters and 
transcriptional activity. High transcriptional activities were found in "rapid FHB” and 
their symptomless contacts. Rapid FHB is characterised by undetectable viral antigens 
with rapid seroconversion to anti-HBe and decline into coma within two weeks of the first 
symptoms and a similarly rapid spontaneous recovery. Both symptomless contacts 
studied here were implicated in rapidly progressive FHB in two successive wives each 
(Fagan et al., 1986). Liver cell necrosis and ensuing rapid clinical deterioration is 
explained by the triggering of a massive immune response which, ultimately, favours 
clearance of virus. Similarly, early and complete cessation of virus replication should 
favour liver regeneration and explain the rapid clinical recovery and, ultimately, good 
prognosis associated with this subgroup of patients with FHB. Clearly, high levels of 
viraemia are not always linked to high luciferase activities in vitro because serum HBV 
DNA levels typically were low in such contacts and undetectable in these FHB cases 
except within the first week and only by nested PCR. Also, massive liver injury is not 
inevitable with high transcriptional activity as both contacts had symptomless mild chronic 
hepatitis. In contrast, those patients with 'slow FHB' typically show a more protracted 
clinical and serological course, over several weeks, and have lower transcriptional 
activities than 'rapid FHB'. Early complete cessation of virus replication is lacking; 
seroconversion may be delayed as HBV DNA levels remain detectable for several weeks 
from the first symptoms.
Is a specific variant associated with impaired nuclear factor binding?
We have found that binding of one or more nuclear factors is impaired in most 
cases with increased transcription. Oligonucleotides were synthesised which encompass 
the regions in the BCP which bind several transcriptional regulatory proteins including a
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liver specific factor C/EBP (Lopez-Cabrara et a l, 1990). A recent study found that 
inhibition of binding of nuclear factors by T]762 and A1764 (Buckwold et a l ,  1996) is liver 
specific, as nuclear extracts from HeLa cells led to fewer bands. In our study, the missing 
bands were not liver specific, as nuclear extract from HeLa cells showed the same pattern 
of binding. Figure 3.6 which schematically correlates the variation in the BCP with 
nuclear factor binding patterns, indicates that particular nuclear protein binding patterns 
are associated with BCP variants. The oligonucleotide containing only one variant 
(FHBV-1) showed a similar pattern of binding to the non-FHB control, indicating that 
T]762 alone is unlikely to inhibit binding of nuclear factors. However, the oligonucleotide 
derived from case FHBV-15, which contained one unique variant (C,752) and one variant 
out of its usual genotype context (A1757) showed binding inhibition. Oligonucleotides 
from other FHBV cases with variants in the BCP showed a similar pattern of inhibition. 
This indicates that a number of combinations can lead to lack of binding to transcription 
factors and thus to a similar functional outcome. All of these variant cases were associated 
with high or intermediate luciferase activity; we therefore conclude that these two 
complexes have an inhibitory effect on transcription.
Which factor(s) is responsible fo r  G1896 associated FHB?
A ]896 has not been reported in association with FHB in the regions where 
genotype A is more prevalent (Feray et a l ,  1993; Laskus et a l ,  1993). In the whole 
genome sequencing studies, greater numbers of variants were observed when A ]896 was 
also present, particularly in the X, core and the Enh-II/CP complex. This raised the 
question of the factor(s) responsible for G1896 associated FHB. There is no direct answer 
but it could be explained in different ways: firstly, most FHB cases with G ]896 showed 
slow disease progression (our study; Brahm et a l ,  1991) with a high mortality rate. 
Continuing viral replication and immune elimination of infected liver cells for a longer 
period without producing neutralising antibodies may contribute to this high mortality. 
Secondly, there may be confounding factors. In the study by Laskus et a l  (1993), 10 of 
37 cases were coinfected with HDV, always found with G1896. HDV coinfection was also 
found in the French study by Feray et a l  (1993); in France, the prevalence of A1896 is low 
overall. In our study, HDV coinfection was found in 2 cases with G 1896 and both had a 
fatal outcome. Thirdly, we do not exclude a role for a genetically heightened immune 
response. Recently, it was found that two patients with FHB, but not their contacts, had 
one or more alleles for DR 13 at the HLA class-II locus, which was previously shown to 
be associated with clearance of virus in acute infections (Karayiannis e ta l ,  1995).
Do the variants in our study correlate with the findings of others?
There were a number of variants observed in the Enh-II/CP complex. The two 
other common variants were T1676 and A1757 which occurred in 12 and 6 (out of 19) cases
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respectively in this study and in significant numbers in other studies (Hasegawa et al., 
1994; Stemeck et al., 1996). These variants were also reported from non-FHB cases and 
they were probably linked to a particular genotype. Along with the 3 other variants in the 
Enh-I/XP complex (G 1050, T 1249, C 1250), C ]059 was at higher frequency in our study as 
well as other FHB studies. Stemeck et al. (1996) found that the frequencies of occurrence 
of C 1059, T 1676 and A l757 were 78, 89 and 78 percent respectively in FHB cases in 
comparison to 17, 14 and 26 percent in non-FHB cases and suggested that these variants 
were not genotype D specific. Their presence in higher frequencies in the FHBV cases 
may be important as they occurred in functionally significant areas. They may play a role 
in pathogenesis although they are not absolutely specific for the FHB group. We believe 
that they are genotype D specific and that this genotype may be more likely to cause 
severe disease then other genotypes. In fact, 13 of the 19 FHB cases sequenced in this 
study (and 18 out of 30 FHBV core gene sequences in the phylogenetic analysis) belong 
to genotype D.
A number of variants in the Enh-II/CP complex, some of which are unique to 
FHBV cases. They may not have any obvious effect on pathogenesis when they appear 
singly, as they did not occur in high numbers, but as showed, they may have a functional 
effect when they appear in combination. As the X-ORF overlaps with the Enh-II/CP 
complex at its carboxy-terminal end, some of the variants in this region also lead to amino 
acid substitutions in the X-protein. The X protein functions as a transcriptional 
transactivator (Miller and Robinson, 1987) and the carboxy terminal end (particularly a 
domain between aa 110-143), interacts with TBP (Qadri et al., 1995). The X protein also 
interacts with other cellular proteins to exert its transactivating function (Maguire et al., 
1991). X-gene sequence was available for 17 of our patients, 15 of which showed amino 
acid substitutions in X-protein. A number of cases showed substitution to cysteine, serine 
or methionine at different positions (Table 3.3). The presence of cysteines may contribute 
to an alteration in the secondary structure of the protein and thereby influence the binding 
to other trans-activating proteins. The significance of these additional serine residues is 
unknown and requires further analysis. An additional methionine upstream of the X-ORF 
may cause early initiation of translation and generate an abnormally sized protein 
(Takahashi et al., 1995). Although the significance of additional methionine residues 
within the reading frame is not known, one can imagine that translation from these 
methionines is possible and can generate X-proteins of smaller size. These may still retain 
transactivating activity.
In the core region, variants were discretely distributed and no clusters of amino 
acid substitution were seen. This is not consistent with the findings of Ehata et al. (1993), 
where two subtype specific clusters of amino acid substitution were seen in the patients 
with both FHB and severe exacerbations of chronic hepatitis. Variation in the specific 
amino acid positions (aa 77 and 113) was also noted in one case (Nakayama et al., 1995).
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Here we have shown that a higher number of core variants was associated with A1896 but 
mostly confined to non-antigenic regions. A study by Aye et a l  (1994) also reported a 
higher level of core variation in A1896 FHB cases, but without any definite clustering.
The occurrence of variants in the pre-Sl, pre-S2, S and P-ORFs was also 
examined. Unique or rare amino acid substitutions occurred less frequently in these ORFs 
than in the core or X ORFs. The cysteine residues at positions 48, 65 and 69 in SHBs, 
which are essential for secretion of viral particles (Mangold et a l,  1993), were conserved 
in all FHBV sequences. The SP-I and SP-II promoters remained invariable in all cases. 
No clusters of amino acid variability were observed in the surface and polymerase 
proteins. This is consistent with the recent studies on whole genome sequencing from 
FHB cases (Sterneck et a l,  1996; Karayiannis et a l, 1995; Alexopoulou et a l ,  1996). 
None of these studies could find any specific variants associated with FHB.
Previous studies showed that FHB and their contact cases had identical sequences 
(Aye et a l ,  1994; Karayiannis et al., 1995). In our study we had a pair of patients, where 
the contact had a self limited acute hepatitis but her sibling who shared the same needle 
developed FHB. The sequence analysis showed considerable disimilarity, contradicting 
previous findings. This may be because, unlike other studies, the contact is a an acute 
case.
Does subtype or genotype have any role in FHB?
Transmission of quasispecies from anti-HBe positive mothers with selection of a 
specific subtype or variant has been reported in a number of studies, indicating that certain 
subtypes or genotypes may be more likely to cause severe disease. In our study, in 9 out 
of 12 genotype D FHBV cases, the infection source was either from the UK (8 cases) or 
the USA (1 case), where genotype A is prevalent. The FHBV sequence associated with 
the outbreak in Israel also belonged to genotype D. In Mediterranean countries, where 
chronic HBV with cirrhosis is prevalent, the dominant genotype is D. Similarly, 
contribution of a particular subtype to disease severity is possible. Transmission of 
subtype ayw  from a mixed population in the mother to infants was found to be associated 
with fatal outcome; survival was linked to transmission of both adw2 and ayw  (Bahn et 
a l,  1995; von Weizsacker et a l, 1995). In one study, 2 of 3 newborns had ayw  as a 
dominant population during the phase of severe disease with a fatal outcome. However, 
the infant who survived had a mixed population of adw l and ayw  in the anti-HBe positive 
phase but only adw l after recovery (Bahn et a l, 1995). This indicates that the transmitted 
subtype which is the cause of massive hepatitis is the primary target of an immense 
immune (probably CTL) response.
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In the end, what causes FHB?
From the above discussion it reveals that there is no single 'factor' that can be 
implicated as the cause of FHB. However, in this study we have conclusively shown that:
i) FHBV sequences from unrelated cases have considerable sequence similarity 
indicating a specific viral genetic factor is associated with disease severity.
ii) No single variant can cause FHB (not even A]896, although it plays a significant 
role). Specific combinations of variants, affecting functional properties (e.g. increase in 
rate of transcription and/or replication) can cause FHB.
iii) Anti-HBe positive cases have higher number of variants especially in the ex ­
acting regions, with elevated rate of transcription; indicating that a highly replicative 
strain, in absence of immune modulation via HBeAg, is responsible for massive 
hepatocyte destruction.
iv) Non-synonymous amino acid substitutions in the functionally significant areas 
of X protein and in the non-antigenic areas of core protein reflected the fact that FHBV 
strains are highly evolved and highly replicative.
v) HBeAg positive cases had less number of variants and 2 of our FHBV cases 
did not show any variants in the cis-acting regions. In such cases, several other factors 
can play role: (a) a slow disease progression without producing any neutralising 
antibodies; (b) co-factors such as HDV coinfection or pregnancy and (c) specific HLA 
type which we could not assayed in our study.
Future work
It is clear from this and other studies that looking for a single variant for FHB is 
far too simplistic. In our study, we have shown that combinations of variants which form 
a 'motif is responsible for severe disease via a common functional effect. Higher 
transcription rates were found to be associated with combinations of variants in the ex­
acting regulatory elements. In our study we could assay only a selected number of cases. 
A study with a greater number of cases including various combinations of variants could 
give a more conclusive result, and different parallel experiments for the same assay could 
strengthen the result.
A high rate of transcription must be associated with high replication rate which is 
responsible for high infectivity of FHBV. Thus, it is conceivable that a study on the 
replication efficiency of variant strains will differentiate FHB from non-FHBV cases. In 
fact one study has already shown that two variants in cx-acting region are associated with 
high rate of replication (Baumert et al., 1996). A replication study using annexin-V cells 
(which are susceptible to HBV infection in vitro) transfected with various combinations of 
variants and assaying their replication rate from one passage to another could help to 
dissect out the replication competent strains. Only one study has been reported on
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transmission of FHBV-infected serum to chimpanzees with subsequent development of 
severe hepatitis (Ogata et al, 1993). Although laboratory use of chimpanzee is not ethical, 
at present this is the only animal susceptible for HBV. An animal study on chimpanzees 
infected with cloned variant and non-variant Enh-II/CP will give an idea about in vivo 
pathogenic effect of a particular variant(s).
In a number of FHB cases, mixtures of variant and normal strains are seen. If it is 
possible to obtain and assay samples in different disease phases, it would give us a better 
idea about the strain/genotype/subtype which is the primary target of immune elimination; 
one strain may be more virulent than another.
Most of the FHB cases with G ]896 have shown the least number of variants with 
low luciferase values. A host factor is probably playing the major role in pathogenesis in 
these cases. Recently, Karayiannis e ta l (1995) have shown that patients with FHB, but 
not their chronic contacts, contained one or more HLA class-II alleles which were found 
to be associated with the clearance of virus in acute infection. Although, in that study 
patients were infected with HBeAg negative strain and virus could not be cleared before 
substantial liver damage occurred (as one patient died and one had a liver transplant) 
indicating the involvement of a highly replicating vims; it is clear that HLA typing and Th 
cell proliferation assay should be included. Another reason is that Th cells play an 
important role in producing neutralising antibodies.
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